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ABSTRACT 
Neurons convey information through trillions of connections to affect animal behavior. 
Communication within these connections is primarily chemical and these chemical signals can 
function as modulators, hormones, transmitters, and trophic factors, enacting change at local and 
distant targets. Understanding and identifying local signals that establish and enrich neuron-
neuron interactions can give insight into neuronal network formation and function, and are 
essential for the implementation of key effectors of repair that restore function to a damaged 
neural network. Neuropeptides are a class of signaling molecules that are involved in a wide 
range of physiological functions including sleep, learning and memory, feeding, and pain. 
Abnormal levels of neuropeptides have been implicated in a number of diseases and disorders 
such as depression and epilepsy. To gain a better understanding of the role that neuropeptides 
play, we are interested in sampling and identifying cues within local microenvironments around 
well-defined neuronal networks and assessing the effects of the identified molecules on neuronal 
network function. Within this context, we have combined microfluidic devices with mass 
spectrometry detection to effectively stimulate, sample, and detect neuropeptides from a well-
defined culture. Microfluidics allow us to gain key information regarding the conditions which 
initiate or inhibit release by precisely controlling the extracellular environment. Mass 
spectrometry provides high sensitivity detection over a large dynamic range without requiring 
analyte pre-selection, enabling fast and accurate peptide discovery and detection. 
Here, we demonstrate two separate device designs for culturing neurons, applying 
selective chemical stimulations, and collecting released peptides. The first design employs 
micro-valve controlled stimulation channels to selectively apply chemical stimulations to 
cultured Aplysia californica neurons within the device. By controlling the length of stimulation 
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additions, the amount of stimulation necessary to enact release was determined for two different 
chemical stimulations, elevated K
+
 and insulin. A robust response was observed as the onset of 
peptide release was different for each stimulation. The device system was then applied to a more 
complex system, the dorsal root ganglia (DRG) neurons of Rattus norvegicus. 
In order to study peptide release from DRG neurons, a healthy and viable culture was 
first established. Immunohistochemical staining revealed long, viable process growth in the 
presence of glia. MS profiling was performed on the culture and a large number of signals in the 
peptide region were observed. Both DRG clusters and cultures were stimulated with elevated K
+ 
and several peaks differed between control and stimulation additions. While numerous peaks 
were observed, these putative peptides must be identified and confirmed with liquid 
chromatography (LC)- MS sequencing. To that end, DRG tissue, cell, and release samples were 
sequenced using two LC-MS platforms. Over 500 peptides were identified from 390 unique 
proteins within the DRG samples and a broad range of classifications were observed. Future 
work in this system involves focusing efforts toward neuropeptide detection. 
The second device system consists of a novel method to quantify release using MS 
imaging of microchannels on-chip. As peptides flow down PDMS channels, they interact and 
adsorb to a C18 functionalized silicon substrate. MS imaging is then performed on the channels 
and map of peptide localization throughout the channels is generated. We have created a novel 
method to quantify release by relating the length of peptide adsorption down a channel to the 
amount of peptide present. For each peptide of interest, a calibration curve is created and 
adsorbed peptide lengths can be compared to the calibration curve to determine peptide amount. 
We also demonstrate modifications of this device which yield both quantitative and temporal 
information regarding peptide release by instituting microvalve-controlled collection channels.  
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CHAPTER 1  
INTRODUCTION AND DISSERTATION OVERVIEW 
 
1.1 Background 
The human nervous system contains a vast number of neurons (10
12
) that relay 
information through an estimated 10
15
 connections to maintain homeostasis and proper organism 
function.
1
 The sheer scale of these interactions necessitates a reductionist approach of study, 
resulting in a specialization of research efforts towards distinct subsets of the much larger overall 
nervous system. Ultimately these focused findings must be pieced together to achieve a big-
picture understanding of the nervous system formation and function, enabling the 
implementation of key effectors of repair to damaged neuronal networks. In the Sweedler group, 
research efforts are focused on developing an analytical toolbox for investigating neuronal 
networks, frequently relying on an array of model organisms to better understand the nature of 
chemical signaling involved in neuronal interactions.  
Within the Sweedler group, my dissertation research emphasizes the investigation of 
neuropeptide release from neurons of two different model systems- Aplysia californica and 
Rattus norvegicus. Neuropeptide release has been achieved by designing and creating 
microanalytical platforms which are capable of culturing low-density neurons and sampling their 
extracellular environments to gain a better understanding of the quantitative and temporal nature 
of the peptides involved in and the conditions that govern neuropeptide release. Mass 
spectrometry offers information rich chemical content over a large dynamic range, without 
requiring analyte preselection, positioning it as an excellent tool for investigating neuropeptides.  
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1.2 Neuropeptides 
Chemical signaling within the nervous system plays a key role in the daily functioning of 
many processes within the body. Signaling molecules assist in relaying information or 
maintaining neuronal networks, and are classified into several different types including small 
molecules, amino acids, peptides, and gases. Neuropeptides are endogenous peptides synthesized 
in neurons
2,3
 which play a role in cell-to-cell signaling. Neuropeptides are involved in a wide 
range of physiological processes including learning and memory,
4
 sleep,
5
 pain,
6
 and hunger.
7,8
 
Additionally, abnormal peptide levels resulting from damage or injury within defined pathways 
have been implicated in a number of diseases including depression
9
 and epilepsy.
10
 
Neuropeptides play a number of roles as neurotransmitters, hormones, trophic factors, and 
modulators,
11,12
 for cell and network maintenance or causing inhibitory of excitatory responses. 
In contrast to classical signaling molecules such as serotonin and glutamate which are 
synthesized within the axon terminal and are readily available for replenishment, neuropeptides 
are synthesized in the cell soma and undergo a number of cleavage and packing steps prior to 
release.  
Synthesis begins with translation of a pre-prohormone from the pro-messenger gene. This 
pre-prohormone contains the pro-hormone and a signal peptide, which guides the peptide 
through the endoplasmic reticulum. The signal peptide is cleaved from the prohormone and the 
prohormone is transported to the Golgi apparatus for vesicle packaging into large dense core 
vesicles.
13
 Within the Golgi and the vesicle, the pro-hormone is endoproteolitically cleaved and 
often undergoes a number of post-translational modifications to yield bioactive peptides, with 
these steps including amidation, pyroglutamic acid conversion, and acetylation and several 
others.
14
 After docking to the cell membrane, the vesicle is exocytotically released from the cell 
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following appropriate stimulation. Peptide release generally follows high frequency stimulation 
or burst firing,
15
 and has been shown from axons and dendrites.
15
 Whether a neuron will release 
depends upon the excitatory or inhibitory extracellular environment surrounding the neuron. 
After release, the peptides reach their cognate receptors, usually G-protein coupled receptors 
(GPCR).  The peptides can be internalized through these GPCRs at the target cell. Classical 
transmitters are quickly reincorporated into the cell, while neuropeptides can diffuse to far away 
targets, resulting in slower and longer-lasting responses compared to classical neurotransmitters.
8
  
Both identifying neuropeptides and understanding the extracellular conditions that govern 
their release give key insights into neuronal network formation, function, and repair. A number 
of analytical separation and detection approaches have been applied to identify neuropeptides 
including radioimmunoassays and enzyme immunoassays, liquid chromatography- mass 
spectrometry (LC-MS), and capillary electrophoresis (CE) - MS, and CE- laser induced 
fluorescence.
16
 While these methods are capable of identifying neuropeptides, sampling can be 
more challenging as it requires sampling directly from a region of interest or an in vitro sampling 
method.  
  Microdialysis and electrochemical methods are the most commonly employed in vivo 
techniques for sampling directly from a brain region of interest. Both methods are capable of 
monitoring neuropeptides present within cellular networks, but microdialysis currently cannot 
perform real time analysis, and electrochemical methods are limited to studying electroactive 
species. Furthermore, there exists a large degree of heterogeneity between cell types even in a 
small brain space. The sample volumes encountered in these measurements involves thousands 
of cells, running the risk of averaging signals from a given region and losing the ability to 
distinguish low-abundance analytes within a region, regardless of their spatial resolution. In vitro 
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methods isolate a particular region of interest from the brain or spinal cord, and then study it in a 
more controlled setting, reducing this averaging effect. However, care must be taken to recreate 
the extracellular environment in vitro. Dish-based cultures have provided a wealth of information 
pertaining to cell morphology and injury and regeneration. However, in dish-based cultures, 
neuropeptides are often diluted orders of magnitude prior to collection, making detection 
difficult if not impossible. 
 
1.3 Microfluidics for studying neuropeptides 
Microfluidics offers a versatile platform for the effective sampling of neuropeptide 
release. Microfluidic devices involve the manipulation of small volumes (nL to µL) within 
channels, greatly reducing dilution in sampling and improving detection of limited analytes. 
Devices typically consist of an elastomer, polydimethylsiloxane (PDMS), which is combined and 
cured onto a master. Masters are fabricated using traditional photolithographic processes. 
Microfluidics offer the benefit of low-cost and rapid prototyping usually within 24 h. Many 
unique designs are possible and can be tailored to specific applications. With the advent of 
microvalves
17
 and complex fluid handling systems,
18
 discreet plugs of chemical stimulations can 
be added to neurons within a device to study the effects of chemical exposure on neurons. In the 
fields of studying neurotransmission, devices exist which can selectively stimulate neurons, and 
provide for peptide characterization on-chip.
19
 
Microfluidics offer improved cell cultures due to the precise control and manipulation 
afforded over the extracellular environment. A wide range of neurons from cortical
20
 to 
molluscan
21
 have been grown in these devices. Furthermore, several device designs have been 
created to improve cell culture. Taylor et al. designed a device that isolates axons from their 
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dendrites.
20
 Tourovskaia et al. designed a device to continually perfuse media to cells in the 
channels, leading to several week old cultures.
22
 Finally, microfluidic devices are readily 
amenable to a number of detection platforms including laser induced fluorescence,
23
 
electrochemistry,
24
 and mass spectrometry.
7,25
  
 
1.4 Mass spectrometry characterization 
While radioimmunoassays, enzyme immunoassay, and laser induced fluorescence have 
low LOD’s, they inherently rely on labeling or derivitizing the analyte of interest and thus cannot 
perform unknown analyses. Moreover, immunoassays frequently suffer from cross-reactivity of 
analytes. Mass spectrometry is well-suited for unknown peptide analysis, as analyte pre-selection 
is not necessary. In mass spectrometry analyses, charged molecules and fragments are generated 
and then accelerated into a mass analyzer where they are measured by their mass to charge ratio.  
MS is rapid and offers high sensitivity detection over a large dynamic range. There are two 
major types of soft ionization used for biomolecule analysis- matrix assisted laser desorption 
ionization (MALDI), or electrospray ionization (ESI). MALDI MS, has been implemented for 
neuropeptide applications including homogenate analysis,
26
 cell profiling,
1
 and imaging of tissue 
and individual cells.
26-28
 In MALDI, the sample is co-crystallized with a UV-absorbing matrix. 
When the UV-laser beam is directed at the sample, the matrix absorbs the energy and is desorbed 
from the surface bringing along ionized analyte molecules. MALDI offers excellent detection 
methods (amole), accurate mass and high resolution (>40,000) with proper calibration, no upper 
mass limits when coupled with a time of flight mass analyzer, singly charged analytes for easier 
data analysis, and it is relatively tolerant of salts and detergents.
29
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In electrospray ionization, an analyte solution is passed through a capillary and a 
capillary tip which is held at high voltage. A spray of highly charged droplets is generated, which 
enters the mass analyzer for detection.
30,31
 The sample volumes utilized in ESI are well suited for 
coupling to small volume LC separations. In the study of neuropeptides, ESI with LC separation 
has been used for peptidomics studies of neuropeptides within tissue and cells.
32
  
The main goal of this project was to create a platform that combines microfluidics and 
mass spectrometry to effectively sample and characterize neuropeptide release from a low-
density neuron culture. Microfluidic devices assist in establishing a well- characterized neuron 
culture, sampling neuropeptides, applying selective chemical stimulations, and acquiring 
temporal and quantitative information; mass spectrometry provides the requisite characterization 
of peptides present within a sample over a large m/z range and dynamic range. 
 
1.5 Model systems 
The study of model systems has resulted in a great deal of information regarding 
communication within the nervous system. While human brains have a distinct organization 
from other organisms, a large number of neurochemical pathways are conserved across metazoan 
life. Simpler organisms, like invertebrates Lymnae stagnalis, Caenorhabditis elegans, and 
Aplysia californica and vertebrates Mus musculus and Rattus norvegicus have led to significant 
advances in our understanding of signaling in the nervous system. Our lab has had extensive 
experience studying the signaling molecules found within the Aplysia nervous system and has 
established protocols for culture and isolation.
33,34
 Neurons in Aplysia are well- characterized and 
relatively easy to isolate and culture. Within the abdominal ganglia, the bag cell neurons are 
highly peptidergic, relatively easy to isolate, and are involved in reproduction.
35-37
 To that end, 
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the bag cell neurons of Aplysia californica was chosen as a first model for validating our new 
device systems.  
Following proper validation, neurons within the mammalian nervous system were 
investigated. Rattus norvegicus is a commonly used animal model based on its fast proliferation, 
relative ease of maintenance, and degree of homology to humans. Within the rat nervous system, 
the dorsal root ganglia (DRG) neurons are located directly adjacent to the spinal cord, and a 
single axon from these neurons bifurcates and extends into both the central and peripheral 
nervous systems.
38,39
 DRG neurons are uniquely poised for the study of injury and regeneration, 
as they act as a bridge between the peripheral and central nervous system and thus encounter 
both environments.
40
 Furthermore, the DRG are sensory neurons that are involved in relaying 
sensory information and are known to be involved in neuropathic pain.
6,41
 DRGs are known to 
contain several populations of neurons, with 40% being peptidergic, containing peptides such as 
calcitonin gene-related peptide (CGRP) and substance P.
8,42
 Little has been done toward a full-
scale neuropeptidomic and investigating release from DRGs. To that end, we are interested in 
identifying the neuropeptides that are involved in the DRG, and gaining a better understanding of 
the peptides involved in and the conditions that govern peptide release. 
 
1.6 Dissertation overview 
Within this work, two different microfluidic device designs will be discussed, each 
possessing unique advantages toward identifying and understanding peptide release. MS and 
MSI are applied for characterization following sample collection and preparation. 
Chapter 2 is a review article which investigates the role that microfluidics has played in studying 
neurotransmitters and neurotransmission in vivo and in vitro. Specific in vivo applications 
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include incorporation into microdialysis systems and push-pull perfusion systems. In vitro 
platforms involving improved cell culture, compartmentalized devices, injury and regeneration, 
applying selective chemical stimulations, and identifying and characterizing neurotransmitters 
are also highlighted. 
Chapter 3 introduces a microfluidic device system which more precisely manipulates the 
extracellular environment by temporally controlling exposure to chemical stimulations with the 
incorporation of micro-valves into the design. This device allows for investigations of varying 
lengths of stimulation exposure on a low-density culture of neurons within the device to 
determine the exposure amount necessary for release. Control and release solutions are 
continually collected from the device and are subjected to a sample preparation step prior to 
mass spectrometry analysis. For validation, two different chemical stimulations, elevated K
+
 and 
insulin, were applied to the bag cell neurons from Aplysia californica. A robust difference in the 
onset of peptide release was observed for each of the stimulations, demonstrating that better 
control over the microenvironment allows for a greater understanding of the conditions that 
govern peptide release.  
Following validation work with Aplysia, Chapter 4 presents first attempts at successfully 
culturing, characterizing, and stimulating DRG neurons on a variety of substrates in our group. 
In order to study peptide release from neurons, a healthy and viable culture was established. 
Immunohistochemical staining demonstrated long, healthy process growth, and mass 
spectrometry profiling demonstrated the presence of peptidergic neurons within the culture. 
DRGs were cultured in PDMS wells, and were stimulated with elevated K
+
. Peptide release was 
collected and analyzed with mass spectrometry and a number of new peaks were observed 
following stimulation. In order to verify peptides found in stimulation experiments by mass 
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matching, neuropeptides present in a given tissue and cell population must first be confirmed by 
MS/MS. Therefore, a peptidomics study of rat DRG tissue, cells, and release was performed with 
two LC-MS systems in order to correctly identify peptides in the DRG release samples. Two 
different extraction methods were performed and a number of peptides from proteins and several 
other neuropeptides were identified including.  
The second microfluidic device system is described in Chapter 5. Here, quantitative 
peptide collections and detection occurs directly on-chip with mass spectrometry imaging for 
characterization. This study investigates reducing peptide absorption and provides a model and 
experimental data for label-free quantitation of peptide release from Aplysia californica neurons. 
We show here that up to 50% of peptides can be absorbed into PDMS, drastically reducing the 
ability to accurately quantify release. By OEGylating the PDMS, the amount of absorption can 
be improved by greater than 25%.  This device platform offers a novel method for peptide 
release quantitation by relating peptide adsorption length down a C-18 functionalized silicon 
wafer to the amount of peptide present. A spiked, known amount of peptide and the subsequent 
length of peptide adsorption can be combined to create a calibration curve. Then, the length of 
peptide release adsorption from a small cell population can be compared to the calibration curve 
and peptide amount can be determined. Bag cell neurons from Aplysia californica were 
investigated and peptide amount agreed with previously reported data. 
Chapter 6 describes design modifications and the implementation of microvalves into the 
microfluidic system described in Chapter 5. The additional channels allow for proper controls 
and temporal collections of released peptides, gaining a better understanding of peptide release. 
The addition of microvalves assists in guiding solutions down the measurement channel and 
removes unwanted peptide migration down adjacent channels. The fluidic isolation provided by 
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the microchannels was demonstrated with ink solutions and Angiotensin II adsorption study. 
Finally, the ability to create a calibration curve for peptides from the bag cell neurons was 
validated. 
Chapter 7 concludes the previous chapters and discusses future work on this research 
project. The first device system can be applied to additional regions of the rat nervous system, 
including the hippocampus or hypothalamus to study the effects of chemical stimulations on 
cultured neurons within the device. A full and more complete peptidomics study will be 
performed on the DRG. Future work in the second microfluidic platform involves creating a 
calibration curve specific to DRG neurons and then studying release.  
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 CHAPTER 2 
MICROFLUIDICS FOR STUDYING NEUROTRANSMITTERS AND 
NEUROTRANSMISSION 
 
2.1 Notes and acknowledgments 
 This chapter highlights microfluidic systems that have been used or would be good 
candidates for the study of neurotransmitters or neurotransmission. This tutorial review was 
published in Lab Chip, 2013,13, 1666-1676 and is reproduced here with permission from the 
Royal Society of Chemistry. This manuscript can be found at http://pubs.rsc.org/ using DOI: 
10.1039/C3LC41334A. This work was supported by Award No. P30 DA018310 from the 
National Institute on Drug Abuse, Award NS031609 from the National Institute of Neurological 
Disorders and Stroke, and Award No. DMI 0328162 from the National Science Foundation. I 
was supported by the NIH Cellular and Molecular Biology Training Grant T32 GM007283. 
 
2.2 Introduction 
Animal behavior and physiology is, to some extent, controlled by the interactions 
between networks of neurons and glia within the central and peripheral nervous systems. Within 
these networks, large numbers of molecules act to maintain, inhibit, and excite neurons. After an 
appropriate electrical or chemical signal is received, a neuron may release compounds that range 
from gases to small molecules and peptides. These signaling molecules—neurotransmitters and 
neuromodulators—are involved in an extensive variety of physiological processes including 
learning, memory, sleep, and response to disease.
1
 Damage or injury to these networks can lead 
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to abnormal, limited, or non-existent function, which has been implicated in a wide range of 
conditions including depression and neurodegenerative diseases.
1-5
 Understanding the 
extracellular environment, as well as identifying the signaling molecules that form the basis of 
these connections, could allow us to implement strategies to restore function to damaged neural 
networks.  
To address these challenges, a wealth of sample handling and analysis methods have been 
applied to examine neurotransmission.
6
 Capillary electrophoresis (CE) and liquid 
chromatography provide analyte fractionation / separation, while methods such as laser-induced 
fluorescence, immunoassay, and mass spectrometry (MS) are employed for detection.
6
 Direct 
electrochemical methods and microdialysis are widely used to probe cellular networks in vivo to 
examine molecular changes within the brain and determine correlations between chemical 
dependency and behavior.
7-9
 While in vivo methods are used to sample specific regions of the 
brain, the sample volumes obtained effectively involve at least tens of thousands or more cells, 
resulting in an “averaging” of the extracellular milieu. As neurons (and glia) in a spatially 
defined location oftentimes have distinct chemical constituents and functions, important 
information is often lost.  Alternatively, one can isolate individual cells from a defined region 
and either assay them or culture them in vitro, allowing for the detection of mass-limited 
molecules that may not be detected in bulk averages. For in vitro measurements, care must be 
taken to create an extracellular environment that mimics in vivo conditions.  
In vitro and in vivo methods can yield complimentary information. In vivo analytical 
measurements provide information on the molecules present in a specific region in the brain, 
providing a basis for identification in vitro. The most common in vivo monitoring techniques are 
microdialysis and electrochemistry.
7-9
 Microdialysis is a technique that continuously monitors 
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the chemical environment at the location of a probe inserted into the tissue of interest. The 
approach has been useful for examining activity-dependent (and pharmacological-dependent) 
changes in specific brain regions, although it can be limited to monitoring neurochemical 
changes on the second time scale.
10,11
 Electrochemical sensors implanted into the brain provide 
information from a specific location and can be scaled to the micron level, and have been 
especially useful for examining electroactive transmitters such as dopamine 
7,12
 and serotonin.
13
 
As an example, fast-scan cyclic voltammetry can monitor changes in release and uptake rates in 
near real time.
14
 In vitro analyses of tissues from specific brain regions or cells can involve the 
isolation and investigation of molecules within a specific cellular network, single cells,
15-17
 or 
brain slices.
18,19
 Dish-based cultures and brain slice chambers are the more common methods 
used for culturing neural networks and brain slices in vitro, and have resulted in exciting 
advances in our knowledge of neurochemical release and the pathways involved.  
In recent years, microfluidics has been incorporated into the field of neuroscience, 
providing a unique set of capabilities that enable selected measurements, such as spatially well-
defined cell cultures, axonal / dendritic growth guidance, reduced sample volumes, and improved 
control and manipulation over the extracellular environment.
20,21
 Both perfusion and 
compartmentalized devices have been created to maintain long-term, healthy cultures in small-
volume devices.
22-24
 Physical barriers, gradients, and surface patterning aid in guiding neuron 
growth and investigating processes separately.
23,25-28
  With the advent of microvalves
29
 and 
precise fluid handling, the extracellular space can be precisely tuned and controlled to mimic in 
vivo environments; as a result, the conditions required for neurotransmitter release can be 
determined.
29,30
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Microfluidics has been implemented for in vivo analyses, including microdialysis, to 
shorten analysis times and integrate on-line sample derivatization.
11
 Many of the same detection 
platforms used in traditional neurotransmitter analyses have been coupled to microfluidics. With 
these attributes, microfluidics is becoming an enabling technology for investigating cellular 
environments and for identifying key signaling molecules that are involved in both healthy and 
damaged networks. This review is not comprehensive, but rather, highlights recent advances in 
microfluidics that have furthered our ability to understand the complex nature of cell-to-cell 
signaling in the brain. We also speculate on how devices that have been used for several related 
measurements can be adapted for measuring neurotransmission.  
 
2.3 In vivo analyses 
As mentioned earlier, many in vivo analyses measure the signaling molecules released 
from a defined region. Microdialysis is an effective tissue sampling strategy that has been 
applied to study many areas of the brain.
11,31
 A probe with a semipermeable, size-selective 
membrane with a molecular weight cutoff is surgically implanted into the brain and a solution is 
continuously perfused into and out of the probe; compounds that diffuse across the membrane in 
the probe are thus sampled. Changes in the chemical makeup of the perfusate are monitored by 
selective detection (such as antibodies), or by coupling the output to separation techniques such 
as liquid chromatography or CE with laser-induced fluorescence, MS, ultraviolet or 
electrochemical detection.
10,32
 Microdialysis sampling is currently not assayed in real time, 
therefore the approach does not provide information on changes in neurotransmitter levels on the 
millisecond to second time scale. Several groups have worked to integrate microfluidics into 
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microdialysis probes, enabling faster analysis times and the ability to sample at lower flow rates, 
leading to higher sample recovery and greater temporal resolution.  
As an example, Nandi et al.
33
 reported a serpentine channel system that couples 
microdialysis and microchip electrophoresis for the detection of amino acid neurotransmitters 
from the rat striatum. Glutamate and aspartate were sampled from the brain and derivatized 
online prior to laser-induced fluorescence detection. The channel was fabricated in 
polydimethylsiloxane (PDMS) to allow for more complex designs and to remove the bonding 
challenges associated with glass chips. The serpentine channel increased the separation length 
over traditional microchip CE setups and improved the resolution. Following offline 
optimization, the device was applied in vivo to continuously monitor glutamate and aspartate 
from the rat brain. 
As analytes migrate along a channel, dispersion will occur within that channel, leading to 
a reduction in temporal resolution. To reduce the effects of this dispersion, the Kennedy group
34
 
introduced an ingenious segmented flow system into an online microdialysis setup. Aqueous 
microdialysates were collected from rat brain and segmented into aqueous droplets surrounded 
by an oil phase, creating thousands of discrete analyte plugs. As analytes traveled along the 
channels, diffusional broadening was limited to a droplet and so for a longer analysis, the total 
broadening was greatly reduced. They described a two-device system to collect amino acids from 
rat striatum with 35 s temporal resolution. The system consisted of a PDMS flow chip, which 
created the plugs, that was connected to a glass electrophoresis chip (Figure 2.1 A). The plugs 
were derivatized online and extracted into a glass CE microchip where the plug contents were 
analyzed by laser-induced fluorescence. 
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In a subsequent study by Kennedy’s group,35 they described a technique that directly 
combined microdialysis and segmented flow with electrospray ionization MS for in vivo 
monitoring of acetylcholine. The setup consisted of a microdialysis probe connected to the brain 
of a live rat, an oil channel interface for creating segmented plugs, and a diluent for MS. MS is 
well suited for neurotransmitter study as it allows for detection of a wide range of 
neurotransmitters within a single mass spectrum without a need for analyte pre-selection. The 
authors were able to measure basal and elevated acetylcholine levels and achieve a temporal 
resolution of 5 s. Since neurotransmission occurs on the millisecond to minute time scale, the 
enhancements shown in the previous two examples represent important advances toward real-
time analysis over the physiological range of transmission.  
Low-flow, push-pull perfusion devices offer an alternative to microdialysis sampling. 
Instead of analyte migration taking place across a membrane, push-pull perfusion requires two 
different tubes, one that infuses artificial cerebrospinal fluid into tissue and one that withdraws 
solution from the region.
6,36
 While push-pull perfusion was previously shown to damage tissue 
within the sampling region, smaller capillaries and lower flow rates have greatly improved the 
application of perfusion devices.
6
 Sampling areas are smaller than microdialysis probes and thus 
yield better spatial resolution, an important consideration because of the cell-to-cell 
heterogeneity that exists among different regions and within the same region of the brain. To 
improve spatial resolution, Kennedy and colleagues
37
 coupled a push-pull perfusion system with 
a segmented flow system to monitor L-glutamate release from an elevated K
+
 stimulation. They 
were able to achieve a temporal resolution of 7 s with a spatial resolution of 0.016 mm
2
, an 80-
fold improvement over a relatively small microdialysis probe. As the extracellular fluid was 
withdrawn from the tissue, it was combined with an oil to form the plugs, and the Teflon tubing 
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with the sample plugs was stored. The sample plugs in the tubing were then combined with 
another microfabricated unit that added enzyme and fluorogenic dye to the plugs, and then 
analysis was performed by fluorescence. This offline storage and analysis system is flexible and 
can be applied to a number of detection platforms and cell-sampling schemes.  
 The final device system highlighted in this section has application for both in vivo tissue 
analysis and in vitro cellular analysis. The chemistrode is a microfluidic platform that consists of 
a droplet-based device with a delivery channel, a droplet and sample interface, and collection and 
analysis channels.
38
 Stimulation solutions are delivered by a plug and contact the hydrophilic 
surface. The released molecules are captured and reformed into a segmented plug format (Figure 
2.1 B). The plugs contain aqueous solutions surrounded by a fluorocarbon carrier fluid. Channels 
within the device are functionalized with hydrophobic and fluorophilic coatings to retain the 
carrier fluid on the wall of the chemistrode when it comes into contact with the hydrophilic 
surface. Analyte plugs reform in an exit channel and then can split into different channels for 
analysis. With high spatial (<15 µm) and temporal resolution (~50 ms), the chemistrode has a 
wide range of potential applications related to stimulating and analyzing neurotransmission. This 
system was applied to study insulin release from a single glucose-stimulated islets of 
Langerhans, demonstrating its applicability to live cell studies. The chemistrode could allow for 
precise control of stimulation addition and analyte collection and detection for both in vivo and 
in vitro neurotransmission experiments.  
 Overall, we expect that microfluidic systems specifically designed to study 
neurotransmission in vivo will continue to be advanced. The greater our ability to sample and 
stimulate at high spatial and temporal resolution in vivo, the more likely we are to attain a better 
understanding of neurotransmitter signaling in defined brain regions. 
  
20 
 
2.4 In vitro analyses 
In what follows, we describe a number of microfluidic devices that have been used for 
cell culturing, selected sampling from defined locations, examining network formation, injury 
and repair, and characterization of the extracellular media.  Although these examples have 
relevance to cell-to-cell signaling research, several of them have not yet been used in this 
context. 
 
2.4.1 Refining neuron culture 
To study neurotransmission in vitro, it is important to create an extracellular environment 
that closely mimics physiological conditions. The effective culture of cellular networks and 
single cells requires careful O2, CO2, and temperature control, delivery of essential nutrients, and 
waste removal. The optimization and study of cell growth and culture in dishes has greatly 
improved our understanding of the precise environmental conditions necessary to grow healthy, 
viable cultures that can be interrogated using a number of approaches.
39
 Microfluidics expands 
on the ability to culture neurons by providing spatially defined and temporally controlled 
culturing environments. 
Many microfluidic systems have been used to culture a wide range of neuronal types, 
from the mammalian hippocampus
27,40,41
 to molluscan neurons of Aplysia californica.
26,27
 There 
are two particularly noteworthy device types, perfusion and compartmentalized, that enhance cell 
culture and allow access to the cells within the device. Perfusion culture platforms, such as the 
one detailed by Tourovskaia et al.,
42,43
 continuously deliver media and remove cellular waste, 
which allows for long-term culturing. Compartmentalized devices isolate cell bodies and axons, 
enabling the investigation of a wide range of physiological processes.
44
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While cell culture in devices offers ease of fluid handling, optical transparency, and gas 
permeability, the approach also presents several challenges that are unique to small-scale 
culturing due to the materials used. For example, PDMS has long been the material of choice in 
fabricating microfluidic devices, but contamination caused by uncrossed oligomers and metal 
catalysts entering bulk solutions have been noted as issues that affect cell viability.
45
 The 
absorption of small molecules and essential media components into the polymer has also been 
reported.
45-49
 To combat these challenges, a number of groups have instituted extraction 
procedures that render the PDMS more amenable to cell growth,
40,45
 allowing long-term, low 
density cultures. Continuing to improve neural culturing approaches that better mimic in vivo 
conditions should yield more physiologically accurate results when studying a wide range of 
processes. 
 
2.4.2 Investigating signaling molecules at defined cellular locations 
The brain consists of billions of individual neurons and glia, and much of the chemical 
communication between these cells occurs through synapses. Neurons are typically composed of 
a cell body with an axon and multiple dendrites. In many cases, chemical messengers are 
released across the synapse from the presynaptic side of one neuron to the dendritic spine of 
another. However, some signaling molecules can be released at other locations; as examples, 
neuropeptide release can occur at the soma or dendrites, and nitric oxide diffuses across 
membranes and so can modify signaling at a range of target cells. Receptors for the transmitters 
are located at the postsynaptic neuron, or in some cases, on distant cells; they can be located on 
axons, dendrites, or the cell soma.
50-52
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The past decade has seen the design of compartmentalized devices that isolate individual 
cell bodies from their axons so that each region (soma, axon and dendrite) can be investigated 
separately.
44
 These devices typically consist of two main channels with small (~10 µm high), 
fluidically isolated interconnects. Cell bodies are loaded into the somal compartments and axons 
grow through the small channel interconnects into the axonal side. Fluidic isolation allows for 
the selective stimulation of one region of the neuron and collection of released molecules in 
other compartments. In some cases, two separate cultures are investigated within the same 
device. Compartmentalized devices have been used to examine a wide range of neural functions, 
from axonal transport to injury and regeneration.
44
 Although these devices have not always been 
applied to studying neurotransmission, they are adaptable to examining signaling molecules 
found in individual neurons as well as those found at neuron-neuron and neuron-glia synapses. 
The ability to access both the somal and synaptic compartments should allow for separate 
stimulation and investigation of released molecules during growth, development, and network 
formation. 
In 2005, the Jeon group
23
 demonstrated that axons could be selectively interrogated from 
cell bodies by the growth of a high density neuronal culture. The platform and its subsequent 
modifications polarized the growth of axons through interconnects into a fluidically isolated 
axonal compartment. The device was originally applied to study injury and regeneration, axonal 
mRNA and transport, and co-cultures of oligodendrocytes and neurons. Since then, the device 
design has been modified for a variety of applications, including the investigation of synapse 
formation within compartmentalized microgrooves (Figure. 2.2).
41
 The device has been used to 
allow segregation of two neuronal populations and to deliver essential nutrients to neuronal 
connections, but can be adapted for analyte collection at the connections between two cell 
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cultures to study neuron-neuron, glia-neuron, or even glia-glia interactions. Glia-neuron 
interactions are particularly interesting because communication between both cells can be 
chemical and their two-way communication is considered to be essential for the central nervous 
system to function properly.
53
 Nevertheless, the current molecular information regarding glia-
neuron communication is limited and investigations are needed to understand the full extent of 
their interactions.  
More recently, new devices have been designed to effectively co-culture axons and glia. 
Hosmane et al.
54
 incorporated open, circular access ports to reduce the difficulty in cell loading 
and improve access to cell bodies for chemical or electrophysiological studies. Similar to 
previous designs, axons are guided through interconnects to an axonal compartment where they 
are then co-cultured with glia through a PDMS microstencil. H2O2 was applied to one access port 
to study the response of glia to axonal degeneration, when compared to non-damaged cells. 
In a device described by Majumdar et al.,
55
 a co-culture of primary hippocampal neurons and 
glia was accomplished by placing the cultures into two different chambers that were separated 
with a microvalve-controlled channel. During culture, the valve was deactivated so that chemical 
interactions between the two cultures were possible. Following culture, the valve was activated 
and both compartments were fluidically isolated for specific investigations. The authors observed 
that in the absence of glia or glia-conditioned media, neuron viability was limited to one week, 
whereas cultures were healthy for more than three weeks during the co-culture conditions.   
Compartmentalized devices offer a unique way to isolate individual neurons and co-
cultures, allowing processes and synapses to be interrogated. These systems have not yet been 
used to monitor neurotransmission, but we believe that the addition of channels for analyte 
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collection, or modification of these devices for online analysis, will be implemented in the not so 
distant future.  
 
2.4.3 Neuronal injury and regeneration 
Damage or injury to neural networks has been implicated in a number of 
neurodegenerative diseases. Comparisons between healthy and diseased nervous systems, and 
identifications of molecules involved in repair, will provide essential information for repairing a 
damaged network. When studying injury and regeneration in vitro, different means of injury 
have been used, including chemical and mechanical. Chemical injury involves focusing an injury 
stream or directly applying the chemical of interest to the entire channel. These solutions can be 
localized to a small region or can dissolve the entire neural process. Mechanical injury involves 
severing processes with a knife or needle, aspirating the channel, or applying a laser for 
transection. One of the first applications demonstrated in a compartmentalized device by Taylor 
et al.
23
 was to vacuum aspirate the axonal compartment and collect somal fractions to study 
changes in mRNA expression.  
Compartmentalized devices offer many advantages for modeling disease in vitro. When 
neurons are isolated, any chemical or mechanical injury that is induced in the axonal 
compartment will be specific for axons only. Therefore, using compartmentalized devices to 
study axon injury and regeneration can aid in the understanding of what factors and 
environmental conditionals are essential for repair during process regeneration. Kunze et al.
56
 
modified a compartmentalized device to model Alzheimer’s disease by creating healthy and 
diseased cortical neuron cultures (Figure 2.3 A). Two identical cultures were loaded into separate 
somal compartments, and neurites then extended through small interconnects to the main 
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channel. One set of cells (located on one side of the device) were exposed to okadaic acid, which 
induces hyperphosphorylation in tau proteins, a condition implicated in Alzheimer’s disease; the 
other culture remained healthy and viable (Figure 2.3 B). Although signaling molecules were not 
studied in this device, slight modifications for sample collection would be straightforward and 
could provide molecular information on healthy and diseased cell populations for comparisons. 
To mechanically induce injury, a device was designed that incorporated a 180 ps duration 
laser to either partially or fully transect an axon of interest.
57
 The design contained alternating 
micropatterned substrates fabricated on glass to facilitate cell growth. Cortical cells were loaded 
into a PDMS channel and grew down the micropatterned substrate. Following injury, neuron 
regrowth and regeneration was monitored in standard and ethylene glycol tetraacetic acid media 
to study the effects of extracellular calcium on axonal degeneration.  
 Hosmane and colleagues
58
 designed a system that induced axonal injury on hippocampal 
neurons through a micro-compression platform. The platform was connected to a valve system 
that delivered varying amounts of pressure to an axon to induce injury. Degeneration and growth 
were monitored under mild to severe injury conditions.  
Each of these devices offers a different approach for inducing injury to a neural culture. With 
modification for molecular collection and detection, these devices will offer a significant 
contribution toward understanding the molecular interactions within a diseased network and 
identifying essential molecules for repair. 
 
2.4.4 Engineering the extracellular environment 
Tissue and cell homogenates, single cell analyses, and in vivo collections give insight into 
the molecular complement of a given region or cell type. However, the presence or even the 
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release of a molecule does not prove its function as a neurotransmitter. The classification of a 
molecule as a neurotransmitter requires that it fit several criteria, including its synthesis within a 
neuron, its release upon appropriate physiological stimulations, and the creation of the 
appropriate response in the postsynaptic cell. Microfluidics offers unique advantages for 
addressing these criteria as these devices can provide an appropriate environment for exposing 
specific cells to putative transmitters, allowing one to follow the cells' response, while also 
aiding the collection and characterization of transmitter releasates. The ability to precisely 
control the extracellular environment through nutrient delivery, fluid flow, and surface gradients 
helps to create a milieu that more closely mimics in vivo conditions. Studying neurotransmission, 
controlling and understanding the application of chemical stimulations that result in transmitter 
release, and engineering the environment for better neurotransmitter identification, will give 
further insight into the conditions that govern cell-to-cell communication. To that end, this 
section is in two parts: designs that primarily address chemical stimulation and those that focus 
on identifying released molecules. 
 
2.4.4.1 Selective chemical stimulations 
Chemical communication within the nervous system is dynamic, adjusting to the 
extracellular environment and the input and output of molecular signals. Neurons are constantly 
exposed to a complex chemical milieu. Whether or not a neuron will release its contents depends 
on the amount and length of exposure and whether a particular chemical initiates inhibitory or 
excitatory responses in the cell. It is important to consider both the concentration and duration of 
exposure when creating a chemical stimulation delivery system. The relative ease of operation of 
the fluid handling and valve systems in microfluidic devices enables precise control and 
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localized additions of chemical stimulations. Several groups have developed devices that 
precisely deliver chemical stimulations to cells or brain slices. Sabounchi et al.
59
 reported a 
biochemical pulse generator that traps cells onto one side of a channel by negative pressure. An 
upstream pulse channel delivered a reagent pulse to several adjacent cells. During the entire 
experiment, cells were subjected to a constant buffer stream that both directed and removed 
reagent from the cells. If this device were modified for cell culture, cells could be stimulated in a 
localized fashion and collected downstream. 
Our group recently described a device that used microvalve-controlled stimulation 
channels to administer controlled and increasing periods of chemical stimulations to a cultured 
network of Aplyisa californica bag cell neurons (Figure 2.4).
60
 Following stimulation, 
neuropeptide solutions were collected off-line and characterized with MS. When providing 
additional temporal control over the duration of stimulation, the amount of chemical stimulation 
necessary for release can be determined. A robust difference in the temporal dynamics of peptide 
release was observed for two different chemical stimulations, elevated K
+ 
and insulin, 
demonstrating the importance of temporally controlling the secretogogue duration. A bath 
application of both stimulations would not have identified the difference in extracellular 
conditions necessary for release. This device can be applied to a variety of cell types, including 
amino acid and small molecule transmitters. 
Brain slice analysis is a reliable neuroscience tool used to isolate and conserve local 
connections within a brain region of interest under a precisely controlled environment.
18,61
 The 
open nature of brain slice chambers simplifies investigations using microscopic or 
electrophysiological approaches.
19
 In traditional brain slice analysis, the efficient delivery of 
essential nutrients and finely controlling the environment around the entire slice can be 
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challenging.
19
 Microfluidics has been incorporated into the approach to achieve added control 
over the neurochemical environment and to improve nutrient delivery and waste removal. For 
neurotransmitter studies, microfluidics has enabled the selective delivery of chemical 
stimulations to localized regions within the slice. 
One such strategy developed by Mohammed et al.
62
 employed a series of vertical 
openings underneath the brain slice that perfused solutions to precise regions on the slice. The 
specific addition of solutions was used to stimulate microscale areas of the brain slice. The setup 
monitored dopamine delivery into the tissue with cyclic voltammetry. One of the major benefits 
of this technique is the ease with which it can be integrated with standard brain slice chambers. 
In another approach to couple brain slice analysis with microfluidics, Tang et al.
63
 used 
microposts to support the slice. Several posts were replaced with fluid ports, which were used to 
selectively deliver or withdraw stimulation solutions to regions of the brain slice. To demonstrate 
the utility of the device, cortical spreading depression was induced by applying elevated 
potassium to the tissue, which depolarizes the cell membrane. With this design, specific brain 
regions could be selectively stimulated and the molecules of interest collected and analyzed. The 
ability to selectively stimulate brain regions can yield molecular information about a precisely 
controlled region while preserving morphology. As discussed above, both microvalves and fluid 
ports can be fabricated to better interrogate networks and brain slices.  
Designing a system that allows precise stimulation addition to a neural network or brain 
slice will provide information regarding the duration and concentration of stimulation necessary 
to elicit neurotransmitter release. Brain slice chambers that allow the user to selectively 
interrogate specific brain regions will yield details about the molecular content of the region of 
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study. By modifying these devices to enable molecular collections, we can assay the complex 
chemical environment dictating inhibitory or excitatory responses from a cell. 
 
2.4.4.2 Identifying and quantifying released molecules 
The previous section described selective chemical stimulations of single cells, networks, 
or brain slices. Here we highlight approaches to measure and identify released neurotransmitters. 
The small volumes afforded by microfluidics lead to a reduction in dilution, allowing for the 
collection and detection of mass-limited neurotransmitters. Through the incorporation of 
optimized designs and surface modifications, more efficient analyte collections become feasible 
compared with bulk dish-based methods.  Several of these devices are discussed below. 
 One challenge in neurotransmitter analysis involves chemically complex samples, where, 
for example, matrix effects and high salt concentrations often limit detection capabilities. To 
reduce sample complexity, cleanup / preparation steps involving separation-based methods such 
as liquid chromatography, CE, spin columns and packed pipet tips are often used. Incorporating 
sample clean-up and analyte detection on chip is particularly advantageous for reducing sample 
loss and minimizing the time spent in sample cleanup. Lin and colleagues
64
 reported a method 
that connected a cell culture device to an extraction device to study changes in glutamate 
transmission. The first device maintained and stimulated PC12 cells in culture, while the second 
consisted of an extraction region to capture glutamate within a packed column. After extraction, 
the cell chip was removed and the extraction chip directly connected to an electrospray-
quadrupole-time of flight mass spectrometer. This approach reduced sample loss by collecting 
secretions in-line with the cell chamber. Additionally, a wide range of cell types can be cultured 
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in the cell culture chip. Combining these capabilities into one device and adding additional 
extraction chips would further reduce sample loss and allow for temporally-resolved collections.  
 Our group has published two device designs for collecting and analyzing neuropeptide 
release on-chip with mass spectrometry imaging. In an initial study, Aplysia bag cell neurons 
were cultured on a silicon wafer and stimulated with elevated K
+
.
65
 Released peptides migrated 
down PDMS channels across a C18 functionalized silicon wafer and were adsorbed to the surface 
through hydrophobic interactions. The PDMS channels were removed and matrix was applied to 
the surface. The entire chip was imaged via matrix-assisted laser desorption / ionization MS. A 
mass spectrum was generated at each laser spot and the peptide localization was visualized 
throughout the channels. By increasing the number of collection channels, better insight into the 
qualitative and temporal aspects of release can be determined using this approach. Since matrix-
assisted laser desorption / ionization MS is not inherently quantitative, the device was modified 
to quantify peptide release on chip by correlating the peptide adsorption length down a channel 
to the amount of peptide present.
47
 Figure 2.5 shows false color images of peptide localization 
throughout the channels for increasing amounts of peptide. Each pixel corresponds to a mass 
spectrum containing the peptide of interest. After the creation of a standard curve relating the 
two variables, peptides from the bag cell neurons were collected and quantified and the results 
were in agreement with previous data. One advantage of this technique is that both device 
designs are amenable to multiple cell types, enabling the study of a variety of neuropeptides and 
neurotransmitters. 
 Further reductions in sample complexity to isolate and study single clusters or even 
individuals cells within a network should provide added insight into the heterogeneity of a cell 
population. An automated approach has been described that simultaneously quantified insulin 
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release from 15 islets of Langerhans on-line by microchip electrophoresis and fluorescence 
detection.
66
 Individual islets were loaded into a reservoir containing 10 mM glucose to evoke 
release. The sample stream was then derivatized on-line and periodically injected into an 
electrophoresis channel. Immunoassasys were performed at 10 s intervals. This design offers a 
high-throughput approach to quantify release. Alternatively, measuring the effects of different 
stimulations on single cells could be possible. 
 Gao et al.
67
 created a system that measures catecholamine exocytosis from single 
chromaffin cells trapped on electrodes by amperometric detection. Cells were loaded into one 
cellular channel, which was connected to an exit channel through interconnects. At each 
interconnect, there was a docking station that acted as a cell trap and contained an amperometric 
sensor fabricated underneath the docking station (Figure 2.6 A). When stimulated, catecholamine 
release was detected on chip, reducing the need for off-line sample preparation and analysis 
(Figure 2.6 B). The on-chip analysis offers reduced sample cleanup or loss that occurs when 
samples are analyzed off chip. This device has the potential to more closely mimic in vivo 
interactions if the cells are cultured in the device and allowed to form networks.  
In a device that combined on-chip sample preparation with off-line ion-mobility MS, 
Enders et al.
68
 examined a wide range of biological responses of cell populations in near-real 
time. These preliminary experiments were done with yeast and Jurkat cells. The device consisted 
of two sets of channels and valves that directed cell effluents into a pre-treated C18 column to 
collect peptides, metabolites, etc. While the material was eluted from the first column, the new 
cellular effluent flowed through a different C18 column in an alternating fashion to reduce 
sample loss. Samples were spotted onto a mass spectrometry target prior to ion mobility MS 
detection. While not employed for neurotransmitter analysis, with the ability to collect and 
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concentrate cellular effluents on chip, this device could be modified to temporally study 
neurotransmitter release.  
 The Martin group has reported several approaches for on-chip detection of release from 
PC12 cells. A study by Li et al.
69
 temporally quantified catecholamine release on-chip with a 
carbon microelectrode. Cells were loaded into collagen coated PDMS microchannels and were 
exposed to calcium to elicit release. Catecholamine release was measured and showed an 
increase in response to larger cell populations. Bowen and Martin
70
 reported a culture and 
analysis system where PC12 cells were cultured on a thin PDMS micropallet. After culture, the 
entire micropallet was loaded into the reservoir. Dopamine and norepinephrine secretions were 
injected into a microvalve-controlled electrophoresis channel. Detection was performed with a 
carbon microelectrode. Culturing neurons on a micropallet utilizes the benefits of established 
dish-based culture methods. Placing micropallets into the device is a unique idea to reuse devices 
and analyze multiple micropallets.  
 Thus far, most of this review has focused on classical and neuropeptide transmitters. 
However, several gases meet some of the definitions of a neurotransmitter. These unconventional 
transmitters include H2S, CO, and NO. Few studies have incorporated microfluidics into the 
study of gas release from neurons. In cell culture applications, the gas permeable nature of 
PDMS allows for necessary gas exchange in culture. However, when studying release, these 
molecules can escape from the channels prior to detection. Therefore, alternative materials are 
required for such studies or detection must be performed close to the cells of interest. Halpin and 
Spence
71
 fabricated a microfluidic device for the detection of NO on chip by a standard 
microtiter plate reader. The device design consisted of two PDMS layers with a porous 
polycarbonate membrane placed in between. Following device optimization, erythrocytes were 
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pumped into L-shaped channels and any released NO flowed through the polycarbonate 
membrane into wells. The wells were then aligned to the microplate reader and NO 
concentrations were determined by fluorescence. This device offers the ability to detect and 
quantify NO and to incorporate a standard laboratory technique for detection.  
 Amatore and colleagues72 reported another study that investigated NO and other reactive 
nitrogen species by amperometry on a low density macrophage culture. The microfluidic device 
consisted of three microelectrode bands on a glass substrate that were oriented orthogonally to 
the flow channel. They observed a robust response in oxygen and nitrogen species production 
following the introduction of a calcium ionophore. This device design offers a method for 
studying NO release from a low-density culture directly on-chip with real time analysis. 
By developing approaches that enhance the ability to identify neurotransmitters we can expect to 
gain further insight into the signaling molecules found within neurons. Reducing sample 
preparation time and performing analyses directly on chip can facilitate the detection of mass-
limited samples, which are often lost in off-line sample preparation procedures. Incorporating 
temporal control that better mimics in vivo conditions and quantifying neurotransmitters will 
provide a better understanding of release. Finally, designing devices that readily adapt to existing 
detection platforms streamlines the integration of microfluidics technology into neuroscience 
laboratories. 
 
2.5 Conclusions and future directions 
In this tutorial review, we have highlighted a number of microfluidic device designs that 
we believe have contributed, or have the potential to contribute, to the study of 
neurotransmission both in vivo and in vitro. Microfluidics offers improved analysis times and 
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spatial resolution when coupled to microdialysis and electrophoresis, allowing for more real-time 
analyses of released molecules. Compartmentalized devices provide the fluidic isolation features 
that are necessary for interrogating release at synapses, furthering the study of neuron-neuron 
and neuron-glia interactions. Several groups have created methods to examine injury, 
regeneration, and disease within microfluidic devices. Comparisons can be made between 
damaged and normal cultures, as well identification of factors that affect regeneration. A number 
of groups have focused their efforts on engineering the extracellular environment for better 
stimulation delivery or improved identification of released molecules.  
While many of the devices discussed herein are good candidates for studying 
neurotransmission, not all of them have been applied for this purpose. One complicating factor is 
the requirement of having to maintain mammalian cultures outside of an incubator. Oftentimes, 
long-term signaling experiments take several hours and require complicated setups of syringe 
pumps and valve systems, combined with the need to monitor cell viability under a microscope. 
Performing long-term studies outside of an incubator requires that the appropriate CO2 and 
temperature levels for viability be maintained. Commercial or home-built incubators can be used 
to enclose a microfluidics setup or provide access ports for fluid entry, and a number of devices 
have been developed that incorporate these considerations into their design.
73-76
  Needed 
developments include more robust designs that can be applied to current neuroscience 
measurement and characterization approaches. As mentioned earlier, designs that readily adapt 
to existing techniques will facilitate their incorporation into neuroscience research laboratories.  
Challenges aside, we have highlighted the substantial progress made in the 
implementation of microfluidics in the investigation of neurotransmission. With continued 
advances in device designs that improve upon traditional methods of detection, microfluidics 
  
35 
 
promises to be an excellent, more widely used platform for understanding the complex nature of 
neurotransmission within the nervous system. While the use of microfluidics in academic 
laboratories is widespread, it has yet to be applied in many industrial settings. We expect this to 
change as these devices become more robust and readily available. Their ability to provide 
efficient sample preparation and be interfaced to on- or off-chip detectors are key factors driving 
the future of this technology. 
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2.6 Figures 
 
 
Figure 2.1 Microfluidic device designs that incorporate segmented flow for improved cellular 
sampling. (A) Schematic of a dual-chip design for in vivo monitoring of amino acid transmitters 
from the rat striatum. The first chip creates plugs that contain dialysate and a fluorogenic 
reagent. Plugs flow to the glass electrophoresis chip for separation and detection with 
fluorescence (aCSF = artificial cerebral spinal fluid; NDA = naphthalene-2,3-dicarboxaldehyde; 
KCN = potassium cyanide; LIF = laser induced fluorescence). Adapted with permission from M. 
Wang, G. T. Roman, M. L. Perry and R. T. Kennedy, Anal. Chem., 2009, 81, 9072–9078. 
Copyright 2009 American Chemical Society. (B) Bright field images of chemistrode stimulation 
plugs contacting the surface and forming a response plug. Used with permission from D. Chen, 
W. Du, Y. Liu, W. Liu, A. Kuznetsov, F. E. Mendez, L. H. Philipson and R. F. Ismagilov, Proc. 
Natl. Acad. Sci. U. S. A., 2008, 105, 16843-16848. Copyright 2008 National Academy of 
Sciences, USA. 
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Figure 2.2 Microfluidic devices that use a series of small interconnects to allow independent 
control of solutions in the larger channels and to separate cell to separate cell soma from 
processes. (A) An example of synapse formation between two neuron cultures within a 
compartmentalized device. Cell bodies expressed green and red fluorescent protein on the left 
and right, respectively, with processes extending into interconnects between the two cultures.  
(B) Compartmentalized device with a perfusion channel in between somal compartments. 
Adapted with permission from A. M. Taylor, D. C. Dieterich, H. T. Ito, S. A. Kim and E. M. 
Schuman, Neuron, 2010, 66, 57-68. 
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Figure 2.3 A compartmentalized device used to model disease by creating healthy and diseased 
neuron cultures. (A) Schematic showing the culture of two healthy neural networks and the 
application of okadaic acid (OA) to create a diseased network with phosphorylated tau proteins, 
a condition implicated in Alzheimer’s disease. (B) Two cells representing (left) healthy and 
(right) diseased cultures. The diseased neurons show the clustering of phosphorylated tau 
clusters in (1) neurites and (2) soma. Adapted with permission from A. Kunze, R. Meissner, S. 
Brando and P. Renaud, Biotechnol. Bioeng., 2011, 108, 2241-2245. 
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Figure 2.4 Top. Schematic of a device used to selectively apply chemical stimulations to 
neuronal networks maintained in the device. Microvalve-controlled channels are opened to apply 
increasing periods of stimulation to determine the temporal dynamics of release. Bottom. Mass 
spectrum shows the detection of peptides released from the bag cell neurons of Aplysia upon 
insulin stimulation (AP = acidic peptide; BCP = bag cell peptide). Adapted with permission from 
C. A. Croushore, S. Supharoek, C. Y. Lee, J. Jakmunee and J. V. Sweedler, Anal. Chem., 2012, 
84, 9446-9452. Copyright 2012 American Chemical Society. 
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Figure 2.5 False color mass spectrometry images demonstrating the length of peptide adsorption 
down a C18 functionalized substrate corresponds to the amount of peptide present. Each pixel 
corresponds to a mass spectrum containing the peptide of interest. Used with permission from M. 
Zhong, C. Y. Lee, C. A. Croushore and J. V. Sweedler, Lab Chip, 2012, 12, 2037-2045.  
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Figure 2.6 (A) Schematic of a microfluidic device used for cell capture with amperometric 
detection of catecholamines. Cells are loaded into the device and negative pressure is applied to 
the exit reservoir, drawing cells down the channel and into the cell docking sites. (B) Recording 
of catecholamine exocytosis over several second intervals, with each spike representing release 
of an individual granule. Adapted with permission from Y. Gao, S. Bhattacharya, X. Chen, S. 
Barizuddin, S. Gangopadhyay and K. D. Gillis, Lab Chip, 2009, 9, 3442-3446. 
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CHAPTER 3 
MICROFLUIDIC DEVICE FOR THE SELECTIVE CHEMICAL 
STIMULATION OF NEURONS AND CHARACTERIZATION OF 
PEPTIDE RELEASE WITH MASS SPECTROMETRY 
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3.2 Introduction 
Neuropeptides are an important class of signaling molecules that are involved in cell-to-
cell communication in both the central and peripheral nervous systems. They are synthesized and 
stored in neurons and, upon stimulation, are exocytotically released from the cells to function as 
neurotransmitters, neuromodulators, trophic factors, and neurohormones. Known to influence a 
wide range of physiological processes, neuropeptides influence learning and memory, food 
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intake, pain, and disease.
1-3
 Identifying neuropeptides that both establish and enrich neuron-
neuron interactions, and understanding the physical and chemical conditions necessary for their 
release, will aid in uncovering the key effectors of formation and repair in neural networks. 
Characterizing neuropeptide release in vitro from low-density culturing environmentsallows cells 
of interest to be isolated from their potentially heterogeneous neighbors, which oftentimes 
contain a different chemical complement from nearby cells.
4
 
The study of neuropeptide signaling can be challenging; because only a fraction of the 
mass-limited neuropeptide content of a cell is released after stimulation, sample amounts can be 
low. Furthermore, in the commonly employed dish-based culturing systems, released peptides 
are diluted by orders of magnitude before collection, rendering their characterization difficult. 
There is a need for neuronal culture, collection and detection systems that both identify released 
neuropeptides and provide information regarding release conditions. Here we describe an 
approach to maintain a neuronal network in a controlled environment, selectively apply chemical 
stimulations, collect peptide releasate with minimal dilution, and couple the releasate collection 
to off-line mass spectrometry (MS) for peptide characterization. 
Microfluidic devices are well suited for examining neuropeptide release. With the 
evolution of microvalves, fluid control, surface patterning, and chemical gradients,these devices 
provide the ability to precisely controlthe microenvironments around neurons while significantly 
reducing sample volumes.
5-8
 By enabling detection of these mass-limited samples, we gain a 
broader understanding of peptide release conditions. Additionally, these devices offer a number 
of advantages that improve cell culture: biocompatibility, gas permeability, and optical 
transparency. 
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In recent years, progress has been made towards integrating microfluidics and 
neuroscience with cell culture, manipulation, and electrophysiology studies.
9-13
 
Compartmentalized devices fluidically isolate cell bodies from processes, allowing these 
structures to be examined separately.
14
 Whole Caenorhabditis elegans, the well-studied neural 
development model, have been placed in microfluidic chambers for the interrogation of a number 
of factors, including odor recognition and Ca
2+
 imaging,
15,16
 dynamic cellular processes,
17
 and 
high throughput genes and drug screening.
18
 Finally, several devices have been employed to 
study the injury and regeneration of neuron processes as well as to model disease within a 
device.
19-21
 While microfluidic technologies have been used to address a wide range of topics in 
neuroscience, little of this research has involved the investigation of neuropeptides. 
A number of detection platforms have been used to investigate neuropeptide release, 
including enzyme immunoassays, radioimmunoassays, and capillary electrophoresis coupled to 
laser-induced fluorescence.
22,23
 While highly sensitive and quantitative, these techniques require 
analyte pre-selection prior to analysis, followed by either a derivatization procedure to render the 
peptide fluorescent, or the creation of an antibody. In contrast, MS provides high sensitivity and 
information content for the entire peptide complement, without analyte pre-selection. Matrix-
assisted laser/desorption ionization (MALDI) MS offers high salt tolerances, and a relative ease 
of coupling to microfluidics. For all of these reasons, MS has proven to be a great detection 
platform for peptide release studies.
24-27
 
We present a microfluidic design that allows the user to selectively apply chemical 
stimulations to neurons maintained in the device. The resulting neuropeptide releasates are 
collected off-line and detected with MALDI- time-of-flight (TOF)-MS. This approach provides 
information regarding peptide release content and the physiological conditions necessary for 
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release. Previously, we reported several devices that employed MALDI-MS imaging to collect 
and quantify neuropeptides on chip.
28,29
 In this study we achieve further control over the 
extracellular microenvironment by creating a microvalve-controlled device that exposes a low-
density neural network to measured time periods of exposure to a defined chemical stimulation. 
With the added temporal control over stimulation and collection, the onset of peptide release can 
be determined and compared. By collecting peptide releasates and characterizing them via MS, 
off-chip, multiple-day stimulations can be performed on the same neural network and the 
specific released peptides can be characterized. Bag cell neurons from the marine mollusk 
Aplysia californica are widely used in neuropeptide studies. We exposed these neurons to both 
general and bag cell-specific chemical stimulations, followed by the subsequent collection and 
detection of peptide releasates. We observed both the onset and refractory period of bag cell 
peptide release for elevated K
+
 and insulin exposures; our results show a robust difference in the 
time frame required to detect peptides after exposure to distinct chemicals. 
 
3.3 Experimental section 
 
3.3.1 Reagents  
Chemicals were purchased from Sigma Aldrich (St. Louis, MO) and organic solvents 
were purchased from Fisher Scientific (Fairlawn, NJ) unless otherwise noted. The 
polydimethylsiloxane (PDMS)prepolymer kit, Sylgard 184, was purchased from Dow Corning 
(Midland, MI). 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane (OEG, 90%) was 
purchased from Gelest, Inc. (Morrisville, PA). Filtered artificial sea water (ASW, pH 7.8) 
contained 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 26 mM MgSO4, 2.5 mM 
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NaHCO3, and 15 mM HEPES. Negative photoresist SU-8 2075 and developer were obtained 
from MicroChem Corp. (Newtown, MA). Positive photoresist AZ 4620 and developer were from 
AZ Electronic Materials Corp. (Somerville, NJ). 
 
3.3.2 Device fabrication  
The device consists of two separate layers, a flow channel and a pressure channel layer. 
Silicon masters were prepared using a traditional photolithographic process as reported 
previously.
30,31
 The flow channel master was made with AZ4620 photoresist to a height of 25 
µm. Wafers were heated to 200°C for 20 min to create rounded corners in the channels, in order 
to effectively open and close channels. Octadecyltrichlorosilane was evaporated onto the wafer 
for 4 h or longer to allow for the removal of PDMS from the wafer. For the pressure channel 
master, SU-8 2075 photoresist was spun and patterned to make channels 100 µm in height. Small 
pieces of silicone tubing (Helix Medical, Carpinteria, CA) were glued onto the SU-8 features on 
the master. Uncured 20:1 PDMS was spun onto the flow channel master at 2050 rpm for 60 s; 
5:1 PDMS was poured onto the pressure channel master. Both masters were allowed to partially 
cure at 70 °C until just set. Then both PDMS blocks were aligned and adhered together and 
cured at 90 °C overnight. The main reservoir and outlet were made with an AcuPunch biopsy 
punch (Acuderm, Inc., Ft. Lauderdale, FL) of1 mm. The PDMS block was then adhered to a 30 
mm cell culture dish (Greiner Bio-One, Monroe, NC) and uncured PDMS was poured around the 
device to prevent leakage. The device was cured again at 70 °C for 1 h and both the flow and 
pressure channels were filled with ASW. Pressure channels were connected to an in-house built 
pneumatic solenoid valve system that is controlled by LabView software (National Instruments, 
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Austin, TX). The program controls the application or removal of pressure to the pressure 
channels for closing or opening the channels, respectively. 
To reduce analyte losses into the PDMS material,
29,32
 channels were treated with 5:1:1 
H2O:HCl:H2O2 for 5 min, rinsed with deionized water (DI; Milli-Q Biocel, Millipore 
Corporation, Billerica, MA) for 5 min, OEG for 30 min, and finally flushed with DI water for a 
minimum of 4 h to yield OEGylated PDMS, as described previously.
33
 Prior to use, PDMS 
devices were washed with methanol and dried with N2. 
 
3.3.3 Cell culture experiments 
Aplysia californica (100–150g; National Resource for Aplysia, Miami, FL) were 
anesthetized by injecting 390 mM of MgCl2 equal to ½ the animal’s body weight. The abdominal 
ganglia was dissected and incubated at 34°C in ASW containing 10mg/mL protease from 
Streptomyces griseus, 60 mg/L penicillin G, 100 mg/L streptomycin, and 100 mg/L gentamicin 
for 90 min. This treatment of the ganglia allows for removal of the connective tissue surrounding 
the bag cell neurons. Individual bag cell neurons were then isolated and loaded into the main 
reservoir of the microfluidic device. A small, thin piece of PDMS was placed over the main 
reservoir to direct flow through the flow channels. Cells were cultured in ASW for 24 h prior to 
stimulation experiments. 
 
3.3.4 Stimulation experiments  
Two syringes, containing either a solution of 60 mM of KCl in ASW or 5 µM of insulin 
in ASW, were attached to a syringe pump (Harvard Apparatus, Holliston, MA) and connected to 
the stimulation channels on the device. A syringe filled with ASW connected another syringe 
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pump to the inlet reservoir. Pre- and post-controls were performed with ASW as cell culture 
media. Each series of chemical stimulation measurements was performed on a network of 
cultured cells in the microfluidic device. Both the ASW and chemical stimulation solution were 
flowed through the device at a flow rate of 0.5–1 µL/min. When ASW was flowed, the 
microvalves were closed to prohibit chemical stimulation solution from entering the channels. 
When chemical stimulations flowed through the device, ASW flow was stopped and the 
microvalves opened. Small pieces of silicone tubing connected the pressure channels to an in-
house built solenoid valve system. Prior to cell loading, each pressure channel was filled with 
water to prevent bubble formation in the channels. If bubbles entered the channels, a small 
amount of negative pressure was applied to the channel to remove them. During each stimulation 
experiment, cells were visualized to monitor cell viability with an inverted fluorescence 
microscope (Carl Zeiss, Inc. Peabody, MA). 
 
3.3.5 Sample preparation and mass spectrometric detection  
Sample solutions exited the device through polytetrafluoroethylene tubing (Cole Palmer 
Instrument Company, Vernon Hills, IL) and between 10 and 20 µL of sample were collected and 
then desalted and concentrated using ZipTip C18 pipet tips (Millipore, Billerica, MA) according 
to manufacturer instructions. Briefly, the ZipTip was wetted with 100% acetonitrile (ACN), 
equilibrated with 0.1% trifluoroacetic acid (TFA) in deionized water, loaded with sample 
containing 0.1% TFA, washed with 5% methanol/0.1% TFA in deionized water, and eluted onto 
a ground steel MALDI target (Bruker Daltonics Inc., Billerica, MA) first with 50% ACN and 
then with 75% ACN solutions. Samples were then combined with 50 mg/mL 2, 5-
dihydroxybenzoic acid matrix in 1:1 acetone:water for analysis.  An UltrafleXtreme™ TOF mass 
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spectrometer (Bruker Daltonics) in the reflectron mode was used to analyze peptide releasates. 
Mass calibration was performed with peptide calibration standard II (BrukerDaltonics). Between 
500 and 1500 shots were collected per spot. Individual mass spectra were analyzed with 
flexAnalysis (version 3.3, Bruker Daltonics). 
 
3.4 Results and discussion 
 
3.4.1 Device design and fabrication  
The goal of this work was to create a small-volume cell culturing region that allows 
neuronal network formation and access to cells. Fluidics were added to enable the extracellular 
media to be exchanged with various solutions (media or stimulation solutions) and a collection 
port/channel to enable off-line sample characterization, in this case via MS. In order to enable 
temporal control of the media surrounding the cells, we used microvalve-controlled stimulation 
channels (Figure 3.1 A).  
The main and outlet reservoirs are 1 mm in diameter; this reduces dilution within the 
device while allowing for effective fluid flow. The main reservoir serves as the cell culture 
chamber and is open for cell loading (and physiological recordings, if necessary). Flow channels 
are 200 µm wide by 50 µm high and rounded; pressure channels are 200 µm wide by 100 µm 
high. Rounded channels are necessary to completely close the valve system and prevent leaking. 
These channels can be selectively opened (or closed) to allow for chemical stimulation additions 
to the cultured neurons within the device. Studies were performed with colored ink solutions (as 
shown in Figure 3.1 B) to verify that this arrangement allows fluidic isolation between the 
stimulation channels and the main channel. PDMS channels are OEGylated to reduce peptide 
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losses into the PDMS.
29
 The culture chamber is where the neurons are cultured and form the 
network.  
 
3.4.2 Cell culture  
A significant amount of chemical heterogeneity exists among different cell types, and, 
perhaps surprisingly, even among cell populations that are considered to be homogenous. One of 
the challenges in studying high-density or larger cultures is due to the small chemical differences 
that can be lost when measurement approaches report average values from within a high-density 
cell population. There are a number of reports documenting high-density cultures in microfluidic 
devices,
34-37
cbut significantly fewer protocols exist for low-density cultures. While individual 
cells can be assayed for their peptide contents using MS,
24,25,38,39
 chemical signaling requires 
multiple cells and so, sparse neuronal networks appear to be of the appropriate scale for 
investigation of signaling networks using microfluidics. For these reasons, we fabricated a device 
that is capable of maintaining low-density cultures. Each device reported here contained 10 to 20 
bag cell neurons that were removed from the animal and cultured for 24 h prior to stimulation 
experiments. A representative image of a bag cell culture is shown in Figure 3.1 C; this image 
shows the cells forming a network with putative chemical or electrical connections between the 
neurons.  Even after 1 day in vitro (DIV), neurons appeared healthy and viable with long process 
growth and network formation. Cells can be maintained for at least 12 DIV (data not shown) 
with media changes, allowing for multiple-day stimulation experiments on the same cell cluster 
in the device. 
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3.4.3 Elevated K
+
 stimulation 
Following cell culture, neurons within a device were exposed to media that was known or 
expected to cause the release of peptides. Elevated K
+
 acts as a secretagogue, which causes the 
exocytosis of neurotransmitters from a neuron through the depolarization of the cell membrane.
40
 
The addition of K
+
 to bag cell neurons and the detection of peptide release have been extensively 
studied and their subsequent peptide profiles have been widely documented.
29,41-44
 Therefore, A. 
californica provides an excellent model for validating this system; by observing known released 
peptides, we validate device function. To that end, nine different devices, with each containing a 
different network of bag cell neurons, were subjected to increasing time periods of K
+
 exposure 
(Figure 3.2). A pre- and post-control was performed on each group of neurons with ASW before 
and after chemical stimulation, respectively. ASW is a minimal culture media (as it contains the 
required inorganic ions) and should not elicit peptide release. We did not observe peptide release 
with the addition of ASW, which suggests that we did not induce release via flow-induced stress 
and motions across the culture chamber, or by damaging the cells upon chemical stimulation. 
Each neural network was exposed to elevated K
+
 for a combination of exposure times. 
For example, a group of neurons may have been exposed to K
+
 for 1 min, 3 min, 5 min, 10 min, 
and 20 min, or a subset of these exposure times, sequentially, with ASW as the pre- and post-
control. Following stimulation exposure, the microvalves were closed and ASW was flowed 
through the device until the total time reached 40 min, allowing any released peptides to be 
washed out of the device for collection. Solutions were collected twice during the 40 min period 
to gain additional temporal release information. After collection, samples were desalted and 
concentrated with C18 pipet tips and eluted onto a MALDI target for analysis.  
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In this study, nine different groups of bag cell neurons, each in separate devices, received 
increasing periods of K
+
 stimulations and peptide release was detected. The resulting mass 
spectra were collected twice during each exposure time. Figure 3.2 shows a representative series 
of intensity-normalized mass spectra following 1, 3, 5, and 10 min exposures to K
+
. A number of 
well-studied peptides were detected following 5 min of K
+
 exposure, demonstrating that a 5 min 
exposure is sufficient to cause release. In general, peptide release was observed in both 20 min 
collections after the 5 min stimulation period (n = 4; out of seven devices where peptide release 
was observed). Peptides were not observed in the pre- and post-conditions, indicating that the 
shear stress caused by flow does not stimulate or lyse the cells. Due to its relatively good 
detection limits compared with the other egg-laying hormone-related peptides, the detection of 
acidic peptide (m/z 2959.5) at S/N ≥ 5 was used to indicate when peptide release had occurred. 
Figure 3.3 shows the percentage of the time that acidic peptide was detected versus the elevated 
K
+
 exposure time.  
Regardless of previously applied K
+
, exposure to 5 min of K
+
 resulted in the observance 
of release 80% of the time, whereas, when the same neurons were exposed to K
+
 for a shorter 
period (< 5 min), release was detected less than 50% of the time. This demonstrates that 
exposure times of less than 5 min usually did not elicit release. For subsequent exposure periods 
(> 5 min), acidic peptide detection decreased. In part, this decrease is due to the refractory period 
that bag cells enter following release.
44
 During this period, regardless of the length of stimulation 
applied, the cells are not able to sustain peptide release. Since bag cell neurons are involved in 
reproduction, this refractory period is consistent with the fact that the animals can only lay eggs 
periodically. Furthermore, this shows that the temporal resolution of our platform is able to 
capture both the onset of peptide release and the refractory period after release. We did observe 
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differences in the temporal aspects of release between experiments, which may represent 
differences in the release dynamics between individual animals.  
 
3.4.4 Insulin stimulation  
Elevated K
+
 is a general secretagogue that causes release of vesicles (including dense 
core vesicles containing peptides) in a neuron through the depolarization of the cell membrane. 
Therefore, it should elicit release from most, if not all, neuronal subtypes. In contrast with the 
depolarization caused by K
+
, which directly affects potassium channels, insulin is a cell-specific 
chemical stimulation that is internalized through the phosphorylation of receptor tyrosine 
kinases.
45,46
 Therefore, cells without this receptor will not respond to insulin application. 
Previous studies have shown that bag cell neurons contain insulin receptors.
47
 Unlike the widely 
accepted model of neurotransmitter exocytosis, which involves the influx of external Ca
2+
, bag 
cell neurons are unusual because the release of intracellular Ca
2+
 (such as caused by insulin 
exposure) is enough to result in peptide secretion.
48
 The application of 5 µM of mammalian 
insulin causes peptide release through such an extracellular Ca
2+
-independent process.
48
 While 
the structure of mammalian insulin is distinct from Aplysia insulin peptides, it is similar enough 
to still function in Aplysia.
39,47,48
 To demonstrate that the networks maintained in our device 
exhibit a similar physiology to semi-intact animals in previous reports,
39,47,48
 and to document 
that small numbers of bag cell neurons in our reduced network respond to insulin (something not 
shown before), nine additional devices, each containing a distinct network of bag cell neurons, 
were exposed to increasing periods of insulin to determine the temporal dynamics of peptide 
release. In contrast to K
+
, 20 min of insulin exposure was necessary to detect peptide release. 
The slower response is not surprising given that insulin-evoked release may require peptide 
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internalization, a process that is expected to take longer than the release induced via potassium 
ions.  
In addition to acidic peptide, a number of egg laying hormone-related peptides were 
detected (Figure 3.4). It was previously reported that internal Ca
2+
 increases within 5–20 min of 
exposure to insulin.
48
 Our data agrees with this; at least 20 min was necessary for peptide release 
to occur. Furthermore, in the majority of devices where release occurred following 20 min of 
insulin exposure, peptides were only observed in the first collection (n = 4; out of 7 devices 
where peptide release was observed). Devices where peptides were collected in both 20 min 
collections, signal intensities were at least 2.5 times greater in the first collection (n = 3; out of 7 
devices where peptide release was observed). 
Jonas et al.
48
 showed that the egg-laying hormone (which is stored in the same 
peptidergic vesicle that contains acidic peptide) was released following insulin application. 
However, their use of radioimmunoassay required the pre-selection of one particular peptide of 
interest. MS allows us to view an entire complement of released peptides. The egg laying 
hormone prohormone, the source of these peptides, has a tetrabasic site that is cleaved prior to 
vesicle packaging, resulting in the N- and C-terminal ends of the prohormone being packaged 
into distinct vesicles.
49
 The α, β, and γ- bag cell peptides are located near the N terminus of the 
egg laying prohormone, and acidic peptide and egg laying hormone are located near the C 
terminus, and each are packaged into these two peptide-containing vesicle populations. We 
observed both N- and C-terminal peptides, indicating that both types of vesicles are released 
upon insulin stimulation, at least under our culturing conditions. Furthermore, insulin [M + 
2H]
2+
was observed for all exposure periods. This demonstrates that the stimulation solution fills 
the device in the time allotted for exposure.  
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Acidic peptide detection versus exposure time was again plotted to show the amount of 
insulin exposure time necessary for peptide release. Our observations were robust, with acidic 
peptide being detected 88% of the time following 20 min of exposure, whereas release was 
detected less than 50% of the time following a shorter insulin exposure. Similar to the refractory 
period seen with K
+
 stimulations, we observed fewer peptides in the 30 min exposure period.   
In the study done by Jonas et al.,
48
 entire bag cell clusters, each containing hundreds of cells, 
were perfused with insulin for 70 min. They found that the amount of insulin-induced peptide 
release was similar to that of an afterdischarge. Their application of electrical stimulation would 
resemble our application of K
+
, in that both trigger action potentials and an afterdischarge. Here, 
we show our ability to see peptide release following both K
+
 and insulin exposure. However, our 
microfluidic valve system enables release studies from significantly fewer cells with higher 
temporal resolution. This increase in temporal resolution shows that two similar peptide releases 
(in terms of amount and peptide content) have different kinetics and, presumably, biochemical 
pathways. 
 
3.5 Conclusions 
Overall, this approach can maintain a neuronal culture and detect peptide release 
following appropriate physiological stimulations. The difference in exposure time necessary to 
elicit peptide release between K
+
 and insulin demonstrates that by further controlling the 
microenvironment, we can gain a greater understanding of the conditions necessary for peptide 
release to occur. This knowledge increases our ability to apply essential molecules of repair to 
restore function to a damaged neural network. The ease of fabrication and cell culture, as well as 
the coupling to MS, make this device readily amenable to many neuronal types.  
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The system demonstrated here can be extended to work with other cell types and culturing 
platforms to enable the interface of culturing, stimulation and release characterization.  Potential 
enhancements include the ability to quantify the amount of peptides released such as via the 
approach for Zhong et al.,
29
 or other direct MS approaches such as the method described by 
Rubakhin and Sweedler.
50
 In addition, via appropriate interfacing to CE-LIF
51-53
 and CE-MS,
54,55
 
more complete characterization of the extracellular media can be performed.  Finally, as this 
system is transparent and contains an accessible culturing platform, future efforts can include 
Ca
2+
 imaging or electrophysiology to enable a new range of studies on neuronal release 
dynamics. 
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3.6 Figures 
 
 
Figure 3.1. (A) Schematic of the device, 8 mm wide, 8 mm long and 2 mm high. Bottom layer 
(blue) denotes the flow channels whereas the top layer (red) denotes the pressure channels. (B) 
Image of an ink solution in the stimulation channels with both valves closed. Ink is not observed 
in the main channel, indicating that valves fluidically isolate stimulation solutions from the main 
channel. Scale bar = 500 µm. (C) Representative bag cell culture after 1 DIV. Neurons cultured 
in the device appear viable and form networks. Scale bar = 100 µm. 
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Figure 3.2. Series of representative mass spectra of bag cell neuron peptide release following 
KCl stimulation at increasing stimulation exposure times. A number of previously identified 
peptides from the bag cell neurons were observed following 5 min of exposure to KCl (βBCP, 
m/z 728.4; αBCP1-7, m/z 922.5; αBCP, m/z 1122.6 ; AP, m/z 2959.5; pELH30-43, m/z 1471.8; 
δBCP1-36, m/z 4022.7; δBCP, m/z 4406.9).  Right of MS, an example of a time course for the 
chemical stimulation protocol series. Red bars represent chemical stimulation addition; gray bars 
indicate ASW addition. Each exposure was 40 min in duration with stimulation time and ASW 
addition varying. Two collections were done during each exposure time at t = 20 min and t = 40 
min.  
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Figure 3.3. Percentage of the time that acidic peptide (m/z 2959.5), a known peptide of the bag 
cell neurons from Aplysia californica, is detected versus stimulation exposure time for KCl and 
insulin. The n represents the number of distinct repeats (individual devices containing a distinct 
network of neurons) used that were stimulated for the indicated time. Stimulation time courses 
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Figure 3.3 (cont.) were varied to demonstrate that peptide release is independent of previously 
applied stimulations to the cells.(Top) Five min of KCl exposure time was necessary to elicit 
peptide release 79% of the time. (Bottom) Twenty min of insulin exposure was necessary to 
elicit peptide release 88% of the time. 
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Figure 3.4. Representative mass spectrum of peptide release following 20 min of insulin 
exposure (αBCP1-7, m/z = 922.5; αBCP, m/z = 1122.6; AP8-27, m/z = 2316.2; AP, m/z = 2959.5; 
δBCP1-36, m/z = 4022.7; δBCP, m/z = 4406.9)  
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CHAPTER 4 
CHARACTERIZATION AND PEPTIDOMIC STUDY OF DORSAL ROOT 
GANGLIA CULTURE 
 
4.1 Notes and acknowledgments  
 
 This study involves collaborative efforts with Emily Tillmaand, Elena Romanova, 
Stanislav Rubakhin and Ning Yang in the Sweedler group, and Anika Jain in Martha Gillette’s 
lab. The method used for DRG isolation and culture was adapted from notes from a former group 
member, Amy Maduram. Stanislav Rubhakin removed the DRG tissue from the rat. I performed 
the majority of the isolations, culture, immunostaining, and MALDI profiling with assistance and 
discussions from both Emily and Anika. Elena Romanova assisted with capillary LC-MS runs. 
Ning Yang performed the FT-MS measurements; this work is ongoing and will lead to a more 
complete understanding of the peptide complement of these cells. This work was supported by 
PHS 1 R01 DE018866 and DMI0749028. 
 
4.2 Introduction 
 Sensory information within the mammalian nervous system is conveyed from the 
periphery to the spinal cord and brain stem via sensory neurons. Many sensory neurons are 
located in the Dorsal Root Ganglia (DRG) on the posterior root of each spinal nerve.
1,2
 A single 
axon extends from the soma and bifurcates, sending one process to the dorsal region of the spinal 
cord, while the other process extends peripherally to innervate the skin, muscle, and internal 
organs.
1,3,4
 The DRG consists of a heterogeneous population of cells which vary in morphology, 
necessary trophic factors, and chemical and receptor content.
2
 Axons are both myelinated and 
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unmyelinated, generally corresponding to large diameter, and intermediate and small diameter 
neurons respectively.
5
 DRG neurons innervate a number of target organs, and are involved in 
mechanoreception, limb proprioception, thermoreception, and nociception acting at the majority 
of the body surface and most muscles and joints.
5,6
 Positioned as a bridge between the central 
and peripheral nervous systems, DRG neurons serve as an excellent model for studying both 
injury and regeneration, and pain. 
 The absence of growth factors, unfavorable topography, and the presence of inhibitory 
molecules impedes regeneration in the CNS.
7
 In contrast, peripheral axons readily regenerate 
following mechanical damage. Significant work has reported studying the trophic factors, 
neuropeptides, neurotransmitters, and cytokines involved in regeneration in the PNS.
3,5,7
 Once 
identified, several trophic factors and other compounds have been applied to inactivate inhibitory 
molecules, improving regeneration in the dorsal root entry zone (DREZ), which is the region 
connecting the PNS to the CNS.
3,7
 Lesions of peripheral nerves can lead to dysfunction and can 
lead to the chronic pain condition known as neuropathic pain. 
 The DRG is directly involved in both types of pain, nociceptive and neuropathic. 
Nociceptive pain is the pain experienced following an intense or noxious signal, which is relayed 
by sensory neurons transferring information from the periphery to the spinal cord and brain.
8
 
Neuropathic pain is chronic pain produced from lesions or dysfunction of nerves and can be 
maintained by a number of different mechanisms in the absence of stimulation.
8
 The 
involvement of the DRG in both processes lends it to be an excellent model for studying the 
chemical signaling involved in pain. 
While much is known about the overall role of the DRG in regeneration and pain, fewer 
studies have investigated the specific nature of cell signaling in the DRG during normal 
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functioning, pain signaling, and regeneration. Neuropeptides are an important class of signaling 
molecules within the nervous system. Neuropeptides are peptides synthesized in neurons that 
play a role in a wide range of physiological processes from learning and memory
9
 to sleep
10,11
 
and pain.
2,12
 Neuropeptides have also been implicated in a number of diseases and disorders 
including depression
9,13,14
 and epilepsy.
15
 Roughly 40% of the DRG cell population consists of 
peptidergic neurons, which are further subdivided based on peptide content.
1,2
 A number of 
neuropeptides have been identified within the DRG including substance P, calcitonin gene-
related peptide (CGRP), cholecystokinin (CCK), and dynorphin and individual neurons can 
contain all or a subset of these peptides.
9
  
Substance P is the best characterized neuropeptide found within the DRG, and is released 
in response to inflammation in the CNS, and increasing vascular permeability following an insect 
sting.
2
  Less information exists about the release of other neuropeptides present in the region, 
including CGRP, CCK, VIP, neuropeptide Y, galanin, and dynorphin.
16
 In contrast to classical 
transmission, neuropeptide release often follows high-frequency or burst stimulation and can 
affect changes in either local or distant targets in the nervous system.
17
 Identifying additional 
peptides present in the DRG and understanding the conditions that govern peptide release will 
give key insight into the chemical signaling involved in normal network formation and function. 
This information can then be employed to better understand pain and injury states.  
Several analytical approaches are employed in the study of peptide release. Liquid 
chromatography-mass spectrometry (LC-MS) and radio- and enzyme- immunoassays are the 
characterization methods of choice for studying peptides.
18-25
 However, effectively sampling 
from a neuron population is less straightforward. While sampling directly from DRG neurons 
with microdialysis in vivo is possible, such a study would be limited by spatial resolution, and 
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could be susceptible to averaging peptide signals among the heterogeneous cells, especially for 
low-abundance analytes. Isolating DRG neurons and culturing them in vitro can greatly reduce 
analyte averaging. Dish based approaches have provided a wealth of information pertaining to 
cell growth and morphology. However, the large volumes associated with dish cultures greatly 
increase dilution of any release peptides, making detection difficult. We have previously reported 
a microfluidic device that is capable of culturing and maintaining neurons, temporally applying 
selective chemical stimulations, and collecting peptide release.
26
 The design consists of two 
microvalve controlled stimulation channels, which can add varying amounts of chemical 
stimulations to neurons cultured within the device. Following collection, samples are 
characterized by a matrix assisted laser desorption ionization time of flight MS (MALDI-TOF). 
By gradually increasing chemical exposure length to a low-density Aplysia  californica culture 
within the device, a robust difference in the onset of peptide release for two different chemical 
stimulations was observed.  
Here, we work towards employing the same device system to investigate peptide release 
from a normal functioning DRG. A robust and well-characterized DRG culture was established. 
Cells were cultured and maintained on a variety of substrates including glass, indium tin oxide 
(ITO), and PDMS. Immunohistochemical staining confirmed healthy, viable process growth, and 
the presence of glia. MALDI MS profiling confirmed the presence of ion signals within the 
peptide region from a fixed DRG culture. DRG cultures were then grown in PDMS punches and 
were stimulated with elevated potassium. A number of peaks were observed following chemical 
stimulation that were not detected after control additions. A full peptidomics study of the DRG 
has not been reported. In order to confirm the identity of peptides found within profiling and 
release experiments, an LC-MS/MS peptidomic study of DRG tissue, cells, and release was 
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performed. Over 550 peptides from 390 unique proteins were identified from tissue extracts, cell 
extracts, and release collections. Furthermore, several known hemoglobin-derived peptides were 
observed. Classifications of identified peptides for each sample are discussed.  
 
4.3 Experimental 
 
4.3.1 Materials and reagents 
Chemicals were purchased from Sigma Aldrich (St. Louis, MO) and solvents were 
purchased from Fisher Scientific (Fairlawn, NJ) unless otherwise noted. The 
polydimethylsiloxane (PDMS) prepolymer kit, Sylgard 184, was purchased from Dow Corning 
(Midland, MI). Negative photoresist SU-8 2075 and developer were obtained from MicroChem 
Corp. (Newtown, MA). Positive photoresist AZ 4620 and developer were from AZ Electronic 
Materials Corp. (Somerville, NJ). Poly-D-lysine (PDL) was purchased from BD Biosciences 
(Franklin Lakes, NJ). 0.25% trypsin with EDTA, Hanks balanced salt solution (HBSS) without 
Ca
2+
 and Mg
2+
 and phenol red, fetal bovine serum (FBS), neurobasal A without phenol red, B-
27, GlutaMAX, Penicillin-Streptomycin, phosphate-buffered saline (PBS), and nerve growth 
factor (NGF) were purchased from Life Technologies (Carlsbad, CA). 0.25% type 2 collagenase 
was obtained from Worthington Biochemical Corp. (Lakewood, NJ). Brain derived growth factor 
(BDNF) was purchased from Prospec Bio (Rehovot, Israel). Primary antibodies used in this 
study included chicken polyclonal to GFAP (Abcam, Cambridge) and rabbit polyclonal to MAP2 
(Millipore, Billerica). Secondary antibodies were obtained from Life Technologies and included 
Alexa Fluor 488 goat anti-chicken IgG and Alexa Fluor 594 goat anti-rabbit IgG.  
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4.3.2 Device fabrication 
The device system was fabricated as described elsewhere.
26
 Briefly, the device design 
consists of two separate layers- the flow channel, for fluid control, and pressure channel, for 
controlling the valve system. The flow channel master was prepared by spinning and curing 
AZ4620 photoresist to a height of 25 μm. The master was heated to 200°C for 20 min to create 
rounded channels. Octadecyletrichlorosilane was evaporated onto the wafer to assist in the 
removal of PDMS from the substrate.  Uncured 20:1 PDMS was poured onto the flow master 
and spun at 2050 rpm for 60 s. The PDMS was incubated at 70°C until partially cured. The 
pressure channel consists of a 100 μm height SU-8 2075 photoresist. Small pieces of silicon 
tubing (Helix Medical, Carpinteria, CA) were glued onto the features of the pressure channel 
master. 5:1 PDMS was poured onto the master and was cured at 70°C just until set. Both the 
pressure and flow channel PDMS blocks were then aligned and cured together at 90°C overnight. 
Reservoirs were made with biopsy punches (Acuderm, Inc., Ft. Lauderdale, FL) to 1 mm. The 
PDMS device was then adhered to a glass coverslip and uncured PDMS was poured around the 
device to prevent leaking. Pressure channels were connected to an in-house built pneumatic 
solenoid valve system that is controlled by LabView software (National Instruments, Austin, 
TX). The program controls the application or removal of pressure to the pressure channels for 
closing or opening the channels, respectively. 
 
4.3.3 Cell culture protocol 
 In accordance with the University of Illinois Institutional Animal Care protocols, 
Sprague-Dawley male 21-28d post-natal rats (N=6, Charles River, St. Constant, QC) were 
sacrificed and their dorsal root ganglia were rapidly dissected and isolated from lumbar and 
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thoracic spinal cord vertebra in ice-cold Hibernate-A (BrainBits) solution. Within 24 h of 
isolation, DRG were pelleted for 20 sec at 1.1 RPM and Hibernate-A media was replaced and 
incubated at 37 °C in 0.25% with collagenase solution for 1.5h, which was part one of the 
proteolytic digestion. The DRG were then spun down again and the collagenase was replaced 
with a Hank’s Balanced Salt Solution (HBSS) wash step. Cells were again pelleted and HBSS 
was replaced with the second proteolytic digestion- 0.25% trypsin with EDTA for 15 min. 
Following centrifugation, the trypsin was replaced with Neurobasal A media and 1% Fetal 
Bovine Serum for 50 sec to inactivate the trypsin. The cell pellet was triturated and the 
supernatant was removed and pelleted down. An HBSS wash step replaced the Neurobasal A and 
FBS media, and the dissociated cell bodies were reconstituted in serum-free media containing 
Neurobasal A, 100 U/mL penicillin/streptomycin, 0.5 mM glutamax, 50 ng/mL NGF, 50 ng/mL 
BDNF, and 500 µL B27. DRG were housed in a humidified incubator set at 37 °C and 5% CO2 
for 7 days. Prior to cell plating, glass coverslips were treated with concentrated H2SO4 for 24 
hours to remove any contaminants and were thoroughly washed with distilled water. ITO slides 
and PDMS were sterilized by placing in an O2 plasma cleaner for 30 sec at 100 W. PDL and 
laminim was then incubated on the glass coverslips, ITO, and PDMS punches for at least 1 hour. 
10 to 15 minutes before seeding, the PDL/ laminin solution was replaced and washed with DRG 
media. DRG neurons could be maintained on ITO substrates, PDMS, and glass coverslips for at 
least 7 days. 
 
4.3.4 Immunohistochemical staining 
 DRG media was replaced with 4% paraformaldehyde (Ted Pella,CA) to fix the cell 
culture for 15 to 20 min at room temperature. The culture was then rinsed with PBS (five times, 
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last rinse five min). The PBS rinse was replaced with 0.3% Triton X (Sigma) for 10 minutes to 
permeabilize the neurons. Following another PBS wash step (five times, last rinse five min), a 
5% normal goat serum (NGS) blocking agent was added for 30 min. Another PBS wash step was 
performed (five times, last rinse five min), and the culture was incubated in the primary antibody 
with 2% NGS for 1 hour. A fourth wash step (five times, last rinse five min) was performed, and 
then the culture was incubated in the secondary antibody and 2% NGS for 1.5 hours. Following a 
fifth wash step (five times, last rinse five min), the culture was briefly washed with DI water and 
was mounted with ProLong Gold Antifade (Life Technologies) onto a glass slide. Slides were 
wrapped tightly with foil and were kept at 4°C prior to imaging with a Zeiss LSM 510 META 
confocal nicroscope (Carl Zeiss AG, Oberkochen, Germany). 
 
4.3.5 Mass spectrometry profiling 
 Mass spectrometry profiling was prepared as reported elsewhere.
27
 Briefly, a DRG 
culture was maintained on an ITO glass microscope slide for 7 DIV. Media was gradually 
replaced with a 33% collagenase solution for and was incubated for 1 hour. Following a brief 
wash in 150 mM sodium acetate, the substrate was carefully dried with N2 gas. A 20 mg/mL 2,5-
dihydroxybenzoic acid (DHB) in 1:1 ACN: Water solution was airbrushed onto the slide and 
loaded into and profiled with an UltrafleXtreme MALDI-TOF-MS (Bruker Daltonics, Bremen, 
Germany). Data analysis was performed with flexAnalysis (Bruker Daltonics).  
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4.3.6 Tissue, cell, and release extractions 
 
4.3.6.1 Tissue Extraction 
For LC-MS analysis, tissue and cell extracts were prepared as reported elsewhere. 
Briefly, 20-30 DRGs from two rats were isolated and placed in ice-cold 12 mM HCl in a glass 
homogenizer. After homogenization, tissue extracts were centrifuged and the supernatant was 
collected. The acidic solution was then filtered and concentrated using solid phase extraction 
(Supelco, Bellefonte, PA). Filteredsamples were removed by evaporation in a SpeedVac 
concentrator (Thermo Scientific, San Jose, CA). Peptide content was evaluated by MALDI-TOF-
MS sampling of 0.5 µL. The sample was then subjected to fractionation by an LC-Breeze 2 
(Waters, Milford, MA) followed by LC-MS/MS separation on two separate platforms- an 
capillary LC Ultimate 3000 (Dionex, Sunnyvale, CA) coupled to an ion trap tandem MS 
AmaZon ETD (Bruker Daltonics) and an LC Eksigent 1D Plus (AB Sciex, Framingham, MA) 
coupled to a 11Tesla Finnigan LTQ_FT (Thermo Electron Corp., Waltham, MA; FT-MS). 
 
4.3.6.2 Cell Extraction 
 Cell extraction method involved isolating cells according to cell culture protocols. Instead 
of suspending cells into DRG media, the cells were placed in ice cold 12 mM HCl and were 
homogenized using a rounded-edge Pasteur pipet or tungsten needles. Extracted solutions were 
then centrifuged and the supernatant was enriched using Microcon filters (Millipore, Billerica, 
MA). Samples were then dried down in a SpeedVac concentrator and peptide content was 
evaluated by MALDI-TOF-MS sampling of 0.5 µL. The sample was then sequenced using both 
the capillary LC-MS, and by the FT-MS system.  
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4.3.6.3 Release Collections 
 A 1:0 PDMS block was made and 2 mm in diameter punches were created using a biopsy 
punch. The punch was treated with O2 plasma and was adhered to a H2SO4- treated glass 
coverslip. A high-density cell culture was prepared according to the above method and cells were 
maintained for 7 DIV. Solutions within the well were replaced with either DRG media for 
controls or 60 mM K
+
 for stimulation. Following control or release addition, solutions were 
collected and then desalted and concentrated with C18 Zip Tips (Millipore). Samples were 
evaporated using a SpeedVac concentrator, reconstituted in 5% formic acid, and peptide content 
was evaluated by MALDI-TOF-MS sampling of 0.5 µL. Samples were then sequenced with the 
capillary LC-MS system and the FT-MS system. 
 
4.3.7 LC-MS/MS procedure 
For the FT-MS analyses, peptide extracts were separated through a 2 cm long lab-made 
trap column packed with Michrom Magic C18 5 µm beads. After sample loading, the trap column 
was flushed with solvent A (95% H2O, 5%ACN, 0.2% formic acid) at 2uL/min for 25min. The 
elution gradient started after 25min (Mobile phase A:95% H2O, 5%ACN, 0.2% formic acid; 
mobile phase B:95% ACN, 5%H2O, 0.2% formic acid). A five-step linear gradient was 
generated by mixing mobile phases A and B as follows: 0%-30% B in 80 min, 30%-45% in the 
next 35 min, 45%-60% in next 15 min, 60%-85% in next 5 min, isocratic 85% B for 10 min, 
85%-0% B for 15 min, and isocratic 0% B for 10 min. The tandem MS/MS method employed 
Top5 data dependent acquisition with collision induced dissociation. The isolation window was 
set at 10 Da with a collision energy of 35 eV and an activation time of 50 ms. 
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For capillary- LC-MS analyses, a C18 reverse phase column (Dionex, 300 µm i.d., 
particle size 3, and pore size 100 Å µm) was coupled to an AmaZon ion-trap mass spectrometer 
via an electrospray ionization source (ESI) (Bruker Daltonics, Bremen, Germany). A four step, 
linear gradient was generated by mixing mobile phase A (100% water, 0.01% formic acid), and 
B (80% acetonitrile, 20% water, 0.04% formic acid) as follows: isocratic 4% B for 5 min, 4%-
50% B for the next 50 min, 50%-85% for the next 2 min, isocratic 85% B for the next 6 min, 
85%-4% for the next 2 min, and finally isocratic 4% B for 15 min. The flow rate was 4 µL/min 
and column temperature was 45°C. Mass spectrometric detection was controlled by Hystar 
software (Bruker Daltonics) in a data-dependent approach. Tandem MS precursor selection was 
limited to 3 ions per min which were sorted by signal intensity. The preferred charge state was 
set at 2+ or greater. The scan m/z range for both MS and MS/MS was 300-2200. 
 
4.3.8 Peptide identifications 
 Peptide identifications were performed according to previously reported protocols.
28,29
 
Following capillary LC-MS/MS, tandem mass spectra were converted to .mgf file format 
(Mascot generic file) and processed using Peaks Studio 5.3 software (Bioinformatic Solutions, 
Inc., Waterloo, CA). Automatic sequencing was performed against the ipi_rat database. Post 
translational modification (PTM) parameters included acetylation, amidation, pyro-glu, pyro-gln, 
and disulfide bond, with the maximum number of PTM’s set to 2. The mass error tolerance for 
parent and fragment ions was set to0.5 Da. 
 Peptide assignments and protein confirmation was based on confidence scores reported 
by PEAKS. Peaks assigns a confidence score to each sequenced peptide based on a logarithmic 
score, which involves matching peaks and their intensities, precursor mass error, enzyme 
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specificity, de novo sequence, and peptide size (Peaks User Manual 5.3 
http://www.bioinfor.com/doc/peaks53/53.pdf). Our criteria for data selection was based on using 
a -10lgP = 15 or greater, which is equivalent to a P value of 0.01 or better.  
 For the FT-MS peptide data analysis, resulting files (.raw) were analyzed using 
ProSightPC 2.0 (ThermoFisher Scientific, Waltham, MA), which contains a software component 
named cRAWler. The cRAWler program compiles precursor mass files regarding user specified 
preferences, and then averages and interprets precursor and fragmentation to create a 
monoisotopic mass list. This information is collected into an upload file (.puf). Each .puf file is 
searched against a lab-built rat proteome, and experimental fragment masses are matched with 
theoretical fragment masses from the determined candidates.   
 
4.4 Results and discussion 
 
4.4.1 Establishing a robust neuron culture 
 The DRG contains a heterogeneous population of neurons. In addition to small, medium, 
and large cell bodies, several classes exist within the DRG which differ in chemical content, with 
roughly 40% of DRG neurons are peptidergic. Studying peptide release from the DRG 
necessitates the establishment of a healthy culture containing peptidergic neurons. A robust 
culture was optimized and characterized by MS profiling and immunohistochemical staining. 
Following dissection, DRGs were subjected to a two-step proteolytic process to break down 
tissue sheathing around the cluster of cells. Cells were suspended in serum-free DRG media, 
plated, and house in a cell incubator kept at 37°C and 5 % CO2 for the duration of the 
experiment. 
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 Neurons extended processes within several days and established putative network 
connections within 7 DIV. Figure 4.1 A shows a bright field image and a fluorescence image of 
DiA membrane label (Life Technologies, Carlsbad, CA) demonstrating long process growth. The 
DRG contains a number of other cells in addition to neurons, including glia, lymphocytes, 
macrophages, etc.
12
 Figure 4.1 B distinguishes between the neurons (green; MAP2 neuron stain) 
and other cells in the culture, which are stained with a cell nuclei stain, DAPI (blue). These 
images show the large amount of heterogeneity within the culture.  
Glia are known to assist in neuron growth and development within cultures. A recent 
study investigated neuron growth in a presence and absence of glia. Neuron growth was limited 
to 1 week in the absence of glia or glia-conditioned media, whereas neuron growth was 
maintained for over 3 weeks in co-culture conditions.
30
 This study demonstrates the importance 
of glia in helping to maintain neuron cultures. Figure 4.1 C shows the distribution of neurons and 
glia surrounding an individual DRG neuron. Cells were then isolated and cultured on an ITO 
slide. The cells were fixed and profiled with MALDI-MS imaging and a number of signals were 
identified in the peptide region, indicating the high likelihood of the presence of peptidergic 
neurons within the culture. While microfluidic devices offer a number of benefits toward cell 
culture, uncured monomers and curing agents have been known to leach into the bulk solution, 
affecting cell growth. To ensure that our DRG cultures were able to be maintained in PDMS, a 
series of punches were created in a PDMS block and cells were cultured and maintained inside 
for 7 DIV. Figure 4.2 shows long process growth and healthy cultures for a low-density DRG 
culture within the PDMS, even in small diameter punches. The 3, 2, and 1.5 mm punches were 
used for stimulation studies. Overall, a robust, healthy, and well-characterized DRG culture has 
been established. This protocol was used for all subsequent cultures. 
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4.4.2 Elevated K
+
 stimulation experiments 
 To ensure enough material and to create a list of expected peptides, released peptides 
from an entire DRG cluster were the first stimulation studies performed. Moreover, a 
comparative study can be performed between clusters and cultures to yield information about the 
peptide differences observed in vitro versus in vivo measurements, as clusters contain more intact 
connections and thus should more closely mimic the in vivo environment. Figure 4.3 shows a 
series of MALDI-TOF MS mass spectra of signals in the peptide region from a DRG cluster 
within the device. Pre- and post-controls were performed with DRG media additions. Elevated 
K
+
 (60 mM) was added for two exposure periods: 15 min and 30 min.  Several peaks appeared 
following stimulation that were not observed in the pre-control (m/z 3094.6, 4963). Furthermore, 
a number of peaks also increased in intensity from the pre-control to the stimulations (m/z 
1509.8, 2174.0, 2702.3). Finally, several peaks were found to change in the post-control from the 
stimulation solutions (m/z 3074.3, 3094.6, 4963). 
 Following cluster stimulation, a low-density DRG culture containing ~20 neurons within 
a 1.5 mm PDMS wells was stimulated with elevated K
+ 
for 30 minutes. Peptides were again 
collected and characterized with MALDI-TOF-MS.  Putative peptides were collected following 
control or stimulation addition. A series of mass spectra of signals in the peptide region are 
shown in Figure 4.4. Similar to cluster stimulation data, a number of peaks increased in intensity 
following the application of elevated K
+
, suggesting a released response to stimulation. 
Interestingly, when compared together (Figure 4.5), few peaks overlap between the cluster and 
culture stimulation data. The most probable explanation for this is that cluster data contains 
signals that are released or secreted in abundance within the tissue, shadowing lower abundance 
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peptides. By isolating a much smaller subset of the cluster into the culture, it is most likely that 
cells that contain a different chemical content were selected for in comparison to cluster data. 
The next step in this process is to confirm the presence of peptide peaks against known MS/MS 
databases with de novo sequencing. Unfortunately, while MALDI-TOF-MS is a highly sensitive 
platform and is capable of detecting very small amounts of analyte (attomoles), it lacks the 
appropriate mass accuracy to perform de novo investigations necessary for peptide 
identifications on small sample amounts such as peptide releasates. Additionally, the amount of 
material present in the release samples is typically too small for de novo identifications using 
LC-MS/MS sequencing platforms. Therefore, performing a sequencing study on released 
material is challenging with today’s sequencing platforms. Using more material should yield 
better results and peptide identification. As a full peptidomic database for the DRG has not been 
reported, the next step of this project was to work toward identifying and creating a library of 
peptides found within the DRG for future MS/MS identifications and mass-matching with 
MALDI. 
 
4.4.3 Peptidomic study of the rat DRG 
 Peptidomics refers to a characterization approach for investigating peptide content within 
a given region or cell.
20
 Peptidomic analyses typically focus on studying the native form of a 
peptide, in contrast to proteomics, which generally involves the creation of peptide fragments 
from a digestive enzyme such as trypsin.
31
 As the main focus of this project is toward identifying 
peptides and understanding release conditions within the DRG, the goal of this peptidomics 
study was to create a full library of peptides present, with a particular focus on neuronal peptides 
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and neuropeptides.  This information can then be used to confirm observed peptides in release 
measurements. 
Common peptidomics strategies involve the isolation and homogenation of tissue or cells 
in the presence of organic solvents and/or acids. A sample cleanup step is instituted to desalt and 
concentrate the extracted peptides. Depending on sample complexity, LC fractionation can be 
used to further promote peptide detection. Finally, the sample or fraction is measured and 
sequenced. MS/MS fragmentation data are then loaded into identification software programs and 
a list of putative proteins/ peptides is generated following a database serach. Throughout this 
process meticulous sampling, optimized LC separations, and suitable MS detection are 
imperative for proper peptide analysis and identification.
28
 Here, we utilize several different 
approaches for the peptidomic investigations of DRG tissue, cells, and release. Extraction 
methods began with the most material (tissue), and progressed to the least (release). 
Two LC-MS platforms were employed, with the expectation of gaining complimentary 
information from each instrument and thus, identifying more peptides. The first instrument was a 
capillary LC-ion trap- MS. This instrument performs the faster separations, possesses higher 
sensitivity detection, and has good sequencing capabilities. However, it has lower mass accuracy 
than the other instrument. The second instrument employed was an LC-FT/MS instrument, 
which is more accurate, higher resolution instrument for sequencing, but offers lower sensitivity. 
A larger amount of sample is necessary for analysis when compared to the other instrument. 
Utilizing both platforms should yield a greater number of detected peptides than using just one 
instrument. 
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4.4.3.1 Peptidomics of DRG tissue 
The best option for obtaining peptidomic data with enough material for LC-MS/MS 
sequencing was to start with whole tissue extracts. To that end, approximately 20-30 DRGs were 
isolated from 2 rats. Tissue samples were extracted and homogenized with an acidic solution. 
The sample was then centrifuged and the supernatant with the extracted peptides was desalted 
and concentrated using solid phase extraction. Samples were subjected to LC fractionation and 
putative peptides were confirmed in each fraction by MALDI. Fractions were analyzed by the 
capillary LC-ion trap- MS and the LC-FT-MS. Tandem MS data was then loaded into the Peaks 
software, which performed a de novo sequence analysis, and approximately 250 peptides were 
identified from 100 unique proteins.  
Peptides were broken down into several different classes as seen in Figure 4.6. The 
neuronal category consisted of a number of peptides related specifically to neurons or processes 
involved in neuron formation, function, and maintenance. Several noteworthy proteins within the 
neuronal category will be highlighted here. A full table of identified proteins from tissue can be 
seen in Table 4.1 A, B. The metabotropic glutamate receptor 1 was detected from tissue samples. 
Glutamate is a well-known neurotransmitter found within the DRG.
32
 Several proteins involved 
in neurotransmission and implicated in neurodegenerative diseases were identified. Complexin-1 
is known to assist in neurotransmitter transport and insulin secretion.
33
 Gamma-synuclein has 
been implicated in both Parkinson’s and Alzheimer’s disease.34 A number of proteins were 
involved in axon growth and myelination. For example, Vimentin was found in tissue extracts 
and has been known to be involved in axonogenesis, Schwann cell migration, and glial cell 
proliferation.
35
 Periaxin, a protein involved in maintenance of the myelin sheath was detected.
36
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The majority of bioactive peptides are generated from larger precursor proteins. However, in 
recent years it has been shown that bioactive peptides can also be generated from the breakdown 
of cytosolic proteins.
37
 Hemoglobin has been shown to be broken down to yield at least ten 
bioactive peptides.
38
 These Hemoglobin-derived (Hb) peptides have been found in a number of 
cells types within the body- from lens and alveolar cells to macrophages, and have also been 
found within neurons, oligodendricytes, and sciatic nerves.
38
 Several hemoglobin-derived 
peptides were observed within the tissue samples from the DRG- hemorphin-7, VV-hemorphin-
7, LVV-hemorphin-7, and a lengthened form of neokyotorphin. Furthermore, lengthened 
versions consisting of several additional amino acids of the VV-hemorphin-7 and LVV-
hemorphin-7 were observed.  While it is possible that hemoglobin could have been incorporated 
into the tissue extracts, the peptide sequence coverage does not reflect that of degradation 
coverage, for which most of the protein is accounted (Figure 4.7). Very specific regions of the 
sequence are covered, leading further credibility to the prospect of Hb-derived bioactive peptides 
within the tissue extracts.  
The four Hb-derived peptides that were observed act on opioid receptors and most have 
functions relating to antinociception. The DRG are known to be involved in nociceptive pain, 
rendering their presence in tissue to appear normal. Furthermore, Hb-derived peptides were 
shown to be one of the most abundant peptides in the brain.
37
 The peptide, LVV-hemorphin-7 
has also been shown to regulate blood pressure and play a role in learning and memory as well as 
cholinergic transmission.
38
 Neokyotorphin has been shown to be a non-opiod analgesic that is 
involved in a wide variety of processes including thermoregulation, protection from seizures, and 
antibacterial properties.
38
 Hb-derived peptides have been implicated in a number of diseases and 
thus make excellent targets for drug delivery systems. Further study into the nature of Hb-
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dervied peptides within DRG tissue and cells could yield a better understanding of neuropathic 
pain. 
 
4.4.3.2 Peptidomics of DRG cells 
 The next step towards confirming the identity of peaks within the stimulation data was to 
reduce the complexity of the sample to only study DRG cells. The DRG cells were subjected to 
the same steps reported for the DRG culture. Unlike the tissue extracts, cells were isolated from 
tissue and then subjected enzymatic digestion, wash steps, and trituration. Isolated cells were 
extracted in acid with a rounded-end Pasteur pipet and tungsten needles. Cell extracts were 
desalted and concentrated with spin columns. Since the sample was less complex than the tissue 
samples, cell extracts were then analyzed directly by all three instruments. Data from the 
capillary- LC-MS were loaded into the Peaks software and searched against the IPI rat database. 
FT-MS database searches were performed using a laboratory constructed library.  
In total, 230 peptides were identified from 100 unique proteins. Figure 4.8 shows the 
distribution of peptides found within the cell extract data. Here, a much larger component of the 
peptides are classified as neuronal. A major portion of the neuronal category for the cell data 
pertains to neurofilaments. Neurofilaments are a major component of the neuronal cytoskeleton, 
and thus should be present in a culture that contains many neurons. Similar to tissue extracts, 
vimentin and gamma-synuclein were both identified, as well as myelin basic protein, a protein 
believed to be important in myelination of neurons. A full table listing the peptides identified in 
this study can be seen in Table 4.2. Two Hb-derived peptides were found to be present in the cell 
extracts- hemorphin-7 and LVV-hemorphin-7.  Figure 4.9 shows a Venn diagram comparing the 
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number of unique peptides between the tissue, cell, and release samples. Interestingly, very few 
peptides were shared among all three samples and between individual samples.  
 
4.4.3.3 Peptidomics of DRG culture release 
 Obtaining enough material for a peptidomic study of released material is challenging. 
However, by increasing cell density and collecting in small wells, a number of peptides were 
identified from releasate collections. DRG cells were grown within a 2 mm PDMS well and both 
control (DRG media) and stimulation (60mM K
+
) solutions were added to the culture. Samples 
were collected and enriched with C18 pipet tips and releasates were analyzed by the capillary-LC-
MS and the LC-FT-MS system. The capillary LC-MS system did not yield any peptides from the 
sample. However, 107 peptides from 90 unique proteins were identified with the FT-MS system. 
Figure 4.10 shows the breakdown of identified peptides in each release sample- pre, stimulation, 
and post. Many unique peptides were observed during each collection. A full table listing of 
identified peptides can be seen in Table 4.3 A-C.  
 Both LVV-hemorphin-7 and VV-hemorphin 7 as well as two longer fragments of both 
peptides were observed following pre-stimulation and stimulation additions. Several different 
classes of peptides were also identified, including serum albumin peptides, as well as those 
involving neuronal processes like neuferricin and neurotrypsin. Neuferricin is involved in 
neurogenesis,
39
 and neurotrypsin has been implicated in mental retardation.
40
 The classification 
of each sample- pre, stimulation, and post, is shown in Figure 4.11.  
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4.5 Conclusions and future work 
 The DRG plays an essential role in transmitting information from the periphery to the 
spinal cord, and it is uniquely poised for investigations into the nature of pain and injury and 
regeneration. To better understand more complex issues, a proper understanding of normal DRG 
functioning is required. Here, we have presented significant data towards better understanding 
neuropeptides present within the DRG and the conditions that govern their release. A robust, 
healthy, and well-characterized culture was demonstrated. Both cluster and culture chemical 
stimulations were performed and a number of peaks appeared to change in intensity between 
stimulations. Finally, we have performed a large-scale peptidomic study of the DRG, 
investigating tissue, cell, and release samples. In total, 558 peptides from 390 unique proteins 
were identified. Using two sequencing platforms allowed us to obtain complimentary 
information from each sample, resulting in more peptide identifications. Known Hb-derived 
bioactive peptides which target opiod receptors and are involved in antinociception were 
identified in all three samples.  Finally, over 50 unique peptides related to neurons were 
identified. 
While many different peptides were identified within this peptidomic study, no known 
neuropeptides were found. One possibility for not observing peptides is that both tissue and cell 
samples contain a heterogeneous population of cells, including macrophages and glia in addition 
to neurons. Approximately 40% of neurons contain neuropeptides, resulting in low levels of 
neuropeptides within our sample collections. By working to further isolate out neurons from 
tissue samples, we should greatly improve neuropeptide detection.  
The most likely reason for the lack of identified neuropeptides pertains to the fact that 
neuropeptides present in the peptidomics samples were at significantly lower levels than the 
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level of high-abundance proteins which result from protein degradation following dissection.
20,41-
43
 Many of the peptides identified here have been reported by other studies of brain tissue as 
protein degradation peptides.
41,42
 In order to mitigate degradation, several groups have reported a 
significant decrease in ex-vivo protein fragments following microwave irradiation or tissue 
stabilization involving heat and pressure. For example, Che et al. were able to observe 2-3 times 
more neuropeptides within the hippocampus following microwave irradiation.
41
 The same study 
also revealed a large number of peptides derived from hemoglobin. However, unlike the study 
presented here, a large extent of sequence coverage was observed within the non-microwaved 
samples. When samples were microwave-irradiated, many of the hemoglobin peptides did not 
appear and those that did were not known bioactive or longer forms of bioactive peptides. The 
Andren group reported a novel instrument which can stabilize and inhibit protein degradation in 
both freshly-isolated and frozen tissue samples.
42
 When comparing this new stabilization 
approach, microwave-irradiated, and flash-frozen samples treated with protease and phosphatase 
inhibitors, a significant number of protein degradation products were observed in the flash-
frozen samples and substantially less were observed in both stabilized and microwave-treated 
tissue samples. This demonstrates the importance of reducing and eliminating ex vivo protein 
degradation.  
To that end, a current study is underway which focuses efforts toward reducing protein 
degradation and identifying neuropeptides. Our present method applies immediate heat-treatment 
to DRG tissue to denature proteases prior to extraction. The first part of the extraction method 
involves boiling tissue in water for 10 minutes in an aqueous extraction solution. Second and 
third extractions involve slightly acidic and acidified acetone extractions, respectively, to extract 
the greatest number of neuropeptides. Samples are currently being sequenced. Future work may 
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add a micro-wave irradiated extraction method similar to that described above if neuropeptides 
are not identified. Furthermore, cell extracts will focus on reducing other cells within the culture 
and centering peptidomics studies on neurons. When possible, peaks observed in stimulation data 
will be compared to peptiomics database to identify and verify the peptides. 
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4.6 Figures and tables 
 
Figure 4.1 A. Left. Fluorescence microscopy image of Dye A membrane label of DRG culture. 
Right. Bright field image of DRG culture. B. Immunohistochemical fluorescence microscopy 
images of DRG neurons and cell nuclei on a glass coverslip. Left. MAP2 neuron stain. Middle. 
DAPI nuclei stain. Right. Ensemble image with zoomed in region.  C. Immunohistochemical 
fluorescence microscopy images of individual DRG neuron. Red = MAP2 neuron stain. Green = 
GFAP glia stain. 
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Figure 4.2 Fluorescence and fluorescence/ bright field composite images of DRG neuron culture 
within 3, 2, 1.5, and 1 mm PDMS punches following stimulation with elevated potassium. Green 
= MAP2 neuron stain. 
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Figure 4.3. Mass spectrum of DRG neuron cultured on ITO substrate. A number of signals 
within the peptide region were detected. 
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Figure 4.4 Series of mass spectra showing signals within the peptide region following control 
and stimulation additions to an entire DRG cluster. Peaks which increased in intensity or 
appeared are highlighted with an asterisk. 
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Figure 4.5 Series of mass spectra of putative peptides collected from ~20 DRG neurons within a 
1.5 mm PDMS well. Pre- and post- controls were performed with DRG media; Elevated K
+
 was 
added as a chemical stimulation to induce peptide release. 
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Figure 4.6. Mass spectra comparing peaks from stimulation collections from cluster (maroon) 
and culture (blue). While a number of signals in the peptide range are observed for both samples, 
very few peaks overlap. 
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Classification of Peptides Identified from Tissue Extracts 
 
Classification of Peptides Identified from Cell Extracts 
 
Figure 4.7 Two pie charts demonstrating the different classes of peptides found within tissue 
(top) and cell extracts (bottom).  
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Figure 4.8 Peptide sequence coverage of two subunits of hemoglobin- Beta-1 subunit (top) and 
the Alpha ½ subunit (bottom).  
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Figure 4.9 Venn diagram comparing shared and unique peptides identified in all three samples- 
tissue, cells, and release. 
 
 
Figure 4.10 Venn diagram demonstrating shared and unique peptides identified from release 
collections. 
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Figure 4.11 Three pie charts showing classifications of identified peptides from DRG release 
collections for pre, stimulation, and post samples.  
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Table 4.1A 
Peptides Identified from Tissue Extracts using FT-MS 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
Accession 
Number 
10 kDa heat shock protein, 
mitochondrial 
AGQAFRKFLPLFDR 1706.93 1664.92 24611.4 1.91E-7 P26772 
40S ribosomal protein S19 
PGVTVKDVNQQEFVRALAAFLKKSGK
LKVPEWVDTVKLAKHKELAPYDENW 
5819.16 5819.16 -0.8 7.01E-7 P17074 
40S ribosomal protein S5 TEWETATPAVAETPDIKL 2012.99 1970.98 20868.6 3.26E-24 P24050 
ADP/ATP translocase 1 GDQALSFLK 1019.528 977.518 41205.9 7.07E-16 Q6P9Y4 
ADP/ATP translocase 1 GDQALSFLKD 1134.56 1092.55 37027.2 1.82E-14 Q6P9Y4 
Alanine—tRNA ligase, cytoplasmic FANAGMNQFKPIFL 1596.81 1596.81 -1.29 1.25E-13 P50475 
Aldose reductase 
IRFPIQRNLVVIPKSVTPARIAENFKVF
DF 
3514 3514 0.84 3.24E-15 P07943 
Alpha-2B adrenergic receptor GVPTSAKVPTLVSPLSS 1638.93 1638.92 6.12 4.67E-10 P19328 
Alpha-crystallin B chain MDIAIHHPWIRRPFFPFHSPSRLFDQF 3435.72 3393.71 12227.1 2.7E-13 P23928 
Alt Splice Form 2 in Breast carcinoma-
amplified sequence 1 homolog 
GNPHGVSAGKDIVDSEERKQEVDTL 2679.32 2679.31 5.42 5.55E-15 Q3ZB98-2 
Alt Splice Form 2 in Hormone-
sensitive lipase 
DNMAFFSSQGPGETARRLSNVFAGV
REQAL 
3254.58 3254.59 -3.58 1.12E-11 P15304-2 
Alt Splice Form 4 in Myelin basic 
protein S 
DENPVVHFFKNIVTPR 1911 1911 -1.03 4.83E-24 P02688-4 
Alt Splice Form 4 in Myelin basic 
protein S 
SQRTQDENPVVHFFKNIVTPR 2511.3 2511.3 -0.86 3.45E-45 P02688-4 
Alt Splice Form MAP2b in 
Microtubule-associated protein 2 
DEELEVLMAAEAQAEPKDGSPDAPAT
PE 
2909.33 2909.31 5.37 4.56E-12 P15146-2 
Alt Splice Form OGP precursor in 
Histone H4 
DVVYALKRQGRTLYGFGG 1999.06 1999.06 -0.38 8.22E-27 P62804-2 
Alt Splice Form OGP precursor in 
Histone H4 
VVYALKRQGRTLYGFGG 1884.04 1884.04 -0.25 3.41E-26 P62804-2 
Alt Splice Form OGP precursor in 
Histone H4 
YALKRQGRTLYGFGG 1685.9 1685.9 -0.69 2.41E-19 P62804-2 
ATP synthase subunit beta, 
mitochondrial 
DEGLPPILNA 1037.54 1037.54 0.13 1.58E-12 P10719 
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Table 4.1A, continued 
 
      
ATP synthase subunit delta, 
mitochondrial 
AQAAASPAPAAGPGQMSFTFASPTQ
VF 
2623.23 2607.24 6094.07 4.61E-12 P35434 
ATP synthase-coupling factor 6, 
mitochondrial 
NKELDPVQKLFLDKIREYKAKRLASGG
PVDTGPEYQQEVDRELFKLKQMYGK
GEMDKFPTFNFEDPKFEVLDKPQS 
8921.55 8921.55 -0.23 4.02E-19 P21571 
Calreticulin WQVKSGTIFDNF 1440.7 1440.7 0.86 1.05E-22 P18418 
Complexin-1 DTVIKYLPGPLQDM 1604.81 1588.82 9966.24 4.67E-15 P63041 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
ELRPTLNELGISTPEELGL 2080.11 2080.11 1.6 1.11E-18 P11240 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
ELRPTLNELGISTPEELGLDKV 2422.3 2422.3 -1.6 4.57E-34 P11240 
Cytochrome c oxidase subunit 6A1, 
mitochondrial 
VALPGVGVSML 1057.58 1041.59 15123.4 8.07E-14 P10818 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
LTVGGTAYAIYM 1274.62 1258.63 12547.8 8.84E-10 P35171 
Cytochrome c oxidase subunit 7C, 
mitochondrial 
TVYFGSGFAAPFFIVRHQLLKK 2525.39 2525.39 -0.94 1.66E-12 P80432 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 9 (Predicted) 
LDAVIEAEHTLRELDALDANDELTPLG
RIL 
3314.73 3314.74 -2.8 3.13E-13 D4A9D6 
Desumoylating isopeptidase 1 AGCPRAIVAAATGP 1253.67 1253.66 4.81 4.48E-13 F1M410 
Doublesex and mab-3 related 
transcription factor like family A1 
(Predicted) 
MTVAALGAGASRHPGSRSVPAFEVF
QQDFAE 
3232.69 3232.57 36.82 2.54E-10 D3ZIZ0 
Elongation factor 1-gamma AAGTLYTYPENWRAFKAL 2113.05 2071.05 19878.5 3.43E-29 Q68FR6 
ES1 protein homolog, mitochondrial TELHHIHDGIGAMVKKVLELTGK 2541.37 2525.38 6293.38 2.54E-13 P56571 
Eukaryotic translation elongation 
factor 1 beta 2 
GFGDLKTPAGLQVL 1414.78 1414.78 -0.75 1.02E-13 B5DEN5 
Fructose-bisphosphate aldolase A 
PHPYPALTPEQKKELADIAHRIVAPGK
GILAADESTGSIAKRLQSIGTENTEEN
RRFYRQLLL 
7005.74 7006.75 -143.82 1.95E-17 P05065 
Gamma-synuclein SVNTVATKTVEEAENIVVTTG 2161.1 2161.11 -2.9 5.49E-26 F1LQ96 
Glutamate dehydrogenase 1, 
mitochondrial 
SEAATDREDDPNFFKMVEGF 2319.99 2304 6893.78 1.15E-13 P10860 
Heat Schock Protein 70 
VVTVPAYFNDSQRQATKDAGTIAGLN
VL 
2947.55 2947.54 2.45 4.63E-22 F1LZI1 
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Table 4.1A, continued 
 
      
Hemoglobin subunit beta-1 AGVASALAHKYH 1223.64 1223.64 -0.95 2.41E-11 P02091 
Hemoglobin subunit beta-1 DDVGGEALGRL 1100.55 1100.55 -0.51 3.95E-36 P02091 
Hemoglobin subunit beta-1 DDVGGEALGRLL 1213.63 1213.63 -1.21 8.27E-28 P02091 
Hemoglobin subunit beta-1 DVGGEALGRL 985.519 985.519 -0.47 5.89E-30 P02091 
Hemoglobin subunit beta-1 DVGGEALGRLL 1098.6 1098.6 -0.61 2.03E-27 P02091 
Hemoglobin subunit beta-1 FQKVVAGVASALAHKYH 1825 1825 -1.68 3.5E-15 P02091 
Hemoglobin subunit beta-1 
GDLSSASAIMGNPKVKAHGKKVINAF
NDGLKHLDNLKGTF 
4192.22 4192.22 0.53 4.99E-12 P02091 
Hemoglobin subunit beta-1 GKVNPDDVGGEALGRL 1595.83 1595.83 -0.54 1.23E-42 P02091 
Hemoglobin subunit beta-1 GKVNPDDVGGEALGRLL 1708.91 1708.91 -0.92 6.8E-34 P02091 
Hemoglobin subunit beta-1 KVNPDDVGGEALGRL 1538.81 1538.81 0.09 7.03E-13 P02091 
Hemoglobin subunit beta-1 KVVAGVASALAHKYH 1549.87 1549.87 -1.4 3.85E-15 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRY 1323.7 1323.7 -0.05 3.76E-25 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRYFDSF 1819.89 1819.89 -1.08 4.06E-38 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRYFDSFGD 1991.06 1991.94 -443.62 1.28E-13 P02091 
Hemoglobin subunit beta-1 NPDDVGGEALGRL 1311.64 1311.64 -0.51 4.28E-33 P02091 
Hemoglobin subunit beta-1 NPDDVGGEALGRLL 1424.73 1424.73 -1.03 6.79E-20 P02091 
Hemoglobin subunit beta-1 PDDVGGEALGRL 1197.6 1197.6 0.03 1.87E-27 P02091 
Hemoglobin subunit beta-1 PDDVGGEALGRLL 1326.67 1310.68 12055.3 8.33E-12 P02091 
Hemoglobin subunit beta-1 PWTQRY 849.413 849.413 -0.55 3.98E-16 P02091 
Hemoglobin subunit beta-1 QKVVAGVASALAHKYH 1677.93 1677.93 0.5 2.12E-23 P02091 
Hemoglobin subunit beta-1 VGGEALGRL 870.492 870.492 -0.53 2.83E-21 P02091 
Hemoglobin subunit beta-1 VGGEALGRLL 983.577 983.577 -0.88 2.05E-18 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGG
EALGRL 
3200.66 3200.66 -0.55 6.85E-83 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGG
EALGRLL 
3313.74 3313.74 -0.17 2.68E-68 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGG
EALGRLLVVYPWTQRY 
4506.34 4506.34 -0.01 2.62E-44 P02091 
Hemoglobin subunit beta-1 VNPDDVGGEALGRL 1411.71 1410.71 711.15 2.47E-10 P02091 
Hemoglobin subunit beta-1 VNPDDVGGEALGRLL 1523.79 1523.79 1.34 3.12E-10 P02091 
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Table 4.1A, continued 
 
      
Hemoglobin subunit beta-1 VVYPWTQRY 1210.61 1210.61 -0.88 6.22E-09 P02091 
Histone H2A 
ILELAGNAARDNKKTRIIPRHLQLAIRN
DEELNKLLGGVTIAQGGVLPNIQAVLL
PKKTSATVGPKAPAGGKKASQASQEY 
8516.77 8517.78 -118.72 1.5E-09 D3ZXP3 
Histone H2A 
ILELAGNAARDNKKTRIIPRHLQLAIRN
DEELNKLLGKVTIAQGGVLPNIQAVLL
PKKTESHKAKSK 
7370.25 7370.26 -1.23 3.3E-10 D4ACV3 
Histone H2A 
VGAGAPVYMAAVLEYLTAEILELAGNA
AR 
2932.54 2932.54 -0.94 6.91E-41 D4ACV3 
Histone H2A type 1 
AQGGVLPNIQAVLLPKKTESHHKAKG
K 
2849.64 2848.64 350.37 1.36E-08 P02262 
Histone H2A type 1 PNIQAVLLPKKTESHHKAKGK 2323.34 2323.35 -2.61 7.16E-15 P02262 
Histone H2A.J 
VGAGAPVYLAAVLEYLTAEILELAGNA
AR 
2914.58 2914.58 -1.22 1.31E-64 A9UMV8 
Histone H2B AKHAVSEGTKAVTKYTSSK 1992.06 1992.06 -1.69 2.66E-15 G3V8B3 
Histone H2B AVSEGTKAVTKYTSSK 1655.87 1655.87 0.63 3.27E-16 G3V8B3 
Histone H2B 
ERIAGEASRLAHYNKRSTITSREIQTAV
RLLLPGELAKHAVSEGTKAVTKYTSSK 
6022.28 6022.28 0.09 4.3E-47 G3V8B3 
Histone H2B HAVSEGTKAVTKYTSSK 1792.93 1792.93 0.13 5E-15 G3V8B3 
Histone H2B 
IFERIAGEASRLAHYNKRSTITSREIQT
AVRLLLPGELAKHAVSEGTKAVTKYTS
SK 
6281.43 6282.44 -160.39 
0.000000
572 
G3V8B3 
Histone H2B KHAVSEGTKAVTKYTSSK 1921.03 1921.03 -2.06 2.26E-09 G3V8B3 
Histone H2B LAKHAVSEGTKAVTKYTSSK 2105.15 2105.15 -1.17 7.05E-10 G3V8B3 
Histone H2B LPGELAKHAVSEGTKAVTKYTSSK 2501.35 2501.35 -1.9 2.01E-08 G3V8B3 
Histone H2B PGELAKHAVSEGTKAVTKYTSSK 2388.27 2388.27 0.31 2.83E-19 G3V8B3 
Histone H2B RLLLPGELAKHAVSEGTKAVTKYTSSK 2884.62 2883.62 345.5 7.63E-27 G3V8B3 
Histone H2B 
VNDIFERIAGEASRLAHYNKRSTITSRE
IQTAVRLLLPGELAKHAVSEGTKAVTK
YTSSK 
6610.58 6610.57 1.73 2.3E-10 G3V8B3 
Histone H3 RFQSSAVMALQEASEAY 1886.88 1886.88 -0.88 2.44E-30 D3ZJ08 
Histone H3.1 RFQSSAVMALQEACEAYL 2015.96 2015.94 7.85 2.68E-08 Q6LED0 
Histone H3.3 RFQSAAIGALQEASEAYL 1923.97 1923.97 -0.76 9.24E-47 P84245 
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Histone H4 AMDVVYALKRQGRTLYGFGG 2217.13 2201.14 7212.89 4.22E-17 P62804 
Histone H4 
AVTYTEHAKRKTVTAMDVVYALKRQG
RTLYGFGG 
3786 3787 -264.2 1.07E-19 P62804 
Histone H4 
RDAVTYTEHAKRKTVTAMDVVYALKR
QGRTLYGFGG 
4074.12 4058.13 3924.88 1.6E-17 P62804 
Histone H4 
TEHAKRKTVTAMDVVYALKRQGRTLY
GFGG 
3352.78 3352.78 0.7 1.99E-15 P62804 
Histone H4 
VIRDAVTYTEHAKRKTVTAMDVVYALK
RQGRTLYGFGG 
4286.27 4270.28 3730.69 2.93E-14 P62804 
Hypothetical LOC294883 
GKGVFSMKGGSRSSVGGSSSSGSKL
KSDELQTI 
3244.65 3244.64 4.36 5.41E-09 Q569A4 
Lactoylglutathione lyase IEILNPNKMATII 1468.83 1468.83 -0.93 1.98E-09 Q6P7Q4 
Macrophage migration inhibitory 
factor 
IVNTNVPRASVPEGFLSEL 2041.08 2041.08 0.85 4.01E-22 P30904 
Malate dehydrogenase, mitochondrial AKVAVLGASGGIGQPLSLL 1750.04 1750.04 -0.27 1.05E-21 P04636 
Mammary cancer associated protein 
RMT-1 
AARICPSEGATGRQAGLRSGLSEAAA
AVPCV 
2968.5 2968.5 1.49 6.89E-10 Q8VBT7 
Matrin-3 VEPFGVISNHLILNKINEAF 2253.21 2253.22 -2.47 2.8E-10 P43244 
Metabotropic glutamate receptor 1 WTYVSAVHTEGNYGESGMDAF 2319.99 2319.97 7.9 9.13E-11 D3ZSM4 
Methionine adenosyltransferase 2 
subunit beta 
GKTKLDGEKAVLENNLG 1785.11 1784.96 81.58 
0.000000
27 
F1LRW4 
Mevalonate kinase ETSIGAPGVSMHSATSIEDPVRQALGL 2722.36 2722.36 -0.17 2.94E-13 P17256 
NADH-ubiquinone oxidoreductase 
chain 2 
STLTLPLSSQLIT 1372.78 1372.78 0.39 1.3E-12 P11662 
Neurofilament 3, medium SSAMLSSAESSLDF 1446.61 1430.62 11056.4 2.23E-16 G3V7S2 
Neurofilament 3, medium TDISTALKEIRSQLE 1702.91 1702.91 -0.98 9.71E-31 G3V7S2 
Neurofilament light polypeptide DLSQVAAISNDLK 1372.72 1372.72 -0.56 1.41E-32 P19527 
Neurofilament light polypeptide LDLSQVAAISNDLK 1485.8 1485.8 0.36 2.18E-17 P19527 
Neurofilament light polypeptide SLMPSLENL 1002.51 1002.51 -1.86 8.8E-11 P19527 
Nuclear receptor corepressor 1 TAADALAALVDAAASA 1400.71 1400.71 0.17 4.64E-15 D3ZN55 
Peptide (Osteogenic growth peptide) 
[90-103] in Histone H4 
ALKRQGRTLYGFGG 1522.84 1522.84 -0.76 3.89E-15 P62804 
Peptide (Osteogenic growth peptide)  KRQGRTLYGFGG 1338.72 1338.72 -0.65 5.61E-10 P62804 
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Periaxin 
ASFGEAGPEIAAPSAEGTVGSRIQVP
QVM 
2855.41 2855.41 -1.6 2.9E-26 D3ZWG4 
Periaxin DTQEGAAVVKVPTLDVAAPSVE 2195.13 2195.13 -1.35 4.91E-20 D3ZWG4 
Periaxin DTQEGAAVVKVPTLDVAAPSVEVD 2409.22 2409.23 -2.19 1.78E-69 D3ZWG4 
Periaxin EVKLPKIPDMAVPDVRLPEL 2258.27 2258.27 -0.78 5.96E-10 D3ZWG4 
Periaxin LELPGTQVAGGDLL 1381.75 1381.75 -1.28 6.48E-26 D3ZWG4 
Periaxin LGAPAAPAVEPPTTGIQVPQVE 2141.13 2141.14 -3.25 5.44E-47 D3ZWG4 
Peroxiredoxin-5, mitochondrial APIKVGDTIPSVEVF 1570.86 1570.86 -0.87 1.76E-18 Q9R063 
Platelet factor 4 
VTRASPEESDGDLSCVCVKTSSSRIHL
KRITSLEVIKAGPHCAVPQLIATLKNGS
KICLDRQVPLYKKIIKKLLES 
8306.49 8310.56 -490.3 
0.000000
19 
P06765 
Predicted sub-sequence in Acyl-CoA-
binding protein 
VEKVEELKKKYGI 1561.91 1561.91 -0.3 2E-12 P11030 
Prefoldin subunit 2 
SAEQVIAGFNRLRQEQRGLASKAAEL
EMELNEHSLVIDTLKEVDETRKCYRM
VGGVL 
6429.32 6429.3 2.35 
0.000000
396 
B0BN18 
Protein disulfide-isomerase A3 SDVLELTDENF 1280.58 1280.58 -0.6 7.64E-18 P11598 
Protein LOC100359684 
QVFLKMNSLKTEDTGVYYCARDTVRE
VQ 
3291.69 3292.62 -282.34 
0.000000
016 
F1M3Q9 
Protein LOC100364909 LDFGSLSNL 964.487 964.487 -1.1 1.83E-09 D3ZFA8 
Protein Olr1347 LACADTTLNEL 1162.55 1162.55 -0.49 2.4E-14 G3V9E6 
Protein RGD1310945 FLIAKREMKN 1248.71 1248.7 9.48 2.35E-12 F1M6P5 
Protein RGD1565025 IGLGDLL 699.417 699.417 -0.66 1.79E-14 D4A806 
Protein Ryr3 HGHDECLTIPSTD 1423.6 1423.6 -1.94 6.94E-13 F1LPJ2 
Protein Serpinb11 LSSSNVGENI 1018.5 1018.49 6.51 1.07E-21 D3ZJI7 
Protein Slc43a2 WMACTAVLENL 1249.58 1249.58 1.71 2.33E-10 D3ZSK2 
Protein Srrd 
CSSALETITECLRKQLEQLQSLTEALG
RL 
3232.68 3232.68 0.54 2E-19 F1LTK4 
Protein Tacc1 LTMEKEQALADLN 1474.73 1474.73 -0.04 7.02E-12 D3ZNW7 
Protein Tpx2 
YHLRNKKDESLLPSKPVNKIVRDPQTP
ILQTKYRARAVTCKSAAEKEAEELEKL
QQYKFKA 
7166.9 7124.87 5865.06 1.91E-09 D3ZA78 
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Protein Vom2r57 
CMQVNDFLKNIRFINPIGDPVTVNQGR
NL 
3313.74 3314.7 -289.72 2.79E-7 D3ZJF1 
Reticulon-4 FALPAASEPVIPSSAEKIMDL 2201.12 2185.13 7264.94 2.17E-18 D4AEM9 
Stress-70 protein, mitochondrial IGIPPAPRGVPQIEVTF 1790.01 1790.01 -0.82 8E-18 F1M953 
Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, mitochondrial 
DVFLKDPATEGIVL 1515.82 1515.82 -0.5 2.26E-31 P13086 
Toll-interacting protein ATTVSTQRGPVYIGELPQDF 2220.1 2178.1 18920 5.46E-20 A2RUW1 
Transit (Mitochondrion (Potential)) [1-
28] in Kynurenine—oxoglutarate 
transaminase 1, mitochondrial 
VHLMWPLW 1080.56 1080.56 -2.1 1.22E-11 Q08415 
Ubiquitin carboxyl-terminal hydrolase 
48 
DCATLGTLGVIPESV 1474.73 1473.74 673.98 9.32E-10 D3ZSQ3 
UMP-CMP kinase 
YTHLSAGELLRDERKNPDSQYGELIEK
YIKEGKIVPVEITISLLKREMDQTMAAN
AQKNKFLIDGFPRNQDNLQGWNKTM
DGKADVS 
9948.12 9949.07 -95.63 1.7E-7 Q4KM73 
Uncharacterized protein 
AGKQLEDGRTLSDYNIQKESTLHLVLR
LRGG 
3466.85 3466.86 -2.21 2.59E-18 F1M4U4 
Uncharacterized protein EADIAAGKFIEHGEF 1632.79 1632.78 3.94 3.87E-11 F1LUK3 
Uncharacterized protein EFQSPLENL 1075.52 1075.52 2.73 4.05E-11 F1LT80 
Uncharacterized protein FVKLISWYDNEYGYSNRVVDL 2579.27 2579.27 -1.3 1.72E-10 F1LZV7 
Uncharacterized protein NIQKESTLHLVLRLRGG 1933.12 1933.12 -0.55 1.32E-24 F1M4U4 
Uncharacterized protein 
QTSEPCHSPRVMIHAKKVNTMSLTVL
GLRL 
3345.77 3345.78 -4.47 1.89E-14 F1LRB0 
Uncharacterized protein SDYNIQKESTLHLVLRLRGG 2298.24 2298.24 0.41 3.29E-18 F1M4U4 
Uncharacterized protein VHIYMCIFVL 1236.64 1236.64 3.91 1.45E-11 F1LX34 
Vimentin SSMPGVRLLQDSVDF 1649.81 1649.81 -1.13 2.18E-15 P31000 
Zero beta-1 globin 
IVIMMGHHLGKEFTPSAQAAFQKVVA
GVASALAHKYH 
3943.07 3944.07 -252.89 8.97E-22 Q62669 
Zero beta-1 globin 
MGHHLGKEFTPSAQAAFQKVVAGVA
SALAHKYH 
3503.78 3487.79 4562.63 9.86E-27 Q62669 
Zero beta-1 globin 
VHLTDAEKATVNGLWGKVNPVEIGAE
SL 
2946.55 2946.55 -0.19 6.26E-38 Q62669 
  
108 
 
Table 4.1A, continued 
 
      
Zero beta-1 globin (Protein Hbb-b1) 
IVIMMGHHLGKEFTPSAQAAFQKVVA
GVASALAHKYH 
3944.07 3944.07 -0.52 4E-44 Q62669 
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Table 4.1B  
Peptides Identified from Tissue Extracts using capillary-LC-MS System 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error Score 
Accession 
Number 
102 kDa protein M.A(+42.01)ESSAATQSPSVS.S 632.34 1262.563 81.4 32.11 IPI00561867 
114 kDa protein R.SAAGSSSGFHSWARTSVSSVS.A 1028.07 2053.945 87.5 37.99 IPI00390850 
15 kDa protein L.RFQSAAIGALQEASEA.Y 825 1647.822 99.4 43.62 IPI00206147 
Histone H3 L.RFQSAAIGALQEASEA.Y 825 1647.822 99.4 43.62 IPI00326699 
Histone H3 L.QEASEAYLVGL.F 590.41 1178.582 189.3 23.53 IPI00326699 
Protein LOC100362366 L.Q(-17.03)VTQPTVGMNFKTPRGAV 957.58 1912.983 84.9 52.19 IPI00567059 
19 kDa protein F.EARAQIGGPESEQSGAK 858.01 1713.828 103.4 62.08 IPI00569885 
19 kDa protein E.ARAQIGGPESEQSGAK 793.48 1584.786 100.8 24.69 IPI00569885 
34 kDa protein N.EDKVSDSASASSGS(-.98).D 663.42 1324.574 189.4 36.63 IPI00189609 
50 kDa protein L.VPYPRIHFPLA.T 655.49 1308.734 176.4 31.24 IPI00561215 
51 kDa protein F.FSETGAGKHVPRAVF.V 802.04 1601.831 145.9 38.93 IPI00561215 
52 kDa protein A.TYAPVISAEKAYHEQ.L 854.04 1705.831 137.2 71.48 IPI00561215 
53 kDa protein A.TYAPVISAEKAYHEQL.T 910.57 1818.915 115.5 19.46 IPI00561215 
54 kDa protein F.SIYPAPQVSTAVVEPYN.S 918.07 1833.915 114.8 39.37 IPI00561215 
Reticulon-3 M.A(+42.01)ESSAATQSPSVS.S 632.34 1262.563 81.4 32.11 IPI00564622 
Ac2-067 M.GFGDLKTPAGLQVLND.Y 823.04 1643.852 129.8 47.24 IPI00372520 
Hemoglobin Alpha-2-globin 
chain 
L.ASVSTVLTSKYR 656.48 1310.719 172.2 36.14 IPI00205036 
Hemoglobin Alpha-2-globin 
chain 
F.LASVSTVLTSKYR 713.02 1423.804 155.7 32.58 IPI00205036 
Hemoglobin Alpha-2-globin 
chain 
A.SVSTVLTSKYR 620.96 1239.682 179.8 27.85 IPI00205036 
Dihydropyrimidinase-related 
protein 2 
V.APPGGRANITSLG 605.98 1209.647 246.7 32.96 IPI00192034 
Fusion (involved in t(12 M.A(+42.01)SNDYTQQATQSYG.A 788.41 1574.648 99.6 26.45 IPI00362587 
Gamma-synuclein M(+42.01)DVFKKGFSIAREG.V 814.03 1625.824 136.4 47.53 IPI00210062 
Heat shock cognate 71 kDa 
protein 
M.S(+42.01)KGPAVGIDLG.T 528.5 1054.566 397.2 24.62 IPI00208205 
Hemoglobin alpha-1/2 subunit L.ASVSTVLTSKYR 656.48 1310.719 172.2 36.14 IPI00287835 
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Hemoglobin alpha-1/2 subunit F.LASVSTVLTSKYR 713.02 1423.804 155.7 32.58 IPI00287835 
Hemoglobin alpha-1/2 subunit A.SVSTVLTSKYR 620.96 1239.682 179.8 27.85 IPI00287835 
Hemoglobin beta-1 subunit VHLTDAEKAAVN.G 634.44 1266.657 164.5 34.89 IPI00230897 
Hemoglobin beta-1 subunit L.VVYPWTQRYFDSF.G 854.52 1706.809 126.6 51.55 IPI00230897 
Hemoglobin beta-1 subunit L.VVYPWTQRYFDS.F 780.97 1559.741 118.2 48.46 IPI00230897 
Hemoglobin beta-1 subunit L.VVYPWTQRY.F 606.45 1210.614 224.3 37.87 IPI00230897 
Hemoglobin beta-1 subunit L.LVVYPWTQRY.F 662.95 1323.698 141.8 54.36 IPI00230897 
Hemoglobin beta-1 subunit F.Q(-17.03)KVVAGVASALAHKYH 554.83 1660.905 338.6 46.99 IPI00230897 
Histone H3.3 L.RFQSAAIGALQEASEA.Y 825 1647.822 99.4 43.62 IPI00231475 
Histone H3.3 L.QEASEAYLVGL.F 590.41 1178.582 189.3 23.53 IPI00231475 
Hemoglobin beta-1 subunit VHLTDAEKAAVNGL.W 719.47 1436.762 113.4 19.93 IPI00230897 
Tubulin beta-2B chain R.SGPFGQIFRPDNF.V 741.45 1480.71 118.5 39.91 IPI00655259 
Tubulin beta-2B chain R.SGPFGQIFRPDN.F 667.92 1333.642 137.7 22.07 IPI00655259 
Malate dehydrogenase, 
mitochondrial 
N.AKVAVLGASGGIGQPLSL.L 819.6 1636.951 142.9 62.28 IPI00566583 
Malate dehydrogenase, 
mitochondrial 
L.LLKNSPLVSRLTL.Y 727.59 1452.903 180.6 50.72 IPI00566583 
Malate dehydrogenase, 
mitochondrial precursor 
N.AKVAVLGASGGIGQPLSL.L 819.6 1636.951 142.9 62.28 IPI00197696 
Malate dehydrogenase, 
mitochondrial precursor 
L.LLKNSPLVSRLTL.Y 727.59 1452.903 180.6 50.72 IPI00197696 
Neurofilament triplet H protein R.SAAGSSSGFHSWARTSVSSVS.A 1028.07 2053.945 87.5 37.99 IPI00188524 
Neurofilament triplet H protein G.APFAPLHGGGSLHY.A 712.45 1422.704 127.1 27.96 IPI00188524 
Neurofilament triplet H protein G.APFAPLHGGGSLH.Y 630.97 1259.641 225.3 29.61 IPI00188524 
Neurofilament triplet L protein 
Y.YTSHVQEEQSEVEETIEATKAEEAK
.D 
955.91 2864.32 135.4 30.22 IPI00231302 
Neurofilament triplet L protein Y.YTSHVQEEQSEVEETIEATK.A 1169.09 2336.065 42.7 88.35 IPI00231302 
Neurofilament triplet L protein Y.TSHVQEEQSEVEETIEATK.A 1087.57 2173.002 56.6 101.44 IPI00231302 
Neurofilament triplet L protein S.SQVFGRSAYSGLQ.S 700.44 1398.689 125.9 25.93 IPI00231302 
Neurofilament triplet L protein S.HVQEEQSEVEETIEATK.A 993.53 1984.923 61.9 91.52 IPI00231302 
Neurofilament triplet L protein R.SGYSTARSAYSSY.S 700.41 1398.605 143 51.95 IPI00231302 
Neurofilament triplet L protein R.AFPAYYTSHVQEEQ.S 835.45 1668.742 85.9 44.84 IPI00231302 
Neurofilament triplet L protein Q.SEVEETIEATKAEEAK.D 882.53 1762.847 112.4 44.05 IPI00231302 
Neurofilament triplet L protein Q.SEVEETIEATK.A 618.41 1234.593 171.9 48.07 IPI00231302 
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Neurofilament triplet L protein L.DLSQVAAISNDLK.S 687.48 1372.72 164.2 47.08 IPI00231302 
Neurofilament triplet L protein G.SITSGYSQSSQVF.G 695.97 1389.641 204.2 47.64 IPI00231302 
Neurofilament triplet L protein A.RAFPAYYTSHVQEEQ.S 913.51 1824.843 88.9 67.15 IPI00231302 
Neurofilament triplet M protein Y.THRQPSVTISSKIQKTK.V 970.1 1938.101 43.5 26.68 IPI00325609 
Neurofilament triplet M protein T.SHAIVKEVTQGD 642.44 1282.652 166.4 43.91 IPI00325609 
Neurofilament triplet M protein T.SEGGDGATKYITKSVTVTQK.V 1035.61 2069.064 68.3 52.03 IPI00325609 
Neurofilament triplet M protein T.SEGGDGATKYITKSVTVTQ.K 971.54 1940.969 49.6 36.65 IPI00325609 
Neurofilament triplet M protein T.SEGGDGATKYITKSVT.V 807.5 1612.794 118.3 20.85 IPI00325609 
Neurofilament triplet M protein T.SEGGDGATKYITK.S 663.93 1325.646 150.1 22.62 IPI00325609 
Neurofilament triplet M protein S.HAIVKEVTQGD 598.96 1195.62 238.7 29.3 IPI00325609 
Neurofilament triplet M protein K.VQHKFVEEIIEETKVEDEK.S 777.19 2328.185 155.9 44.52 IPI00325609 
Neurofilament triplet M protein H.RQPSVTISSKIQKTK.V 851.09 1699.994 100.6 48.27 IPI00325609 
PREDICTED: similar to MITF-2B 
protein 
S.SVYVSSAKTAN(-.98).Y 563.5 1124.583 357.7 28.65 IPI00371793 
Myosin-7b L.RVAPEEHPVLLT.E 680.97 1359.751 128.1 25.67 IPI00208315 
Myosin-7b E.LRVAPEEHPVL.L 630.44 1258.703 128.6 33.5 IPI00208315 
Frizzled-8 
A.P(+42.01)GAGGAGGAGGAATAGA
GAAGAGASSPG(-.98).A 
998.1 1993.92 132.9 26.44 IPI00360182 
Tubulin alpha-1B chain Y.Q(-17.03)PPTVVPGGDLAKVQR.A 823.02 1643.899 76.6 43.4 IPI00339167 
Tubulin alpha-1B chain L.VPYPRIHFPLA.T 655.44 1308.734 100.1 34.04 IPI00339167 
Tubulin alpha-1B chain L.VPYPRIHFPLA.T 655.49 1308.734 176.4 31.24 IPI00339167 
Tubulin alpha-1B chain F.VDLEPTVIDEVR.T 693 1383.725 188.3 35.97 IPI00339167 
Tubulin alpha-1B chain F.SIYPAPQVSTAVVEPYN.S 918.07 1833.915 114.8 39.37 IPI00339167 
Tubulin alpha-1B chain F.SIYPAPQVSTAVVEPYN.S 918.03 1833.915 71.2 30.25 IPI00339167 
Tubulin alpha-1B chain F.FSETGAGKHVPRAVF.V 802.03 1601.831 133.5 40.93 IPI00339167 
Tubulin alpha-1B chain F.FSETGAGKHVPRAVF.V 802.04 1601.831 145.9 38.93 IPI00339167 
Tubulin alpha-1B chain A.TYAPVISAEKAYHEQL.S 910.57 1818.915 115.5 19.46 IPI00339167 
Tubulin alpha-1B chain A.TYAPVISAEKAYHEQ.L 854.04 1705.831 137.2 71.48 IPI00339167 
Tubulin alpha-1B chain A.TYAPVISAEKAY.H 656.96 1311.671 178.5 37.14 IPI00339167 
ribosomal protein S17 L.Q(-17.03)VTQPTVGMNFKTPRGAV 957.58 1912.983 84.9 52.19 IPI00324983 
Reticulon-3 M.A(+42.01)ESSAATQSPSVS.S 632.34 1262.563 81.4 32.11 IPI00421904 
Sec31l1 protein L.KVVLSQASKLGV 615 1227.755 187.4 45.21 IPI00515833 
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Tubulin alpha-1 chain Y.Q(-17.03)PPTVVPGGDLAKVQR.A 823.02 1643.899 76.6 43.4 IPI00189795 
Tubulin alpha-1 chain L.VPYPRIHFPLA.T 655.44 1308.734 100.1 34.04 IPI00189795 
Tubulin alpha-1 chain F.VDLEPTVIDEVR.T 693 1383.725 188.3 35.97 IPI00189795 
Tubulin alpha-1 chain F.SIYPAPQVSTAVVEPYN.S 918.07 1833.915 114.8 39.37 IPI00189795 
Tubulin alpha-1 chain F.SIYPAPQVSTAVVEPYN.S 918.03 1833.915 71.2 30.25 IPI00189795 
Tubulin alpha-1 chain F.FSETGAGKHVPRAVF.V 802.03 1601.831 133.5 40.93 IPI00189795 
Tubulin alpha-1 chain F.FSETGAGKHVPRAVF.V 802.04 1601.831 145.9 38.93 IPI00189795 
Tubulin alpha-1 chain A.TYAPVISAEKAYHEQL.S 910.57 1818.915 115.5 19.46 IPI00189795 
Tubulin alpha-1 chain A.TYAPVISAEKAYHEQ.L 854.04 1705.831 137.2 71.48 IPI00189795 
Tubulin alpha-1 chain A.TYAPVISAEKAY.H 656.96 1311.671 178.5 37.14 IPI00189795 
Tubulin alpha-2 chain Y.Q(-17.03)PPTVVPGGDLAKVQR.A 823.02 1643.899 76.6 43.4 IPI00679220 
Tubulin alpha-2 chain L.VPYPRIHFPLA.T 655.44 1308.734 100.1 34.04 IPI00679220 
Tubulin alpha-2 chain F.VDLEPTVIDEVR.T 693 1383.725 188.3 35.97 IPI00679220 
Tubulin alpha-2 chain F.SIYPAPQVSTAVVEPYN.S 918.07 1833.915 114.8 39.37 IPI00679220 
Tubulin alpha-2 chain F.SIYPAPQVSTAVVEPYN.S 918.03 1833.915 71.2 30.25 IPI00679220 
Tubulin alpha-2 chain F.FSETGAGKHVPRAVF.V 802.03 1601.831 133.5 40.93 IPI00679220 
Tubulin alpha-2 chain F.FSETGAGKHVPRAVF.V 802.04 1601.831 145.9 38.93 IPI00679220 
Tubulin alpha-2 chain A.TYAPVISAEKAYHEQL.S 910.57 1818.915 115.5 19.46 IPI00679220 
Tubulin alpha-2 chain A.TYAPVISAEKAYHEQ.L 854.04 1705.831 137.2 71.48 IPI00679220 
Tubulin alpha-2 chain A.TYAPVISAEKAY.H 656.96 1311.671 178.5 37.14 IPI00679220 
Tubulin alpha-6 chain L.VPYPRIHFPLA.T 655.49 1308.734 176.4 31.24 IPI00364046 
Tubulin alpha-6 chain F.SIYPAPQVSTAVVEPYN.S 918.07 1833.915 114.8 39.37 IPI00364046 
Tubulin alpha-6 chain F.FSETGAGKHVPRAVF.V 802.04 1601.831 145.9 38.93 IPI00364046 
Tubulin alpha-6 chain A.TYAPVISAEKAYHEQL.T 910.57 1818.915 115.5 19.46 IPI00364046 
Tubulin alpha-6 chain A.TYAPVISAEKAYHEQ.L 854.04 1705.831 137.2 71.48 IPI00364046 
Tubulin, beta, 2 R.SGPFGQIFRPDNF.V 741.46 1480.71 132 44.21 IPI00400573 
Tubulin, beta, 3 R.SGPFGQIFRPDN.F 667.93 1333.642 152.7 32.46 IPI00400573 
Tubulin, beta, 4 F.SVVPSPKVSDTVVEPYN.A 909.03 1815.925 66.1 24.94 IPI00400573 
Protein transport protein 
Sec31A 
L.KVVLSQASKLGV 615 1227.755 187.4 45.21 IPI00210147 
Vimentin M.FGGSGTSSRPSSN.R 620.92 1239.548 223.5 24.94 IPI00230941 
Vimentin E.SLPLVDTHSKRTL.L 734.03 1465.825 150.1 40.64 IPI00230941 
Zero beta-1 globin L.LIVYPWTQRY.F 669.98 1337.713 173.4 33 IPI00207146 
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Zero beta-1 globin L.IVYPWTQRY.F 613.46 1224.629 225.3 39.94 IPI00207146 
Zero beta-1 globin F.Q(-17.03)KVVAGVASALAHKYH 554.83 1660.905 338.6 46.99 IPI00207146 
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Table 4.2 
Peptides Identified from Cell Extracts 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
Accession 
Number 
Actin, gamma-enteric smooth 
muscle 
HQGVMVGMGQKDSYVGDEAQSKR 2506.17 2506.17 -0.9 6.59E-18 P63269 
Actin, gamma-enteric smooth 
muscle 
ISKPEYDEAGPSIVHRKCF 2175.08 2175.08 -2.1 1.16E-23 P63269 
Myelin protein P0 GKFHKSSKDSSKRGRQTPVLY 2405.29 2405.29 -1.57 8.74E-20 P06907 
Myelin protein P0 
MEKGKFHKSSKDSSKRGRQTPVLYAMLDHS
RSTKAASEKKSKGLGESRKDKK 
5848.1 5848.11 -1.53 2.49E-21 P06907 
Myelin protein P0 RLSAMEKGKFHK 1430.78 1430.78 -1.02 4.38E-16 P06907 
40S ribosomal protein S15 SITYKPVKHGRPGIGATHSSRFIPLK 2846.59 2846.6 -2.34 1.09E-16 P62845 
6.8 kDa mitochondrial 
proteolipid 
IVYKIRSADKRSKALKGCSPAHAHGHH 2966.59 2966.59 -1.2 2.45E-15 D3Z9R8 
60 kDa heat shock protein, 
mitochondrial 
AVVTEIPKEEKDPGMGAMGGMGGGMGGGM
F 
2913.28 2897.29 5489.56 6.63E-38 D3ZVX2 
Actin, aortic smooth muscle ISKQEYDEAGPSIVHRKCF 2206.08 2206.08 -1.48 9.59E-29 P62738 
Actin, cytoplasmic 2 ISKQEYDESGPSIVHRK 1972 1972 -1.81 3.3E-19 F2Z3T1 
Actin, cytoplasmic 2 ISKQEYDESGPSIVHRKCF 2222.08 2222.08 -1.74 7.49E-48 F2Z3T1 
Actin, cytoplasmic 2 PSIVHRKCF 1085.58 1085.58 -0.8 4.77E-13 F2Z3T1 
Actin, cytoplasmic 2 QQMWISKQEYDESGPSIVHRKCF 2795.32 2795.32 -1.06 1.39E-21 F2Z3T1 
Actin, cytoplasmic 2 WISKQEYDESGPSIVHRKCF 2408.16 2408.16 -1.31 1.38E-44 F2Z3T1 
Acyl-CoA-binding protein 
FIYSHFKQATVGDVNTDRPGLLDLKGKAKWD
SWNKLKGTSKENAMKTYVEKVEELKKKYGI 
7029.68 7029.72 -6.25 1.76E-10 P11030 
Acyl-CoA-binding protein 
SQADFDKAAEEVKRLKTQPTDEEMLFIYSHF
KQATVGDVNTDRPGLLDLKGKAKWDSWNKL
KGTSKENAMKTYVEKVEELKKKYGI 
9932.11 9890.11 4229.02 7.11E-10 P11030 
Agrin LADFNGFSYLELKGLHTFERDLGEKM 3029.52 3029.5 6.18 5.08E-12 F1LQ53 
Aig1 protein IYAYDREMIY 1335.63 1335.62 3.99 2.75E-12 B2RZC0 
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Alpha-internexin KLLEGEETR 1073.57 1073.57 -1.27 3.63E-18 P23565 
Alt Splice Form 2 in 
Hepatoma-derived growth 
factor-related protein 2 
EKERRKERAERGGSSGEELE 2330.19 2331.15 -411.54 1.1E-10 Q925G1-2 
Alt Splice Form 2 in Myelin 
basic protein S 
ASQKRPSQRHGSKYLATA 2027.07 1985.06 20723.6 8.58E-16 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
ASQKRPSQRHGSKYLATASTMDHARHGFLP
RHRDTGILDSIGRF 
5000.54 4958.54 8399.05 2.88E-23 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
FSWGAEGQKPGFGYGGR 1799.84 1799.84 -2.2 2.73E-06 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
FSWGGR 708.334 708.334 -0.66 3.83E-14 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
HGFLPR 725.397 725.397 -1.33 1.08E-22 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
HGSKYLATASTMDHAR 1744.83 1744.83 -1.41 2.4E-37 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
HRDTGILDSIGR 1338.7 1338.7 -1.24 8.19E-43 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
HRDTGILDSIGRFFSGDRGAPKRGSGKDSHT
R 
3482.75 3482.76 -1.83 1.81E-11 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
RGSGKVPWLK 1126.66 1126.66 -1.03 7.87E-23 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
TTHYGSLPQK 1130.57 1130.57 -1.03 3.15E-27 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
TTHYGSLPQKSQR 1502.76 1501.76 666.33 5.8E-19 P02688-2 
Alt Splice Form 2 in Myelin 
basic protein S 
YLATASTMDHAR 1335.62 1335.62 1.15 1.32E-13 P02688-2 
Alt Splice Form 2 in Periaxin KYEDALRL 1006.54 1006.54 -0.76 3.47E-14 Q63425-2 
Alt Splice Form 2 in Periaxin MEARSRSAEELRRAELVE 2173.09 2131.08 19330.7 1.07E-08 Q63425-2 
Alt Splice Form 2 in Poly(U)-
binding-splicing factor PUF60 
SEPAAAAAAAAAAVVAAGDKWKPPQGTESI 2805.45 2805.43 8.53 1.2E-06 Q9WV25-2 
Alt Splice Form 2 in Tubulin 
beta-5 chain 
FKRISEQF 1053.56 1053.56 1.27 1.94E-17 P69897-2 
  
116 
 
Table 4.2, continued 
 
      
Alt Splice Form B0a in 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
NQQPSNYGPMKSGNFGGSRNMGGPYGGG
NYGPGGSGGSGGYGGRSRY 
4601.97 4602 -5.69 6.53E-11 A7VJC2-3 
Annexin A2 STVHEILCK 1070.54 1028.53 39240.7 1.7E-09 Q07936 
ATP synthase subunit beta, 
mitochondrial 
AAQSSAAPKAGTATGQIVAVIG 1968.06 1968.06 -1.61 9.95E-11 P10719 
ATP synthase subunit 
epsilon, mitochondrial 
VAYWRQAGLSYIRFSQICAKAVRDALKTEFK
ANAEKTSGTSIKTVKIKKE 
5631.07 5632.07 -178.31 4E-14 P29418 
ATP synthase-coupling factor 
6, mitochondrial 
NKELDPVQKLFLDKIREYKAKRLASGGPVDT
GPEYQQEVDRELFKLKQMYGKGEMDKFPTF
NFEDPKFEVLDKPQS 
8920.54 8921.55 -113.25 4.05E-08 P21571 
Calmodulin FVQMMTAK 954.467 954.467 -1.43 2.46E-11 D4ABV5 
Calnexin ILNPDNSF 918.445 918.445 -0.83 3.28E-08 P35565 
Calreticulin WQVKSGTIFDNF 1440.7 1440.7 -1.22 2.44E-31 P18418 
Cardiotrophin-like cytokine 
factor 1 
LLKELQTWL 1142.68 1142.67 4.41 7.35E-10 Q4KMB8 
Cytochrome c oxidase 
subunit 7A2, mitochondrial 
FENKVPEKQKLFQEDNGMPVHLKGGTSDAL
LYRATML 
4204.14 4204.15 -2.28 2.81E-14 P35171 
Cytochrome c oxidase 
subunit 7B, mitochondrial 
NLSPVGRVTPKEWRDQ 1880.99 1880.99 -0.99 1.18E-09 P80431 
Cytochrome c oxidase 
subunit 7B, mitochondrial 
SHQKKTPTFHDKYGNAVL 2070.06 2070.06 -1.82 3.04E-17 P80431 
Cytochrome c oxidase 
subunit 7C, mitochondrial 
FIVRHQLLKK 1280.81 1280.81 -1.61 2.09E-27 P80432 
Cytochrome c oxidase 
subunit 7C, mitochondrial 
IVRHQLLKK 1133.74 1133.74 -2 2.44E-12 P80432 
Cytochrome c oxidase 
subunit 7C, mitochondrial 
VYFGSGFAAPFFIVRHQLLKK 2424.35 2424.35 -2.01 7.93E-15 P80432 
Desmin TNEKVELQELNDR 1586.79 1586.79 -0.54 1.44E-16 Q6P725 
Electron transfer flavoprotein 
subunit alpha, mitochondrial 
KVVPEMTEILKKK 1541.92 1541.92 -1.6 8.53E-12 P13803 
Eukaryotic translation 
elongation factor 1 beta 2 
GFGDLKTPAGLQVLND 1643.85 1643.85 -1.38 1.22E-20 B5DEN5 
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Eukaryotic translation 
initiation factor 1 
IGLAKDDQLKVHGF 1539.84 1539.84 -0.3 2.31E-09 B0K008 
Eukaryotic translation 
initiation factor 5A-1 
AAVAIKAMAK 972.579 972.579 -0.89 1.74E-16 Q3T1J1 
Eukaryotic translation 
initiation factor 5A-1 
LQDSGEVREDLRLPEGDLGKEIEQKYDCGEE
IL 
3773.81 3774.83 -269.61 8.02E-10 Q3T1J1 
Fructose-bisphosphate 
aldolase A 
FISNHAY 850.397 850.397 -1.13 5.1E-19 P05065 
Galectin-1 KIKCVAFE 936.51 936.51 -1.46 3.91E-21 P11762 
Gamma-synuclein MDVFKKGFSIAREG 1625.82 1583.81 25839.8 1.14E-16 F1LQ96 
Gamma-synuclein VVRKEDLEPPAQDQEAKEQEEGEEAKSGGD 3296.52 3296.53 -1.75 1.55E-65 F1LQ96 
Glutathione S-transferase P YVARLSARPKIKAFLSSPDHLNRPINGNGKQ 3445.89 3446.9 -291.9 2E-09 P04906 
Glyceraldehyde-3-phosphate 
dehydrogenase 
VKVGVNGFGRIGRLVTRAAFSCDKVDIVAIND
PFIDL 
3974.16 3974.16 -0.22 1.41E-08 P04797 
Hemoglobin subunit alpha-1/2 
LACHHPGDFTPAMHASLDKFLASVSTVLTSK
YR 
3599.79 3599.8 -2.43 8.75E-27 P01946 
Hemoglobin subunit alpha-1/2 
LVTLACHHPGDFTPAMHASLDKFLASVSTVL
TSKYR 
3912.98 3913 -4.05 2.98E-28 P01946 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQ
R 
3344.61 3344.62 -3.73 1.09E-17 P01946 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQ
R 
3344.62 3344.62 -1.48 8.95E-14 P01946 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQ
RM 
3475.66 3475.66 -1.28 5.2E-41 P01946 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQ
RMF 
3622.73 3622.73 -1.01 1.25E-10 P01946 
Hemoglobin subunit beta-1 
IVIVLGHHLGKEFTPCAQAAFQKVVAGVASAL
AHKYH 
3910.12 3910.12 0.16 1.75E-17 P02091 
Hemoglobin subunit beta-1 
IVLGHHLGKEFTPCAQAAFQKVVAGVASALA
HKYH 
3697.97 3697.97 -0.45 5.22E-24 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRY 1323.7 1323.7 -1.56 2.2E-19 P02091 
Hemoglobin subunit beta-1 PWTQRY 849.413 849.413 -2.08 7.11E-14 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGGEALGR
L 
3200.66 3200.66 -1.52 1.75E-95 P02091 
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Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGGEALGR
LL 
3313.74 3313.74 -1.29 1.82E-38 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGGEALGR
LLVVYPWTQRY 
4506.33 4506.34 -1.61 1.92E-51 P02091 
High-mobility group 
nucleosome binding domain 
1 
PKRKVSADGAAKAEPKRRSARLSAKPAPAKV
DAKPKKAAGKDKASDKKAQIKGKRGAKGKQ
AEVADQQTTDLPAENGETENQSPASEEEKE
AKSD 
9987.28 9987.3 -1.87 1.1E-06 Q5U1W8 
Histone H2A VLLPKKTSATVGPKAPAGGKKASQASQ 2619.51 2619.51 -1.59 1.25E-18 D3ZXP3 
Histone H2A VLLPKKTSATVGPKAPAGGKKASQASQEY 2911.61 2911.61 -0.23 1.49E-29 D3ZXP3 
Histone H2A type 1 
TAEILELAGNAARDNKKTRIIPRHLQLAIRNDE
ELNKLLGKVTIAQGGVLPNIQAVLLPKKTESH
HKAKGK 
7778.39 7778.44 -5.85 4.77E-19 P02262 
Histone H2A type 1-C 
TAEILELAGNAARDNKKTRIIPRHLQLAIRNDE
ELNKLLGRVTIAQGGVLPNIQAVLLPKKTESH
HKAKGK 
7805.45 7806.45 -128.75 1.14E-12 P0C169 
Histone H2B 
ERIAGEASRLAHYNKRSTITSREIQTAVRLLLP
GELAKHAVSEGTKAVTKYTSSK 
6022.28 6022.28 -0.64 6.7E-34 G3V8B3 
Histone H2B 
IFERIAGEASRLAHYNKRSTITSREIQTAVRLL
LPGELAKHAVSEGTKAVTKYTSSK 
6282.43 6282.44 -1.19 3.36E-26 G3V8B3 
Histone H3.3 FEDTNLCAIHAKRVTIMPKDIQLARRIRGERA 3721.01 3721.01 -1.04 9.09E-30 P84245 
Kinesin-like protein KIF27 FKIKVSYIEVYKE 1642.87 1644.91 -1238.9 9.3E-13 Q7M6Z5 
Latexin VLWHPQYGTKVKHNSRLPKEAPAE 2784.48 2784.48 -1.71 1.66E-12 Q64361 
Latexin VLWHPQYGTKVKHNSRLPKEAPAE 2784.48 2784.48 -1.32 4.31E-10 Q64361 
Malate dehydrogenase, 
mitochondrial 
AKVAVLGASGGIGQPLSL 1637.95 1636.95 611.58 3.87E-33 P04636 
mercaptopyruvate 
sulfurtransferase 
VEWYMRAQPEHVISQGRGKTL 2484.27 2484.27 -1.96 1.29E-10 P97532; 3 
Microtubule-associated 
protein 1B 
ASSSTVVMQDESFPACKIEL 2140.99 2141 -4.56 5.75E-13 P15205 
Microtubule-associated 
protein 1B 
KEPIAAGKLKDKGKVKVIKKEGKTTE 2822.7 2822.7 -1.58 6.62E-13 P15205 
Microtubule-associated 
protein 1B 
KEVKKETPLKDAKKEVKKDEKKEVKKEE 3367.93 3367.93 -1.47 2.93E-13 P15205 
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Microtubule-associated 
protein 1B 
KTPKVESKEKVIVKKDKPGKVE 2493.49 2493.49 -1.59 7.16E-14 P15205 
Microtubule-associated 
protein 1B 
SKPSVTEKEVPSKEEQSPVK 2212.16 2212.16 -1.2 8.03E-16 P15205 
Myelin protein P0 AMLDHSRSTKAASEKKSKGLG 2201.16 2201.16 -1.48 2.91E-54 F1MAN9 
Myelin protein P0 MLDHSRSTKAASEKKSKGLGESRKDKK 3001.6 3001.61 -1.75 8.48E-26 F1MAN9 
Myelin protein P0 YAMLDHSRSTKAASEKKSKGLGESRKDKK 3235.71 3235.71 -0.21 2.04E-35 F1MAN9 
NADH dehydrogenase 
[ubiquinone] flavoprotein 3, 
mitochondrial 
NLDLSKFRLPQPSSGRESPRH 2420.27 2420.27 -1.14 2.42E-17 Q6PCU8 
Neurofilament 3, medium AAEQNKEAIRSAKEEIAEYRR 2461.26 2461.27 -4.17 1.13E-12 G3V7S2 
Neurofilament 3, medium AAEQNKEAIRSAKEEIAEYRRQLQ 2830.46 2830.47 -2.74 6.71E-37 G3V7S2 
Neurofilament 3, medium AGKDEQKEEEKVEEKKEVA 2202.1 2202.1 -1.3 1.11E-26 G3V7S2 
Neurofilament 3, medium AGKDEQKEEEKVEEKKEVAK 2330.2 2330.2 -1.06 4.05E-15 G3V7S2 
Neurofilament 3, medium AGKDEQKEEEKVEEKKEVAKE 2459.24 2459.24 -1.04 6.02E-11 G3V7S2 
Neurofilament 3, medium AIKEEIKVEKPEKAK 1739.02 1739.02 -1.99 1.43E-19 G3V7S2 
Neurofilament 3, medium ALRKDIEESSMVKVELDKKVQS 2531.35 2531.36 -2.4 3.13E-09 G3V7S2 
Neurofilament 3, medium EEKLVSTKKVEKVT 1616.94 1616.94 -1.65 8.75E-14 G3V7S2 
Neurofilament 3, medium EGGDGATKYITKSVTVTQK 1982.03 1982.03 -0.79 2.89E-18 G3V7S2 
Neurofilament 3, medium FAGYIEKVHYLEQQNKEIEAE 2537.23 2537.24 -2.39 2.69E-13 G3V7S2 
Neurofilament 3, medium FVEEIIEETKVEDEK 1835.9 1835.9 2.2 3.14E-12 G3V7S2 
Neurofilament 3, medium HEETFEEKLVSTKKVEKVT 2260.2 2260.2 -1.4 1.44E-13 G3V7S2 
Neurofilament 3, medium IIEETKVEDEK 1331.68 1331.68 -1.48 1.07E-24 G3V7S2 
Neurofilament 3, medium IKEEIKVEKPEK 1468.85 1468.85 -0.72 4.75E-27 G3V7S2 
Neurofilament 3, medium IKEEIKVEKPEKAK 1667.98 1667.98 -1.6 1.37E-24 G3V7S2 
Neurofilament 3, medium IQASHITVER 1152.63 1152.63 -1.79 1.69E-22 G3V7S2 
Neurofilament 3, medium LDSDHLEEDIHR 1477.68 1477.68 -1.4 3.64E-35 G3V7S2 
Neurofilament 3, medium 
LEKDTKEEKPQQQEKVKEKAEEEGGSEEEV
GDK 
3786.82 3786.83 -2.26 1.5E-10 G3V7S2 
Neurofilament 3, medium 
LEKDTKEEKPQQQEKVKEKAEEEGGSEEEV
GDKSPQESKKEDIAIN 
5225.54 5226.55 -192.49 1.72E-14 G3V7S2 
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Neurofilament 3, medium LGDAYDQEIRE 1307.6 1307.6 -3.57 7.68E-22 G3V7S2 
Neurofilament 3, medium LKERFEEEAR 1305.67 1305.67 -1.05 3.25E-31 G3V7S2 
Neurofilament 3, medium QKQASHAQLGDAYDQEIRE 2186.04 2186.04 -0.9 6.93E-14 G3V7S2 
Neurofilament 3, medium QPSVTISSKIQKTK 1543.89 1543.89 -1.27 1.57E-13 G3V7S2 
Neurofilament 3, medium RQPSVTISSKIQKTK 1699.99 1699.99 -0.92 7.57E-25 G3V7S2 
Neurofilament 3, medium SAKEEIAEYR 1194.59 1194.59 -1.56 8.28E-21 G3V7S2 
Neurofilament 3, medium SDHLEEDIHR 1249.57 1249.57 -1.57 1.51E-18 G3V7S2 
Neurofilament 3, medium SEGGDGATKYITKSVTVTQK 2069.06 2069.06 -1.67 3.8E-13 G3V7S2 
Neurofilament 3, medium SPVEEVKPKPEAK 1436.79 1436.79 -1.16 5.74E-22 G3V7S2 
Neurofilament 3, medium 
SPVPKSPVEEVKPKPEAKAGKDEQKEEEKVE
EKKEVA 
4129.18 4129.18 -0.74 7.55E-20 G3V7S2 
Neurofilament 3, medium SVTVTQKVEEHEETFEEKLVSTKKVEKVT 3360.76 3360.77 -3.53 6.31E-10 G3V7S2 
Neurofilament 3, medium TDISTALKEIR 1245.69 1245.69 -0.69 2.07E-11 G3V7S2 
Neurofilament 3, medium THRQPSVTISSKIQKTK 1938.1 1938.1 -0.7 3.75E-18 G3V7S2 
Neurofilament 3, medium VEAPKLKVQHK 1275.77 1275.77 -1.54 5.68E-17 G3V7S2 
Neurofilament 3, medium VKEKAEEEGGSEEEVGDKSPQESK 2604.2 2604.2 -0.49 2.01E-19 G3V7S2 
Neurofilament 3, medium VKEKAEEEGGSEEEVGDKSPQESK 2604.2 2604.2 -0.98 8.32E-14 G3V7S2 
Neurofilament 3, medium VNHEKAQVQLDSDHLEEDIHR 2511.21 2511.21 -1.9 2.27E-23 G3V7S2 
Neurofilament 3, medium VSPAEEKKGEDRSDDKVVVTKKVEKIT 3013.63 3013.63 -1.38 1.25E-21 G3V7S2 
Neurofilament 3, medium VTISSKIQKTK 1231.75 1231.75 -1.35 8.12E-16 G3V7S2 
Neurofilament 3, medium VTQKVEEHEETFEEKLVSTKKVEKVT 3073.61 3073.62 -2.27 1.03E-27 G3V7S2 
Neurofilament heavy 
polypeptide 
AEEKEPLTEKPKDSPGEAK 2082.05 2082.05 -2.38 2.12E-14 F1M9Y4 
Neurofilament heavy 
polypeptide 
AKEEDKGLPQEPSKPK 1779.94 1779.94 -0.77 1.73E-22 F1M9Y4 
Neurofilament heavy 
polypeptide 
AKEEDKGLPQEPSKPKTEKAEK 2466.3 2466.3 0.14 3.64E-26 F1M9Y4 
Neurofilament heavy 
polypeptide 
KKPEEKPKMEAKAKEEDKGLPQEPSKPKTEK
AEKSSSTDQKDSQPSEKAPEDKAAKGDK 
6505.3 6505.31 -1.9 1.19E-12 F1M9Y4 
Neurofilament heavy 
polypeptide 
QRLDEEARQREEAEAAAR 2127.04 2127.04 0.2 4.84E-11 F1M9Y4 
  
121 
 
Table 4.2, continued 
 
      
Neurofilament heavy 
polypeptide 
SEEKIKVVEKSE 1403.75 1403.75 -0.97 1.63E-16 F1M9Y4 
Neurofilament heavy 
polypeptide 
SPEQVKSPAKEEAKSPEKEETR 2483.25 2483.25 -0.99 2.73E-21 F1M9Y4 
Neurofilament heavy 
polypeptide 
VKAKEPPKKVEEEKTPATPKTE 2463.36 2463.36 -1.41 4.05E-10 F1M9Y4 
Neurofilament light 
polypeptide 
AAKNTDAVRAAKDEVSESR 2017.02 2017.02 -0.97 2.09E-26 P19527 
Neurofilament light 
polypeptide 
AELEKRIDS 1059.56 1059.56 -1.38 3.19E-18 P19527 
Neurofilament light 
polypeptide 
ARYEEEVLSREDAEGR 1907.9 1907.9 -0.87 4.08E-21 P19527 
Neurofilament light 
polypeptide 
ESAAKNTDAVRAAKDEVSESR 2233.09 2233.09 -0.07 4.3E-11 P19527 
Neurofilament light 
polypeptide 
ESAAKNTDAVRAAKDEVSESRRLLK 2743.45 2743.46 -4.94 5.45E-22 P19527 
Neurofilament light 
polypeptide 
LAAEDATNEKQALQGEREGLEETLR 2770.37 2770.37 0.95 5.43E-16 P19527 
Neurofilament light 
polypeptide 
LARAELEKRIDS 1399.78 1399.78 -0.55 1.68E-29 P19527 
Neurofilament light 
polypeptide 
LLKAKTLEIEACR 1486.85 1486.85 -0.85 3.74E-33 P19527 
Neurofilament light 
polypeptide 
LQARYEEEVLSREDAEGR 2149.04 2149.04 -1.19 4.08E-15 P19527 
Neurofilament light 
polypeptide 
LQGEREGLEET 1259.6 1259.6 -2.43 2E-10 P19527 
Neurofilament light 
polypeptide 
LQGEREGLEETLR 1528.78 1528.78 -1.02 1.63E-17 P19527 
Neurofilament light 
polypeptide 
LQGEREGLEETLRN 1642.83 1642.83 -1.62 2.43E-21 P19527 
Neurofilament light 
polypeptide 
LYEQEIRD 1064.51 1064.51 -1.28 1.36E-24 P19527 
Neurofilament light 
polypeptide 
SAAKNTDAVRAAKDEVSESRRLLK 2614.41 2614.41 -0.02 7.26E-08 P19527 
Neurofilament light 
polypeptide 
TDAVRAAKDEVSESR 1632.81 1632.81 -1.45 1.45E-32 P19527 
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Table 4.2, continued 
 
      
Neurofilament light 
polypeptide 
TSHVQEEQSEVEETIEATKAEEAK 2701.26 2701.26 -0.14 1.39E-28 P19527 
Neurofilament light 
polypeptide 
VEETIEATKAEEAK 1546.77 1546.77 -1.14 2.36E-08 P19527 
Neurofilament light 
polypeptide 
VHELEQQNKVLEAE 1664.84 1664.84 -1.06 1.21E-09 P19527 
Neurofilament light 
polypeptide 
VQEEQSEVEETIEATK 1847.86 1847.86 -1.55 1.07E-19 P19527 
Neurofilament light 
polypeptide 
VQEEQSEVEETIEATKAEEAK 2376.12 2376.12 -1.63 1.88E-18 P19527 
Neurofilament light 
polypeptide 
YEEEVLSR 1023.49 1023.49 -1.04 1.27E-24 P19527 
Peptidyl-prolyl cis-trans 
isomerase 
LKIERRSEL 1142.68 1142.68 -1.46 2.45E-19 D3ZZR9 
Peptidyl-prolyl cis-trans 
isomerase 
LLKIERRSEL 1255.76 1255.76 -0.61 1.82E-12 D3ZZR9 
Peptidyl-prolyl cis-trans 
isomerase B 
NDKKKGPKVTVKVYFD 1865.04 1865.04 -1.38 1.33E-11 P24368 
Periaxin ASFGEAGPEIAAPSAEGTVGSR 2059.97 2059.98 -2.94 5.62E-19 D3ZWG4 
Periaxin DTQEGAAVVKVPTLDVAAPSVEVD 2409.22 2409.23 -2.1 3.08E-21 D3ZWG4 
Periaxin DVGLGHEAQAGETAKSEGGLK 2053.01 2053.01 -1.2 3.08E-14 D3ZWG4 
Pleckstrin homology-like 
domain family B member 1 
RSPSPKSALLAQNGTSSLPRNLAATLQDIETK
RQLALQQKVELPPAEPLSPEDPAGHQVIEEQ
RRRLAEL 
7687.13 7686.14 129.08 5.08E-09 F1LQQ9 
Polycomb group RING finger 
protein 6 
EDEEERLINLVE 1485.78 1486.72 -631.03 6.67E-10 Q5XI70 
Predicted sub-sequence [30-
112] in Prothymosin alpha 
GDGEEEDGDEDEEAEAPTGKRVAEDDEDDD
VETKKQKKTDEDD 
4781.96 4781.97 -2.06 8E-22 P06302 
Prohibitin-2 NLQDESFTRGSDSLIKGKK 2122.09 2122.1 -2.48 4.53E-13 Q5XIH7 
Prohibitin-2 QDESFTRGSDSLIKGKK 1894.97 1894.97 -0.88 3.15E-13 Q5XIH7 
Proteasome subunit alpha 
type-1 
EERPQRKAQPSQAADEPAEKADEPMEH 3073.41 3073.42 -4.06 8.58E-11 P18420 
Proteasome subunit alpha 
type-1 
LEERPQRKAQPSQAADEPAEKADEPMEH 3186.5 3186.5 -0.96 5.7E-30 P18420 
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Table 4.2, continued 
 
Protein Glipr2 FEENVPPPKK 1183.62 1183.62 -1.41 8.23E-13 F1M5V2 
Zero beta-1 globin 
IVIMMGHHLGKEFTPSAQAAFQKVVAGVASA
LAHKYH 
3945.07 3944.07 253.62 6.96E-32 Q62669 
Zero beta-1 globin VHLTDAEKATVNGLWGKVNPVEIGAESLAS 3104.6 3104.61 -4.47 5.69E-09 Q62669 
Protein LOC100361934 YYVIKTDRDKKERLIQEGKLDRKFSISY 3490.89 3490.89 -0.62 2.09E-16 F1M7T1 
Protein LOC100364909 QVTQPTVGMNFKTPRGAV 1946 1930.01 8217.59 9.07E-18 D3ZFA8 
Protein LOC681849 GMQKGDLFKAE 1223.58 1222.6 802.02 7.8E-09 F1LWR6 
Protein Psme4 LLLESPLSGEGGSF 1404.7 1404.71 -9.3 8.15E-08 D4A5W2 
Protein RGD1307752 EPPQPQLANGAL 1233.64 1233.64 1.24 9.43E-07 Q5FVK9 
Protein RGD1563155 FLLAMLDYLTDYILE 1830.98 1831.93 -521.56 4.76E-12 D3ZZR0 
Protein S100-A6 IYNEALK 849.46 849.46 -2.08 2.52E-08 P05964 
Protein Snta1 
ASGRRAPRTGLLELRSGAGSGAGGERWQR
VL 
3262.74 3220.74 12873.5 2.88E-20 F1MA17 
Protein Utrn NSTFPSCSPNVPSRPQAI 1900.91 1900.91 -2.24 3.64E-18 G3V7L1 
Pyruvate kinase PKPDSEAGTAFIQTQQLHAAMADTF 2674.27 2674.27 -1.07 5.02E-09 F1MAC8 
RCG32968, isoform CRA_a LRKLNMSIL 1086.65 1086.66 -4.75 8.28E-11 D4A7V2 
Serpin H1 YQAMAKDQAVENIL 1592.79 1592.79 -1.05 2.95E-12 P29457 
Serum albumin EAHKSEIAHRFKDLGEQHFKGLVL 2788.48 2788.48 -0.78 3.7E-13 P02770 
SH3 domain-binding glutamic 
acid-rich-like protein 
LGLTAPPGSKEAEAQAKQQA 1994.04 1994.04 -1.24 6.96E-17 B5DFD8 
SH3 domain-binding glutamic 
acid-rich-like protein 
LTAPPGSKEAEAQAKQQA 1823.94 1823.94 -0.47 5.52E-10 B5DFD8 
Sodium-coupled neutral 
amino acid transporter 1 
KLVIFGATSLQNTGAMLSYLFIV 2501.35 2485.37 6389.21 1.42E-09 D3Z9A6 
Solute carrier family 2, 
facilitated glucose 
transporter member 2 
MYIGEIAPTTLRGALGTLHQLALVTGILISQIAG
LSFILGNQDYWHILLGL 
5474.07 5474.02 9.63 1.4E-07 F1LSF1 
Thiosulfate sulfurtransferase FRRAPPETRVSQGKSGKA 1971.08 1971.08 -0.95 3.13E-15 P24329 
Thiosulfate sulfurtransferase SEWFRRAPPETRVSQGKSGKA 2373.22 2373.23 -2.34 3.4E-15 P24329 
Thymosin beta-10 ADKPDMGEIASFDKAKLKKTETQEKN 2963.49 2921.48 14175.7 4.82E-06 P63312 
Thymosin beta-10 
ADKPDMGEIASFDKAKLKKTETQEKNTLPTK
ETIEQEKRSEIS 
4933.52 4891.51 8515.38 2.62E-32 P63312 
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Table 4.2, continued 
 
      
Thymosin beta-4 KTETQEKNPLPSKETIEQEKQAGES 2828.39 2828.4 -3.66 3.78E-07 P62329 
Thymosin beta-4 LKKTETQEKNPLPSKETIEQEKQAGES 3069.58 3069.58 -1.55 1.66E-08 P62329 
Trifunctional enzyme subunit 
alpha, mitochondrial 
RAIGSLSR 858.504 858.504 -1.94 1.78E-11 F1M9X9 
Triosephosphate isomerase VDIINAKQ 899.508 899.508 -1.29 1.25E-13 P48500 
Tubulin alpha-1C chain FSETGAGKHVPR 1284.66 1284.66 -2.31 2.96E-16 Q6AYZ1 
Tubulin alpha-1C chain FSETGAGKHVPRAVF 1601.83 1601.83 -2.23 5.3E-34 Q6AYZ1 
Tubulin alpha-1C chain YCLEHGIQPDGQMPSDKTIGGGDDSFNTF 3128.34 3128.35 -2.93 1.5E-30 Q6AYZ1 
Tubulin alpha-4A chain KVGINYQPPTVVPGGDLAK 1953.04 1952.07 498.32 9.84E-10 Q5XIF6 
Tubulin beta-5 chain IREEYPDR 1076.53 1076.53 -1.36 3.7E-10 P69897 
Tubulin beta-5 chain VVPSPKVSDTVVEPYNAT 1901.98 1900.98 526.37 2.96E-11 P69897 
Ubiquitin-60S ribosomal 
protein L40 
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDK
EGIPPDQQRLIFAGKQLEDGRTLSDYNIQKES
TLHLVLRLRGG 
8559.61 8559.62 -1.16 1.35E-13 P62986 
Uncharacterized protein FKDGLEMEKC 1198.54 1198.54 -1.39 4.35E-29 F1LYR7 
Uncharacterized protein 
FQYDSTHGKFNGTVKAENGKLVINGKPITIFQ
ERDPANIKWGDAGAEY 
5323.66 5323.67 -1.48 9.54E-11 F1LY57 
Uncharacterized protein ISWYDNEYGYSNRVVDL 2091.94 2091.95 -2.47 1.01E-34 F1LZV7 
Uncharacterized protein 
LQQYGAELGKPGTSVKLSCKVSGYNIRSTYM
HWVNQRPGKGLEW 
4965.53 4965.52 2.73 4.37E-10 D3ZWD9 
Uncharacterized protein MAYMASKE 929.399 929.399 -1.04 7.05E-26 F1LZV7 
Uncharacterized protein RVAPEEHPVL 1145.62 1145.62 -1.89 1.17E-10 F1LTQ2 
Uncharacterized protein VKVGVNGFGRIGRLVTRAAFSCDKVDIVA 3046.69 3046.69 -0.22 8.48E-09 E9PTV9 
Uncharacterized protein 
C16orf86 homolog 
LTHNLPPLVEEVGEEPGGLSS 2173.09 2173.09 -0.31 7.25E-12 D3ZAQ5 
Up-regulated during skeletal 
muscle growth protein 5 
LVLYFKLRPKKTPAVKAT 2073.29 2072.29 482.68 1.68E-11 Q9JJW3 
Vimentin 
ESLPLVDTHSKRTLLIKTVETRDGQVINETSQ
HHDD 
4111.09 4111.09 -0.92 1.23E-11 G3V8C3 
  
125 
 
Table 4.2, continued 
 
      
Vimentin 
ESLPLVDTHSKRTLLIKTVETRDGQVINETSQ
HHDDLE 
4353.21 4353.22 -2.38 4.9E-12 G3V8C3 
Vimentin 
RETNLESLPLVDTHSKRTLLIKTVETRDGQVI
NETSQHHDD 
4724.4 4724.41 -3.04 2.56E-30 G3V8C3 
Zinc transporter 8 
DAAHLLIDLTSFLLSLFSLWLSSRPPSKRLTF
GWYRAEILGALLSVLCIWVVTG 
6044.35 6044.32 4.65 8.07E-08 P0CE46 
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Table 4.3A 
Peptides Identified from Pre-Stimulation Collections in Release Samples* 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
Accession 
Number 
Activity-regulated cytoskeleton-
associated protein 
HVRRTHRHLLTEVS 1739.98 1739.97 5.88 5.1E-10 Q63053 
Adenosine deaminase, RNA-
specific, isoform CRA_b 
IGELVRY 848.476 848.476 -1.14 1.6E-10 G3V8T3 
Aldehyde dehydrogenase family 
16 member A1 
EGRALRQT 929.504 929.504 3.16 2.5E-13 Q3T1L0 
Alt Splice Form 2 in Receptor-
type tyrosine-protein 
phosphatase zeta 
LSILFEIGVEENLDYKAII 2178.19 2178.18 3.87 2.7E-13 Q62656-2 
Cystatin-A YEKFKVVEY 1203.62 1203.62 -2.88 3.6E-11 P01039 
E3 ubiquitin-protein ligase UBR4 SCKQALIRV 1016.58 1016.58 -4.29 1.4E-16 D3ZZA2 
FACT complex subunit SSRP1 FEKLSDF 884.428 884.428 -0.64 1E-16 Q04931 
Formin-binding protein 1 LNDYAGQHEVISENMTSQITVDLVRY 2995.42 2994.44 327.51 1.9E-09 D4ACC9 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQR
M 
3475.66 3475.66 -1.26 3.8E-18 P01946 
Hemoglobin subunit alpha-1/2 
VLSADDKTNIKNCWGKIGGHGGEYGEEALQR
MF 
3622.72 3622.73 -2.64 5.1E-26 P01946 
Hemoglobin subunit beta-1 GKVNPDDVGGEALGRLLVVYPW 2353.24 2353.24 -0.71 1.4E-14 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRY 1323.7 1323.7 -1.11 4.7E-31 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRYFD 1585.79 1585.79 -0.92 6.1E-10 P02091 
Hemoglobin subunit beta-1 LVVYPWTQRYFDSF 1820.89 1819.89 551.29 4.6E-15 P02091 
Hemoglobin subunit beta-1 VHLTDAEKAAVNGLWGKVNPDDVGGEALGRL 3200.66 3200.66 0.2 3.8E-10 P02091 
Hemoglobin subunit beta-1 
VHLTDAEKAAVNGLWGKVNPDDVGGEALGRL
L 
3313.74 3313.74 -1.14 5.4E-37 P02091 
Hemoglobin subunit beta-1 VVYPWTQRY 1210.61 1210.61 -1.38 1.9E-28 P02091 
Hemoglobin subunit beta-1 VVYPWTQRY 1210.61 1210.61 -1.29 2.6E-24 P02091 
Laforin FQKFGKVHS 1076.58 1076.58 -1.36 1.2E-07 F1LPW7 
Mitochondrial fission regulator 1 LQEQQSPSAGCLDS 1461.63 1461.64 -3.47 3.8E-09 G3V9A7 
Myocilin GAVVYSGSLY 1014.5 1014.5 3.48 4.2E-11 Q9R1J4 
Neuferricin TGPPSDQQDNPRHSNRGDLDNPNLEEY 3064.35 3064.35 -1.1 2.5E-08 Q6AY62 
Neuron-specific protein family 
member 1 
FYTVIN 755.385 755.385 -0.88 3.3E-07 P02683 
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Neuropeptide Y receptor type 5 IAIVRY 733.449 733.449 -1.45 1.4E-08 Q63634 
Olfactory receptor 1202 
(Predicted) 
MLTDFVSENIISYVGCMTQLFFFCFFVNSECY
VL 
4008.85 4008.82 6.84 1E-06 D3ZNU9 
Olfactory receptor 1314 
(Predicted) 
FFTFQLT 902.454 902.454 -1.07 3.6E-11 D4A7M9 
Olfactory receptor 830 
(Predicted) 
YLAICKPLHYP 1316.7 1316.7 2.46 6E-11 D4ABI3 
Potassium voltage-gated channel 
subfamily H member 5 
EVTLSIPVD 
1013.50
8 
971.518 41428.7 8.3E-08 Q9EPI9 
Prolactin-like protein P SEVLLKVTID 1115.64 1115.64 -1.13 7.5E-18 Q1KZI1 
Protein ALEX EAWVSRAL 930.492 930.492 0.25 1.8E-12 Q9Z213 
Protein Ankrd17 YVDVVKVLLES 1262.71 1262.71 -0.45 5.1E-12 F1LNJ0 
Protein Atg16l1 SDHTEETSPVRAISRAA 1825.89 1825.89 1.33 1.4E-12 D3Z8U3 
Protein Defa7 FGERLA 691.365 691.365 -0.82 3.8E-17 F1LQB7 
Protein Dntt KDIEGIPCLGD 1158.57 1158.56 5.73 1.9E-12 E9PT58 
Zero beta-1 globin VHLTDAEKATVNGLWGKVNPVEIGAESL 2946.55 2946.55 1.27 8.8E-17 Q62669 
Protein Klk14 PVARSCASPGTPCRVSGWGTTASPIVRYP 2955.39 2972.48 
-
5783.91 
1.7E-13 F1M091 
Protein Lpin1 YVGQLAGQVFVTVKEL 1749.97 1749.97 -2.21 3.9E-14 D4A6P4 
Protein Mbnl1 AFLPPGSILCMTPATSVVPMVHGATP 2593.3 2593.31 -5.42 7.8E-13 F1M9N4 
Protein Myof MDEIISIRVY 1237.65 1237.64 5.44 7.2E-12 D3ZX26 
Protein Olr1626 TRVSEFVLLGLSS 1406.78 1406.78 1.23 3.7E-08 D3ZSF6 
Protein Rexo4 KIRDTQKFKP 1259.74 1259.74 -0.45 9.9E-18 B1WBN4 
Protein RGD1309110 ISKLVFIMGLNLLLNVQLDSAYQL 2704.5 2704.52 -5.64 1.2E-12 D3Z824 
Protein Scgb3a1 FVESLAKPVVEPVAALAPAAEA 2178.19 2178.19 -1.5 1E-13 D3ZKK2 
Protein Sema3e GQQFVGDALDRT 1305.63 1305.63 1.94 1.1E-17 D3Z8E2 
Protein Slc39a2 MTAEALEGIESEIQKFVVQNSTG 2480.22 2480.21 2.55 7.7E-14 D3ZIN1 
Protein Ubl5 LELYY 700.348 699.348 1432.33 1.1E-05 A9UMW0 
Protein Znf536 DIGEEAGRAGG 1030.47 1030.47 2.75 4.9E-19 D3ZJS6 
Serine/threonine-protein kinase 
Sgk3 
EFIQNLVRY 1180.62 1180.62 -1.33 9.2E-17 Q8R4V0 
Serum albumin EAHKSEIAHRF 1339.66 1323.67 11939.2 3.7E-17 P02770 
Serum albumin FYAPELLYY 1177.57 1177.57 -1.24 7.4E-22 P02770 
Serum albumin HPYFYAPELL 1248.62 1248.62 -0.37 5.6E-14 P02770 
Serum albumin HPYFYAPELLY 1411.68 1411.68 -2.53 2.9E-09 P02770 
Serum albumin HPYFYAPELLYY 1574.74 1574.74 -0.99 4.4E-22 P02770 
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Sideroflexin-5 KFTPATR 819.46 819.46 -0.81 4.5E-08 Q8CFD0 
Sideroflexin-5 KFTPATR 819.46 819.46 -1.06 1.9E-06 Q8CFD0 
T-cell-specific surface 
glycoprotein CD28 
APARDFAA 817.408 817.408 -0.94 1.9E-11 P31042 
Tetratricopeptide repeat protein 
36 
RAVTLSGGRGRAARQSFVQ 2017.1 2016.11 490.08 1.2E-09 Q66H45 
Uncharacterized protein FEKDIAY 884.428 884.428 -0.86 4.9E-13 F1M4J9 
Uncharacterized protein KFPQLSF 865.47 865.47 -1.23 1.3E-09 F1M3Z7 
Uncharacterized protein LRQVTGAMRVTLQ 1471.82 1471.83 -3.71 3E-11 D3ZZD4 
Uncharacterized protein QFNAIRLV 959.555 959.555 -0.8 1.2E-14 D3ZP07 
Uncharacterized protein VAATVVYLVTEV 1262.71 1262.71 -1.4 2.8E-14 D3Z903 
Uncharacterized protein VSLHLIPA 847.492 848.512 
-
1205.16 
4.8E-08 D3ZNS9 
Zinc transporter 1 LLLTFMFMVLEVVVSRVT 2096.2 2096.18 7.75 9.1E-16 Q62720 
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Table 4.3 B 
Peptides Identified from Stimulation Collections in Release Samples* 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
Accession 
Number 
Ac1591 SWSRGIL 817.445 817.445 -0.81 9.72E-11 Q7TQ71 
Aldehyde dehydrogenase family 
16 member A1 
EGRALRQT 929.504 929.504 3.05 1.95E-13 Q3T1L0 
Alt Splice Form 3, Predicted in 
Magnesium transporter MRS2 
homolog, mitochondrial 
EYLLILDY 1040.55 1040.54 8.11 3.63E-12 Q9ET09-3 
Cystatin-A YEKFKVVEY 1203.62 1203.62 -2.96 1.83E-11 P01039 
E3 ubiquitin-protein ligase UBR4 SCKQALIRV 1016.58 1016.58 -4.1 2.63E-17 D3ZZA2 
FACT complex subunit SSRP1 FEKLSDF 884.428 884.428 -0.98 2E-19 Q04931 
Formin-binding protein 1 LNDYAGQHEVISENMTSQITVDLVRY 2994.43 2994.44 -2.33 1.06E-12 D4ACC9 
Hemoglobin subunit beta-1 LVVYPWTQRY 1323.7 1323.7 -2.09 4.63E-09 P02091 
Hemoglobin subunit beta-1 GKVNPDDVGGEALGRLLVVYPW 2353.24 2353.24 -1.98 1.05E-17 P02091 
Keratin, type II cytoskeletal 4 SLKSTKNEISELNRMIQRIRSEIENIKKQ 3484.71 3484.92 -60.54 3.38E-10 F1M7R4 
LanC-like protein 1 HSLVKPSVDFVCQLKFPSGNYPSCLDD 2994.44 2994.43 2.15 2.31E-13 Q9QX69 
Myoblast determination protein 
1 
ERISTDSPAAPSLLLPDAPPESPPGPPEETSS
SDAEQG 
3828.76 3827.79 254.3 3.1E-10 A0JPK9 
NAD(P)H-hydrate epimerase VCARHLKLFGYQPTIYY 2071.06 2071.07 -3.46 1.15E-11 B0BNM1 
Neuron-specific protein family 
member 1 
FYTVIN 755.385 755.385 -0.75 4.09E-12 P02683 
Neurotrypsin HSEDAGVICDYYEKKTSGHGNK 2437.11 2437.1 3.95 8.94E-18 G3V801 
Nucleoside diphosphate kinase 
7 
EWYDPNASLLRRYELLYY 2363.17 2363.16 5.47 7.94E-11 F1LVA7 
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Table 4.3B, continued       
Procollagen, type VI, alpha 3 
(Predicted), isoform CRA_a 
VIVVLTDGQSEEDGFALPSAELKSADVNVFA
VGVEDADERTLREIAS 
4960.48 4960.48 -0.25 2.16E-11 D4A111 
Prolactin-like protein P SEVLLKVTID 1115.64 1115.64 -1.4 4.23E-18 Q1KZI1 
Protein Akr1c12 QRYKEWVDQNSPVLLNDP 2200.11 2200.09 8.02 1.47E-12 D3ZPY8 
Protein Atg16l1 SDHTEETSPVRAISRAA 1825.89 1825.89 1.44 6.35E-14 D3Z8U3 
Protein Defa7 FGERLA 691.365 691.365 -0.67 3.79E-17 F1LQB7 
Protein Dntt DIEGIPCLGD 1030.47 1030.46 6.83 9.94E-10 E9PT58 
Protein Invs 
LVFLLLVRNEKGDITTDSENSTPLHASANSIFK
ETVKVFLTHPSVRDDSDL 
5666.93 5667.94 -178.3 1.56E-09 D4A4A8 
Protein LOC100365781 CSSHMIVISISYGSCIFMYVKPSA 2620.24 2622.24 -762.8 9.6E-09 D3ZXS3 
Protein LOC691277 KVPQPSTSL 955.534 955.534 -1.01 2.69E-09 D3ZF53 
Protein Lpin1 YVGQLAGQVFVTVKEL 1749.97 1749.97 -1.18 2.22E-18 D4A6P4 
Protein Reep3 ALYTVIETVADQTLAWFPLYY 2476.26 2476.26 -1.56 1.93E-10 D4A0H1 
Protein RGD1564626 KSTSHKRKRVNSPLSRSK 2096.19 2095.21 
468.5
3 
2.48E-10 F1LTP3 
Protein Scgb3a1 FVESLAKPVVEPVAALAPAAEA 2178.19 2178.19 -0.99 7.47E-16 D3ZKK2 
Protein Sema3e GQQFVGDALDRT 1305.63 1305.63 2.32 4.61E-17 D3Z8E2 
Protein Siglec10 THGAQTTSVLL 1126.6 1126.6 2.69 1.05E-16 D3ZF71 
Protein Susd3 GLKGHNHNNSSSVGGGSGGSSGGGGKPGI 2561.2 2519.19 16404 3.62E-12 D3Z8I2 
Q8R4V0 EFIQNLVRY 1180.62 1180.62 -0.73 9.85E-15 Q8R4V0 
Q8R4V0 EFIQNLVRY 1180.62 1180.62 -1.16 2.39E-13 Q8R4V0 
Serum albumin FYAPELLY 1014.51 1014.51 -0.36 2.95E-13 P02770 
Serum albumin HPYFYAPEL 1135.53 1135.53 -1.29 2.79E-11 P02770 
Serum albumin FYAPELLYY 1177.57 1177.57 -0.82 1.43E-20 P02770 
Serum albumin HPYFYAPELL 1248.62 1248.62 -1.01 1.53E-16 P02770 
Serum albumin HPYFYAPELLY 1411.68 1411.68 -1.75 5.16E-11 P02770 
Serum albumin HPYFYAPELLYY 1574.74 1574.74 -1.18 2.48E-18 P02770 
Sideroflexin-5 KFTPATR 819.46 819.46 -0.93 6.81E-12 Q8CFD0 
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Transmembrane protein 106B 
GDVSQFPYVEFTGRDSVTCPTCQGTGRIPR
GQENQ 
3828.76 3828.76 0.35 2.16E-10 D3ZVZ6 
Uncharacterized protein QFNAIRLV 959.555 959.555 -0.9 1.18E-16 D3ZP07 
Uncharacterized protein VAATVVYLVTEV 1262.71 1262.71 -0.37 4.84E-15 D3Z903 
Uncharacterized protein LRQVTGAMRVTLQ 1471.82 1471.83 -3.78 1.5E-10 D3ZZD4 
Uncharacterized protein YAVRCNSSLGVLKV 1507.83 1507.82 4.07 1.24E-09 D4A693 
Uncharacterized protein KPPNLIMTPSNYQQIDMRGMYQSVAGG 2995.42 2995.44 -5.53 8.77E-12 D3ZYW0 
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Table 4.3 C 
Peptides Identified from Post-stimulation Collections in Release Samples* 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
Accession 
Number 
Aldehyde dehydrogenase family 16 
member A1 
EGRALRQT 929.504 929.504 2.84 2E-17 Q3T1L0 
Autophagy protein 5 TPLKWHYP 1040.55 1040.54 5.8 4E-13 F1LPF9 
Enolase FGANAILGVSLAVCKA 1532.85 1532.84 4 4E-10 D3ZJT8 
FACT complex subunit SSRP1 FEKLSDF 884.428 884.428 -1.09 7E-16 Q04931 
Formin-binding protein 1 LNDYAGQHEVISENMTSQITVDLVRY 2994.43 2994.44 -2.53 2E-17 D4ACC9 
Mapk1ip1 protein KRVTWGDIKTLTHKAETLGK 2281.31 2281.29 8.83 2E-15 B0JYS4 
Olfactory receptor 830 (Predicted) YLAICKPLHYP 1316.7 1316.7 1.09 7E-13 D4ABI3 
Prom1 protein QGLLVYR 847.492 847.492 -1.37 3E-13 A0JN22 
Protein Defa7 FGERLA 691.365 691.365 -0.96 5E-16 F1LQB7 
Protein LOC682397 ALSGSEVKMQIFVKTL 1749.96 1749.97 -3.29 6E-13 F1M0Q4 
Protein LOC686689 SVTLYISEVQLNTMAGASV 1981.99 1982 -4.12 9E-10 D4ACN9 
Protein LOC690082 DYFTTQASYPLRRAIQEGDLH 2480.22 2480.21 3.16 2E-13 D4A410 
Protein LOC691889 PRFLYEQIRRAANAFFLFIAL 2556.34 2555.42 358.73 7E-09 F1LUH8 
Protein Lpin1 YVGQLAGQVFVTVKEL 1749.97 1749.97 -1.41 4E-19 D4A6P4 
Protein Myof MDEIISIRVY 1237.65 1237.64 4.71 2E-15 D3ZX26 
Protein Rbpms LYPAELAPALP 1153.64 1153.64 -3.44 5E-15 F1M7J8 
Protein RGD1310951 IGSAKLIPHVTSAINTE 1749.96 1749.96 1.85 2E-09 D3ZA11 
Protein Slc39a2 MTAEALEGIESEIQKFVVQNSTG 2480.22 2480.21 2.03 1E-14 D3ZIN1 
Protein Sypl1 VATFLWLVSSSAWAKALTDI 2178.19 2178.17 8.69 2E-07 Q66H18 
Serine/threonine-protein kinase 
Sgk3 
EFIQNLVRY 1180.62 1180.62 1.3 2E-19 Q8R4V0 
Serum albumin FYAPELLYY 1177.57 1177.57 -1.75 1E-27 P02770 
Serum albumin HPYFYAPELL 1248.62 1248.62 -0.93 3E-16 P02770 
Serum albumin HPYFYAPELL 1248.62 1248.62 -0.05 3E-13 P02770 
Serum albumin HPYFYAPELLY 1411.68 1411.68 -1.32 6E-10 P02770 
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Table 4.3C, continued 
 
      
Serum albumin HPYFYAPELLYY 1574.74 1574.74 -2.39 9E-09 P02770 
Sideroflexin-5 KFTPATR 819.46 819.46 -0.93 3E-08 Q8CFD0 
Ubiquitin-60S ribosomal protein 
L40 
MQIFVKTLTGKTITLEVEPSDTIENVK
AKIQDKEGIPPDQQRLIFAGKQLEDG
RTLSDYNIQKESTLHLVLRLR 
8444.55 8445.57 -120.54 8E-09 P62986 
Ubiquitin-60S ribosomal protein 
L40 
MQIFVKTLTGKTITLEVEPSDTIENVK
AKIQDKEGIPPDQQRLIFAGKQLEDG
RTLSDYNIQKESTLHLVLRLRGG 
8559.6 8559.62 -2.47 9E-25 P62986 
Uncharacterized protein FYAPELI 852.443 851.443 1175.6 1E-12 F1M2Z1 
Uncharacterized protein EFVVTKI 835.485 834.485 1200.54 7E-17 D3ZEA8 
Uncharacterized protein ETQKSIYY 1030.5 1030.5 2.36 7E-17 F1LY01 
Uncharacterized protein HAKVLLAYHQ 1179.64 1178.66 833.25 7E-12 F1M1Y6 
Uncharacterized protein LRQVTGAMRVTLQ 1471.82 1471.83 -3.71 2E-12 D3ZZD4 
Uncharacterized protein VSLHLIPA 848.472 848.512 -44.39 1E-11 D3ZNS9 
Zinc transporter 1 LLLTFMFMVLEVVVSRVT 2096.19 2096.18 5.69 3E-14 Q62720 
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CHAPTER 5 
LABEL-FREE QUANTITATION OF PEPTIDE RELEASE FROM 
NEURONS IN A MICROFLUIDIC DEVICE WITH MASS 
SPECTROMETRY IMAGING 
 
5.1 Notes and acknowledgments 
This chapter consists of work that was published in Lab on a Chip (2012, 12, pp 2037–
2045) and is reprinted here with permission from The Royal Society of Chemistry. This article is 
available from http://pubs.rsc.org/of using DOI: 10.1039/C2LC21085A. The manuscript has 
been reproduced here for completeness and additional unpublished data has been included. Ming 
Zhong performed the peptide collections, calibration curve, and release collections and analysis. 
Chang Young Lee made the model for the adsorption process and cultured the Aplysia neurons. I 
performed the radioactivity studies and optimized the PEG procedure. Anika Jain, from Martha 
Gillette’s lab provided the extracted PDMS. This work was supported by the National Science 
Foundation, Award No. DMI-0328162, the National Institute on Drug Abuse, Award No. 
P30DA018310, and the National Institute of Neurological Disease and Stroke, Award No. 
R01NS031609. 
 
5.2 Abstract 
Microfluidic technology allows the manipulation of mass-limited samples and when used 
with cultured cells, enables control of the extracellular microenvironment, making it well suited 
for studying neurons and their response to environmental perturbations. While matrix-assisted 
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laser desorption/ionization (MALDI) mass spectrometry (MS) provides for off-line coupling to 
microfluidic devices for characterizing small-volume extracellular releasates, performing 
quantitative studies with MALDI is challenging. Here we describe a label-free absolute 
quantitation approach for microfluidic devices. We optimize device fabrication to prevent 
analyte losses before measurement and then incorporate a substrate that collects the analytes as 
they flow through a collection channel. Following collection, the channel is interrogated using 
MS imaging. Rather than quantifying the sample present via MS peak height, the length of the 
channel containing appreciable analyte signal is used as a measure of analyte amount. A linear 
relationship between peptide amount and band length is suggested by modeling the adsorption 
process and this relationship is validated using two neuropeptides, acidic peptide (AP) and α-bag 
cell peptide [1–9] (αBCP). The variance of length measurement, defined as the ratio of standard 
error to mean value, is as low as 3% between devices. The limit of detection (LOD) of our 
system is 600 fmol for AP and 400 fmol for αBCP. Using appropriate calibrations, we 
determined that an individual Aplysia bag cell neuron secretes 0.15 ± 0.03 pmol of AP and 0.13 
± 0.06 pmol of αBCP after being stimulated with elevated KCl. This quantitation approach is 
robust, does not require labeling, and is well suited for miniaturized off-line characterization 
from microfluidic devices. 
 
5.3 Introduction 
Microfluidics has made significant contributions to analytical chemistry since the 
technology was first introduced.
1,2
 The small volumes of microfluidic devices enable handling of 
mass-limited samples with minimal reagent consumption, control of local microenvironments, 
and integration of multiple processing steps into a single system. Consequently, microfluidics 
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has been extensively used to investigate low-amount analytes
3-6
 and to provide promising 
platforms that mimic in vivo environments for cell-based biological studies.
7-9
   
One of the challenges in this field has been the integration of microfluidic devices with 
information-rich detection modalities. As a detection scheme, mass spectrometry (MS) can 
unambiguously identify multiple analytes simultaneously from a small-volume biological sample 
without prior preselection. In particular, matrix-assisted laser desorption/ionization (MALDI) 
MS offers several advantages, such as tolerance to salts and other contaminants and spectra that 
are easy to interpret, making it quite useful for proteomic and peptidomic studies, including 
investigations of nervous system tissues.
10-12
 Microfluidic systems can be readily interfaced with 
MALDI offline, either by depositing eluents from the device onto a MALDI target
13
 or by 
directly using a substrate as the target.
14-16
 With the development of MALDI MS imaging, spatial 
information can be added to the characterization process by allowing measurements of 
biomolecular distributions across samples.
17,18
 Previously, we demonstrated MALDI imaging 
from a poly(dimethylsiloxane) (PDMS) device comprised of a reservoir for accommodating cells 
and a derivatized surface for collecting secreted materials.
19
 Direct imaging of the surface 
revealed areas in the device containing both known and unknown analytes, without prior 
knowledge of their exact locations. Here, we adapt that earlier device to achieve improved 
accuracy and precision. 
Although we are interested in obtaining qualitative information on the molecules present 
in a sample, it can also be important to know their quantity. However, MALDI is not considered 
quantitative because peak heights are not always directly related to the amount of analyte 
present.
20
 The reasons for the disconnect between peak heights and analyte amounts include 
uneven distributions of analytes within matrix crystals, varied ionization efficiencies that depend 
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on the molecular structure and environment, and ion suppression effects, especially from 
complex mixtures.
21,22
 One solution is to use stable isotopic labeling, which overcomes several 
of the challenges of direct quantitation with MS.
23,24
 For absolute quantitation, an internal 
standard that incorporates a heavy isotope (e.g., 
2
H, 
13
C, 
15
N, or 
18
O) is added for each 
corresponding analyte and accurate measurements are done by comparing the intensity or area of 
paired peaks. For relative quantitation, peptides in two samples are differentially labeled with a 
distinguishable mass difference between two isotopic forms and are then combined for 
comparison. Stable isotopes can be incorporated into peptide molecules either through metabolic 
labeling
25
 or by attachment with isotopic tags.
26
 Owing to the development of a number of novel 
labeling schemes,
24,27,28
 significant progress has been made in quantitative MS; it has been 
applied in the analysis of various biomolecules,
29-32
 enabling measurement of contents from 
single cells.
33
 However, using stable isotopic labeling within microfluidic devices presents 
several challenges: labeling adds multiple steps to the sample preparation process, organic 
labeling reagents may not be compatible with PDMS and are toxic to live cells, and finally, the 
labeling reactions inevitably dilute the mass-limited samples. Therefore, a more amenable and 
simple quantitation strategy is needed for PDMS devices. 
Here we modify an approach used in many diagnostic tests in which the length of color 
change along a strip is related to the amount of analyte. We combine this with off-line MALDI 
MS to demonstrate that the adsorption length in a microfluidic channel is proportional to analyte 
amount.  Because the ability of a surface to adsorb an analyte is fixed per unit length, the larger 
the quantity of sample, the longer the section of channel it will cover. This approach is label-free. 
We have adapted our prior device for such measurements,
19
 improving its design and 
implementing a more controlled solution flow. Calibration curves obtained with multiple 
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standards show the expected linear relationship between length and amount; a model of the 
adsorption process supports the linear nature of length-to-amount for multiple analytes. We 
demonstrate the ability to measure peptide release from a small number of Aplysia bag cell 
neurons, a well-characterized neurosecretory model,
34,35
 and are able to extract absolute 
quantitative information for the released peptides. 
 
5.4 Experimental 
 
5.4.1 Materials and reagents 
Unless stated otherwise, organic solvents were from Fisher Scientific (Fair Lawn, NJ) 
and the other chemicals from Sigma-Aldrich (St. Louis, MO). The PDMS prepolymer kit, 
Sylgard 184, was purchased from Dow Corning (Midland, MI). Silicon wafers were obtained 
from WRS Materials (Spring City, PA); 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane 
(OEG, 90%) was from Gelest, Inc. (Morrisville, PA) and used as received. Negative photoresist 
SU-8 2050 and developer were obtained from MicroChem Corp. (Newtown, MA). Positive 
photoresist AZ 5214-E and developer were from AZ Electronic Materials Corp. (Somerville, 
NJ). Acidic peptide (AP) was synthesized at the Roy J. Carver Biotechnology Center (University 
of Illinois at Urbana-Champaign). α-bag cell peptide [1-9] (αBCP, 80%) was purchased from 
American Peptide Company, Inc. (Sunnyvale, CA). Angiotensin II (Ang II), (5-L-Isoleucine) 
[tyrosyl-3,5-
3
H(N)] (specific activity = 50 Ci/mmol, concentration 1 mCi/mL) was from 
American Radiolabeled Chemicals, Inc. (Saint Louis, MO). Ultima Gold LLT liquid scintillation 
solution was purchased from Perkin Elmer. Filtered artificial sea water (ASW, pH 7.8) contained 
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460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 26 mM MgSO4, 2.5 mM NaHCO3, 
and 15 mM HEPES. 
 
5.4.2 Substrate derivitization 
A piece of silicon wafer was patterned with AZ 5214-E photoresist via standard 
photolithography so that about 2/3 of the bare silicon was exposed. The patterned substrate was 
dipped in a mixture of 15 mL chloroform and 35 mL hexane with octadecyltrichlorosilane (OTS, 
0.8% v/v) for 10 min and then in hexane for 10 min, as modified from previous procedures.
19,36
 
The chip was rinsed with acetone to remove the photoresist and dried at 70 °C for 3 h. The 
partially derivatized surface was immersed in 50 mL toluene containing OEG (0.8% v/v) 
overnight, followed by immersion in toluene for 1 h, rinsing with methanol, and drying at 70 °C 
for 2 h.
37,38
 Substrates were rinsed with methanol and water sequentially and dried with nitrogen 
directly before use.  
 
5.4.3 Device fabrication 
Microfluidic devices consisted of PDMS with channel features sealed onto derivatized 
silicon substrates. The PDMS pieces were formed by molding Sylgard 184 onto a 
photolithographically patterned SU-8 master. Small pieces of silicone tubing (Helix Medical, 
LLC, Carpinteria, CA) were glued onto SU-8 features that served as device outlets.
39
 The PDMS 
prepolymer was then poured onto the master and cured at 70 °C overnight. The inlet reservoir 
was made with an AcuPunch (Acuderm, Inc., Ft. Lauderdale, FL) biopsy punch of 1.5 mm 
diameter. To reduce sample loss to the PDMS material, the channels were sequentially treated 
with 5:1:1 H2O:HCl:H2O2 for 5 min, H2O for 5 min, OEG for 30 min, and finally flushed with 
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500 μL of deionized (DI) water (Milli-Q Biocel, Millipore Corporation, Billerica, MA) to yield 
OEGylated PDMS, as described previously.
40
 For plasma treatment, the PDMS was subjected to 
oxygen plasma for 30 s at 100 W with a March Plasmod (March Instruments, Concord, CA) 
oxygen plasma system and stored in DI water for future use. Extracted PDMS was prepared 
according to the previous procedure.
41
 Prior to use, PDMS pieces were rinsed with methanol and 
water and dried with nitrogen. 
 
5.4.4 Scintillation measurements of peptide absorption 
The radiolabeled Ang II was diluted to 1 pmol/μL with DI water, and 2 μL aliquots of the 
solution were incubated for 4 h in microchannels made of five different types of PDMS: native, 
plasma-treated, extracted, OEGylated, and OEGylated extracted. Incubated solutions were 
pushed out of each device through polytetrafluoroethylene tubing (Cole-Parmer Instrument 
Company, Vernon Hills, IL) and into microcentrifuge tubes. The devices were then rinsed with 2 
µL of DI water and the rinsing solution was pushed into the same microcentrifuge tube. The 
combined Ang II and rinse solutions were pipetted into a 20 mL glass scintillation vial; 5 mL 
aliquots of liquid scintillation solution were added to each vial and counted with a liquid 
scintillation counter (Beckman LS 6500, Beckman Coulter, Inc., Brea, CA); 2 µL aliquots of the 
Ang II solution before incubation were also measured as a control. 
 
5.4.5 Standard peptide calibration experiments 
AP and αBCP were used as received and dissolved in ASW to various concentrations (1–
10 pmol/μL) for storage. The outlet tubing of the PDMS device was connected to a 25 μL 
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syringe (Hamilton Company, Reno, NV) controlled by a Harvard PHD 2000 syringe pump 
(Harvard Apparatus, Holliston, MA) set at the refill mode. For calibration with a single peptide, 
a desired amount of AP was loaded into the inlet reservoir and pulled through the channel to the 
outlet at the rate of 0.1 μL/min. For multiple peptide experiments, AP and αBCP were mixed in 
the inlet prior to assay. Three or more individual samples were tested for each amount, and the 
mean and standard error of adsorption length were calculated. The best-fit straight lines for 
adsorption length versus amount were obtained. 
 
5.4.6 Cell experiments 
Aplysia californica (100–150 g, National Resource for Aplysia, Miami, FL) were 
anesthetized by injecting 390 mM of MgCl2 solution equal to 1/2 of each animal's body weight. 
The abdominal ganglia with adjacent nerves were dissected and incubated in ASW containing 10 
mg/mL protease from Streptomyces griseus at 34 °C for 90 min, modified from previous 
experiments.
42
 This treatment facilitated removal of the connective sheath tissue around the 
ganglia and isolation of individual neurons. After washing with fresh ASW, individual bag cells 
were isolated and plated into the inlet chamber of a microfluidic device. Cells were allowed to 
attach to the substrate for at least 1 h and then stimulated by adding an elevated KCl solution 
(final concentration 55 mM). Following a 15 min incubation, released peptides were collected 
onto the OTS-functionalized surface by transporting the extracellular media with the syringe 
pump. The pump was stopped right before the inlet reservoir became completely empty and the 
remaining liquid was removed. The flow was then resumed until the solution in the channel was 
depleted. 
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5.4.7 MS imaging 
After peptide collection, the PDMS was peeled off of the silicon substrate. A MALDI 
matrix, 2,5-dihydroxybenzoic acid (DHB, 10 mg/mL in 50%/50% acetonitrile/water), was 
sprayed onto the surface with an airbrush (Paasche Airbrush Company, Chicago, IL) placed at a 
distance of ~15 cm. The substrate was then taped onto a modified target plate and MALDI 
characterization was performed with a Bruker UltrafleXtreme time-of-flight (TOF) mass 
spectrometer (Bruker Daltonics, Inc., Billerica, MA) in the reflectron mode. MS images were 
obtained at 100 or 200 μm resolution with each spot summed from 200 laser shots. Mass 
calibration was done with peptide calibration standard II (Bruker Daltonics). The images were 
analyzed with flexImaging software (Bruker Daltonics), with the threshold value for analyte 
detection set at 10% of the maximum intensity on the OTS surface. Individual mass spectra were 
analyzed with FlexAnalysis (Bruker Daltonics) and replotted with Origin, version 8.5 (OriginLab 
Corporation, Northhampton, MA).  
 
5.5 Results and discussion 
 
5.5.1 Minimizing peptide losses 
Our goal was to design a device that allows the efficient collection of the media around 
cultured cells and its subsequent characterization via off-line MS. Because of the small scale of 
the fluidics, there is a large surface-to-volume ratio and so surface loss becomes a significant 
concern. Figure 5.1 show the absorption of a small, fluorescent molecule, Rhodamine B, into the 
PDMS over the course of 20 h. A significant amount of absorption can be observed into native 
  
145 
 
PDMS. Obviously, peptides that either partition into or adsorb onto surfaces in the culturing 
chamber or fluidic channels cannot be measured via MS and are lost. Hence, we carefully 
minimized sample losses using surface derivatization protocols and then characterized those 
losses using sensitive radionuclide detection.  
  In order to minimize partitioning of the molecules into the PDMS material, its chemical 
properties have to be optimized. This includes adsorption due to the hydrophobicity of PDMS, 
and the even the diffusion of uncrosslinked oligomers and remaining platinum catalysts into bulk 
channel solutions.
41,43,44
 Several surface treatment protocols have been employed in the past. 
Oxygen plasma treatment is a widely-used method that renders PDMS hydrophilic, making it 
more amenable to aqueous solutions.
45
 PDMS extraction, which consists of a series of solvent 
washes to remove the uncured oligomers and remaining platinum catalysts used to cure the 
polymer, significantly improves cell viability in low-density cultures.
41
 OEGylation, by 
derivatizing the PDMS surface with OEG, has been shown to reduce protein absorption and to 
provide more hydrophilic channels.
38,40
 The bottom of figure 5.1 shows the overall reduction in 
absorption of Rhodamine B upon OEGylation. By measuring the amount of peptide lost by our 
devices with these treatments, we obtain a more accurate measurement of total peptide release 
from the neurons.   
We measured these losses using radionuclide detection because of its low detection limits 
and absolute quantitation abilities. We incubated 
3
H-labeled Ang II in a PDMS device containing 
1 mm diameter reservoirs and a straight channel (200 μm wide, 100 μm high, 10 mm long), and 
then measured the loss of peptides from the surface-treated PDMS materials compared to the 
native. Recovered peptides from the native, plasma-treated, extracted, OEGylated and 
OEGylated extracted PDMS were quantified. Figure 5.2 shows the signal from radiolabeled Ang 
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II recovered from each type of PDMS compared to non-incubated solutions. Approximately 50% 
of the peptide was recovered from native, plasma-treated, and extracted PDMS; whereas 
recovery of 70–75% was observed for OEGylated and OEGylated extracted PDMS, indicating a 
significant reduction in loss upon OEG treatment (p < 0.05, refer to Figure 5.2). Furthermore, 
although the absorption of Ang II into the extracted PDMS (and also the plasma-treated one) was 
not appreciably different from the native PDMS (p = 0.90), absorption was significantly reduced 
(p < 0.001) when the extracted PDMS was OEGylated. While OEG treatment did not eliminate 
sample loss, it certainly reduced it. There was no significant difference (p = 0.35) between the 
OEGylated and OEGylated extracted PDMS. Therefore, OEGylated PDMS was utilized here; 
however, the combined OEGylated and extracted PDMS will be explored in future studies as it 
may aid cell viability.  Peptide losses also depend on specific device dimensions, possibly 
making these treatments even more important for the smaller scale and longer serpentine 
channels explored below. 
 
5.5.2 Device design and fabrication 
Our microfluidic device contains a serpentine channel (200 μm wide, 50 μm high, 110 
mm long) with inlet and outlet ports (Figure 5.3). The dimensions of the channel permit a stable 
flow at the rate of 50 nL/min to 5 μL/min. The cell culture/sampling chamber is the inlet to the 
device; a diameter of 1.5 mm was optimal for ease of liquid handling and cell loading as well as 
minimizing sample losses that occur with too large an inlet reservoir. Silicone tubing embedded 
into the PDMS structure ensures a good seal at the outlet and thus, stable liquid flow.  
We divided the substrate into two regions, each with different surface chemistries. About 
2/3 of the silicon substrate underneath the channel is functionalized with OTS for peptide 
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collection.
46,47
 The other 1/3 is functionalized with our OEG treatments to reduce peptide losses 
from the sampling/inlet chamber. The PDMS device is carefully aligned with the OTS-OEG 
boundary, as shown in Figure 5.3. 
 
5.5.3 Modeling the molecular adsorption and separation in microchannels 
Before using the device to quantify peptides and to gain insight into the device design 
and operation, we developed a simplified kinetic model to describe the molecular adsorption in 
the microfluidic device. Consider a plug of analytes (A) with a width (W) of 200 μm, length (L) 
of 200 μm, and height (H) of 10 μm. The plug flows through a 10 cm-long microchannel at a 
linear velocity of v (Figure 5.4A). The channel is divided into 200 μm-long segments of the same 
size as the plug (total 500 segments). In each segment the analytes are allowed to adsorb 
irreversibly onto adsorption sites (θ) at the bottom surface, occupying Aθ sites, with the 
adsorption rate constant kA for the time period of τ = L/v.  
 AA Ak  (1) 
The total number of binding sites is constant and determined by the surface area (W × L) and the 
size of the A molecule (assumed 1 nm for this study). From the site and material balance: 
      AT            (2) 
][][][ AAA O           (3) 
where [θ]T and [A]o represent the total binding sites in a segment and the concentration of A 
when entering each segment, respectively. We assume a bimolecular elementary reaction, 
monolayer adsorption, no interaction between analytes, and no surface migration of analytes. 
Therefore, the adsorption rate is 
  
148 
 
          ))((][  AAAkAk
dt
Ad
TOAA   (4) 
Upon completion of the reaction in a segment, the plug then discretely moves to the next 
segment where further adsorption takes place. The process repeats until the analyte plug migrates 
along the entire channel length. 
The solutions are obtained for an initially clean substrate using ODE solvers in 
MATLAB, and Figure 5.4B shows the surface coverage of the analyte ([Aθ]/[θ]T) versus channel 
distance for amounts ranging from 1 pmol to 30 pmol. kA = 10000 M
-1
s
-1
 and v = 2.5 mm/s are 
used, and a coverage of 1 indicates saturation. The length covered by an analyte increases with 
amount. The linear result of length versus amount supports our concept of quantitation. When 
this sample is analyzed using MS imaging, the signal intensity is related to the surface coverage. 
We find that using the end point of the analyte band (i.e., adsorption length), rather than fitting 
the MS intensity profile directly to the model, is a robust measure for quantitation. Here we 
defined the threshold surface coverage above which the presence of analytes can be detected 
with MALDI to be 0.1. With this criterion the adsorption length versus amount is plotted at v = 
2.5 mm/s for kA values of 5000 M
-1
s
-1
, 10000 M
-1
s
-1
, and 50000 M
-1
s
-1
 (Figure 5.4C). The 
adsorption length is linearly proportional to the amount, and turns out to be insensitive to kA. The 
result suggests that our quantitation method, the amount-to-length conversion, can be applied to 
peptides with different adsorption characteristics. 
For a given device design and a system to be analyzed, the only parameter under external 
control is flow rate. Understanding the effect of flow rate thus aids in obtaining reliable 
quantitation. In Figure 5.4D, the surface coverage for 10 pmol is plotted at a linear velocity of 
0.83 mm/s to 42 mm/s, which corresponds to 0.1 μL/min to 5 μL/min for continuous feed (kA = 
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10000 M
-1
s
-1
). To fully utilize the adsorption capability of the substrate, the flow rate should be 
low so that the convection timescale remains longer than the reaction timescale (
AACk
1 ), 
where CA denotes initial analyte concentration. When this condition is met, the adsorption length 
is insensitive to the flow rate and varies only with the amount of analytes, as shown in Fig. 5.4E. 
For a mixture of analytes with different adsorption rate constants, a separation between them is 
expected due to their differential adsorption. Consider a mixture of two analytes (5 pmol each of 
A and B) with adsorption rate constants kA = 10kB = 100000 M
-1
s
-1
. The adsorption is now 
competitive between the two, and a similar site and material balance applies to the rate 
equations. When the analyte plug flows down the channel, preferential adsorption of A occurs, 
followed by adsorption of B as A in the solution is depleted. The result is two distinct analyte 
bands (Figure 5.4F). The same principle applies to a mixture of three different analytes (5 pmol 
each of A, B, and C) as shown in Figure 5.4G. In the actual experiments, analytes are 
continuously supplied to the channel as a long band rather than a plug, and a thin layer 
chromatography-like separation occurs as the mobile phase drives the adsorbates. This separation 
mechanism is not discussed further. 
 
5.5.4 Validation of the model with standards 
Next, we experimentally validated our model using two neuropeptide standards, AP (m/z 
2959.6) and αBCP (m/z 1122.6), two well-characterized peptides released from Aplysia bag cells 
and cleaved from the same egg laying prohormone.
48
 We first performed the calibration 
experiments with only AP to determine optimized conditions. The flow rates of 0.1 and 0.05 
μL/min and analyte concentrations of 1 and 0.5 pmol/μL were tested with the same amounts of 
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AP. As suggested by the model, the detected adsorption length was insensitive to the analyte 
concentration and the flow rate at 0.1 μL/min and below where 1AACk . Therefore, the flow 
rate of 0.1 μL/min was used for subsequent experiments to minimize experimental times. Peptide 
standards (1, 3, 5, 10, or 15 pmol AP in ASW) were added into the reservoir and pulled through 
the channel. The resulting MS images in Figure 5.5A show the adsorbed AP, with AP signals 
visualized in yellow. A representative mass spectrum is shown in Figure 5.5B. These images 
clearly demonstrate that the adsorption length increased proportionally with the amount of 
peptide introduced. Despite the large intensity fluctuation at individual pixels within the MS 
image, the signal remains obvious throughout until the front of the band. The observed profile 
well matches the model’s predictions shown in Figure 5.4B, suggesting the saturation of 
adsorption sites except for the band boundaries. A calibration curve (Figure 5.5C) plotting the 
adsorption length of AP versus its amount shows a good linearity within the tested range (R
2
 = 
0.97). The variance of length measurement, defined as the ratio of standard error of the mean 
(s.e.m.) to mean, is from 3% to 12% from distinct microfluidic devices. The small negative 
intercept of the fit line is primarily due to sample lost to the sampling chamber. Indeed, we 
detected AP signals in the inlet reservoir even with OEG functionalization. However, when the 
AP solution was pulled through the channel above the OEG-functionalized surface, no AP peaks 
were detected, demonstrating the ability of OEG to prevent peptide adsorption. Therefore, the 
signals in the inlet were unlikely from peptide adsorption, but most likely from residual peptides 
left behind as the liquid dried in the reservoir. It is possible that the presence of an inlet 
contributed to the variance of measured length, but the linear length-amount relationship 
indicates that this is not a large effect. The slope of the calibration equation suggests that the AP 
occupies 2.8 mm of channel length per pmol, equaling to a surface coverage of 1.8 × 10
2
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pmol/cm
2
. We previously reported that the value of Ang II is 33 pmol/cm
2
.
19
 Peptide adsorption 
properties depend on chemical structure and polarity;
49
 the slight differences in surface coverage 
for AP and Ang II are expected. In all, experiments on AP demonstrate that quantitation based on 
length of coverage is feasible. 
 As mentioned previously, neurons often secrete multiple peptides during stimulation and 
MS can characterize each. Thus, we wanted to determine whether two peptides can be 
simultaneously measured and if the linear length-to-amount relationship is still maintained. We 
tested our device by mixing AP and αBCP in the reservoir; the amount of AP was fixed at 3 
pmol and αBCP varied from 1 to 15 pmol. MS images for each amount of αBCP are shown in 
Figure 5.6A, with yellow spots for AP and green for αBCP. For each sample tested, two distinct 
bands were clearly visible. A representative mass spectrum for each band is shown in Figure 
5.6B, confirming that these two peptides were separated. Based on our model and the fact that 
AP deposited first on the channel, it appears that AP has a higher adsorption than αBCP. From 
each image, the adsorption length of the αBCP band was measured, and the calibration curve for 
length versus amount (Figure 5.6C) demonstrates a linear relationship (R
2
 = 0.98) in the tested 
sample range. The variance of length measurement is in the range of 3 to 8%. From the slope of 
the linear fit, the surface coverage of αBCP was calculated as 1.6 × 102 pmol/cm2, close to the 
value of AP. The small positive intercept of the straight line was likely caused by the variance in 
length measurement. The series of MS images also indicate that the length of 3 pmol of AP 
remained essentially constant, suggesting that the changing amounts of other analytes have 
limited influence on the band length. This was further confirmed by fixing the amount of αBCP 
at 3 pmol and varying AP from 1 to 5 pmol; the resulting αBCP bands were of constant length, 
and the length of AP was the same as the corresponding length when αBCP was not present. 
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Therefore, this quantitation method is applicable when more than one analyte is present. 
Moreover, because each of the above experiments was done on a different device, the 
reproducibility of imaging profiles demonstrates the robustness of our measurement platform. 
 
5.5.5 Measuring neuronal release 
Aplysia bag cell neurons, located in the abdominal ganglion, are commonly used as a 
model to study activity-dependent neurosecretion. They were used in this study to document the 
capability of our approach for quantifying peptide release from neurons. When the surrounding 
KCl concentration is elevated, the membrane is depolarized, leading to the release of several 
peptides that originate from egg laying prohormone.
35,50
 Previous studies used intact abdominal 
ganglia placed in perfusion systems and the secreted peptides in the perfusate were quantified by 
HPLC
51
 or radioactivity.
50,52
 The results showed high variability in the amounts of peptides 
released from different ganglia, but on average, the amount of each peptide from a single bag cell 
was in the upper femtomole range, assuming about 400 bag cells per ganglion. Compared to 
perfusion systems, microfluidic devices more efficiently collect the extracellular environment 
with minimal sample loss, and allow more precise timing of chemical stimulations. Here, 15 
cells were loaded into the sampling chamber (Figure 5.7A), and control experiments analyzed 
the media surrounding the cells without KCl stimulation. An MS image of a control is presented 
in Figure 5.7B, in which yellow indicates AP and green, αBCP. The peptide signals in the 
reservoir were due to cell lysis occurring when the chamber was dried. No peptide signals 
associated with bag cell stimulation were detected there, indicating that the lysis products did not 
enter the channel. A representative mass spectrum from the channel area of the control device is 
shown in Figure 5.7D. When the cells were treated with 55 mM KCl for 15 min, the peaks for 
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AP and αBCP were detectable in the channel (Figure 5.7C and 5.7D). Both peptides were 
detected as separate, distinct bands, and their identities confirmed via MS. Based on the 
measured lengths and the calibration equations obtained with standards, the amount of AP 
released from 15 bag cells was estimated to be 2.3 ± 0.4 pmol, and αBCP, 1.9 ± 0.9 pmol (mean 
± s.e.m., from 3 samples), meaning that the average isolated cell in vitro released 0.15 ± 0.03 
pmol of AP and 0.13 ± 0.06 pmol of αBCP. These values are consistent with the femtomole 
release expected from a single cell.
51,52
 The results presented here validate our approach for 
quantifying peptide release from a microfluidic device based on the adsorption length measured 
using MS imaging. 
 
5.6 Conclusions 
Microfluidics is receiving greater attention in analytical chemistry because of its ability to 
perform low-volume manipulations and work with samples such as cells. At the same time, MS 
has become the preferred technology for peptidomics and proteomics measurements. By 
combining MS with a microfluidic sampling system, we have successfully developed an off-line 
approach for quantifying the media located around cells for neuropeptides. The adsorption-
length-based approach takes advantage of the imaging capability of MALDI while avoiding the 
challenges of conventional signal-intensity-based quantitation by offering a simple, robust and 
label-free solution for quantitative studies. Validated using peptide standards and releasate from 
Aplysia bag cell stimulation, this approach is flexible and can be adapted to many other 
molecular classes in addition to neuropeptides. Future work will use more complex devices with 
multiple channels and collection areas so that our analyses will include monitoring multiple 
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secretion events with time and/or spatial resolution and comparison of releasate under different 
physiological conditions. 
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5.7 Figures 
 
Figure 5.1 The adsorption of Rhodamine B dye into untreated, native PDMS (top) and 
OEGylated PDMS (bottom) over a 20 hour period.  
 
  
    t = 0 hour                 t = 1 hour       t = 3 hours              t = 20 hours 
Native PDMS 
OEGylated PDMS 
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Figure 5.2 Radiolabeled Ang II peptide recoveries following 4 h incubations from PDMS 
subjected to different treatments, as well as the control solution before incubation. The p-values 
comparing peptide recovery from OEGylated PDMS to other types of PDMS are listed above 
each corresponding bar; the significance (p < 0.05) demonstrates the ability of OEG to reduce 
peptide absorption. Error bars represent s.e.m. 
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Figure 5.3 Device design. The microfluidic device contains a long serpentine channel (200 μm 
width × 50 μm height × 110 mm length). The inlet reservoir is made by punching PDMS with a 
biopsy punch, and the outlet has a short segment of tubing for connection to a syringe pump. 
(Left) The chip design on a transparency mask. (Right) A photomicrograph of the PDMS device. 
Note that the substrate is patterned with OEG and OTS, with their boundary visualized by the 
grey line. The inlet is on the OEG, and the channel and outlet on the OTS. 
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Figure 5.4 A simple kinetic model describes the molecular adsorption in the microfluidic device. 
(A) An analyte plug (W × L × H) flows through a microchannel with liner velocity of v. The 
channel is divided into multiple segments where the analytes in the solution are consumed by 
adsorption. (B) The adsorption length of analytes increases with the amount. (C) The adsorption 
length is insensitive to a wide range of kA. (D) Collection efficiency decreases at high flow rates. 
(E) The relative timescale between the reaction and convection determines the sensitivity of 
adsorption length to flow rates. (F–G) Analytes with sufficiently different adsorption rate 
constants can be separated by the microchannel. 
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Figure 5.5 Characterization of AP peptide via MS imaging of the microfluidic device substrate. 
(A) A series of MS images of the adsorption of 1, 3, 5, 10, and 15 pmol of AP. Each spot where 
AP is detected is colored yellow. (B) Representative mass spectrum showing AP. (C) The 
calibration curve of adsorption length versus amount of AP obtained using the observed length 
from the MS image. Error bars represent s.e.m. 
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Figure 5.6 MS imaging of two peptides (AP and αBCP) from the microfluidic substrate. (A) A 
series of MS images of the adsorption of 1, 3, 5, 10, and 15 pmol of αBCP and 3 pmol AP. 
Yellow color indicates AP and green, αBCP. (B) Representative mass spectra for the AP 
and αBCP bands, respectively. (C) The calibration curve of adsorption length versus amount 
for αBCP. Error bars represent s.e.m. 
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Figure 5.7 Aplysia bag cell release experiments with the microfluidic device. (A) Micrograph of 
the sample chamber showing the 15 neurons loaded into the inlet reservoir. (B) MS image for 
collection of peptide release when no stimulant was added. (C) MS image after neurons were 
treated with elevated KCl (final concentration = 55 mM). Yellow indicates AP and green, αBCP. 
(D) Representative mass spectra for the control, and for the AP and αBCP bands from the release 
experiments, respectively. 
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CHAPTER 6 
LABEL-FREE QUANTITATION OF PEPTIDE RELEASE FROM 
NEURONS IN A MICROFLUIDIC DEVICE WITH MASS 
SPECTROMETRY IMAGING 
 
6.1 Notes and acknowledgments 
This study presents a device design which improves upon the work presented in Chapter 
5. An undergraduate in our lab, Jennifer Weber, assisted with optimizing peptide collections in 
the device. Chang Young Lee and Ming Zhong offered helpful suggestions. This work was 
supported by the National Science Foundation, Award No. DMI-0328162, the National Institute 
on Drug Abuse, Award No. P30DA018310, and the National Institute of Neurological Disease 
and Stroke, Award No. R01NS031609.  
 
6.2. Introduction 
 The nervous system consists of a vast array of neurons and connections which assist in 
regulating and controlling nearly every process in the body. Within this complex system, neurons 
act through numerous signaling molecules to transmit and relay information to local and distant 
targets. Neuropeptides are a class of signaling molecules that play a role in the regulation and 
maintenance of a wide range of physiological processes including learning and memory,
1
 pain,
2,3
 
social bond formation,
4
 hunger,
5
 and sleep.
6,7
 Abnormal levels of neuropeptides have been 
implicated in a number of diseases and disorders.
5
 Increased expression was observed for 
enkalphalins, nociception, neuropeptide Y, Substance P, and neurokinin B in the epileptic 
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hippocampus.
8
  Additionally, the overexpression of galanin is thought play role in memory 
decline in Alzheimer’s disease.9  Finally, substance P was found to be downregulated follow 
neuronal axotomy in the smaller neurons of dorsal root ganglia (DRG).
10
 Levels of peptides in 
the brain reveal certain information about the physiological status of a particular region. Diseases 
and disorders of the nervous system are multifaceted and involve a whole host of cells and 
molecules.
11
 The involvement of neuropeptides is just one factor involved. However, 
understanding both the incoming chemical milieu that yields normal versus abnormal levels of 
peptides, and identifying and quantifying the resulting neuropeptides can give key insight into 
the chemical nature of diseases and disorders and provide an effective route for drug therapies. 
To accomplish such a task, analytical efforts must first be focused on sampling and quantifying 
peptides from a normal functioning region, gaining insight into neuronal network formation and 
function. Then, more complex systems which mimic the disease of interest can be created and 
interrogated, noting differences in peptide expression from the established normal functioning 
model.  
The effective sampling of neuropeptides from complex brain and periphery space can be 
challenging, as neuropeptides are present at low levels over a wide dynamic range. Bulk in vivo 
studies of a particular network or region can suffer from analyte averaging and the loss of low 
level peptide signals, as there exists a large degree of cell-to-cell heterogeneity in the nervous 
system. 
12
 Additionally peptides can be present in a region having been released and diffused 
from other regions. Isolating the network of interest removes the analyte diffusion and peptide 
averaging that results from in vivo collections.  
Microfluidic devices provide a number of benefits toward efficient sampling of 
neuropeptides. The small volumes manipulated in microfluidic devices (nL to µL) offer a 
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significant reduction in dilution of mass-limited peptides compared to those experiences in dish-
based culture samples. Extracellular environments surrounding the neurons can be precisely 
controlled and manipulated to better mimic in vivo conditions, selectively add chemical 
stimulations,
13
 and precisely collect released peptides through the use of microvalves,
14
 device 
designs,
15,16
 and complex fluid handling. Microfluidics is quickly becoming an indispensable 
tool in the field of neuroscience. Applications have included designs for studying axonal 
regeneration,
15
 and provided selective chemical stimulations and improved on-chip detection of 
analytes.
13
 Both liquid chromatography and capillary electrophoresis designs have been 
implemented into device designs
17,18
 and microfluidics are amenable to a number of detection 
modalities including fluorescence, electrochemical methods, and mass spectrometry.
19
  
 The many advantages of mass spectrometry make it well-suited to study neuropeptides. 
MS is a highly sensitive technique which can interrogate a wide range of analytes without prior 
analyte selection.
20
 In recent years, mass spectrometry imaging has been applied to brain and 
spinal cord tissue samples, which involves taking distinct mass spectra at discrete spots over a 
range or map of a sample.
21
 The most common application of MSI involve the investigation of 
the spatial localization of small molecules, lipids, and peptides within a tissue. MALDI imaging 
is employed for peptide samples. MALDI also offers high salt tolerances and spectra which are 
relatively easy to interpret, making it quite useful for peptides and proteins.
20
 MALDI MS is not 
an inherently quantitative technique as peak heights do not always directly relate to analyte 
amount. Several reasons for this involve uneven matrix preparations, ion suppression, and 
variability in ionization efficiencies.
22,23
 Heavy isotope internal standards can be added for 
absolute quantitation, and relative quantitation can be performed by labeling two separate 
samples with heavy and light isotopes and comparing the intensity of their peaks.
24
 However, 
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performing a labeling step within a device is not as straightforward, and reagents use are 
typically toxic to cells and any added solutions would further dilute the sample.  
 As an alternative to quantitation with labeling, previous work from our group presented a 
label-free approach to investigate the quantitative nature of peptide release by combining 
microfluidics and mass spectrometry imaging.
16,25
 The method involves a C-18 functionalized 
silicon wafer which promotes peptide adsorption through hydrophobic interactions. Following 
stimulation, any released peptides will flow through PDMS channels and adsorb to the substrate, 
The substrate is then analyzed with mass spectrometry imaging (MSI). A standard curve is 
created by spiking known peptide amounts into the inlet and measuring the subsequent 
adsorption length of the peptide down the channel that is observed with MSI. Thus, when peptide 
release is studied from a cell population, the length of peptide adsorption can be compared to the 
standard curve and the peptide amount can be determined. The study presented here builds upon 
the previous device design and procedure for quantifying peptide release.  
Neuron populations are highly sensitive to their surrounding chemical milieu as well as 
physical perturbations, such as shear forces, which can result in a cell leaking its contents and 
even cell death.  When studying peptide release, it is essential to perform control studies to 
ensure that any peptide release that follows chemical stimulations has not harmed the culture or 
induced death. Furthermore, peptide release often follows burst firing of neurons and can occur 
anywhere from milliseconds to minutes following stimulation.
26,27
 Studying the onset and length 
of release can yield additional information regarding specific chemical stimulations and can give 
further insight into the formation, form, and repair of neuronal networks. The previous design 
presented by our group did not allow for these necessary control investigations and peptide 
kinetics to be studied. A modified device design is presented which includes the addition of extra 
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channels to the design. Furthermore, the new design includes positive media addition to more 
gently perfuse media and chemically stimulate cultured neurons. Microvalves were also added to 
the design to more specifically direct solutions down the appropriate channel.
28
  The resulting 
device is capable of quantitatively and temporally studying peptide release from a low-density 
neuron culture within the device. 
Here, we demonstrate the fabrication of this new device design with standard peptides. 
Adsorption lengths of acidic peptide from Aplysia californica’s bag cell neurons demonstrates a 
robust response between different spiked standards. Future work involving the quantitation of 
peptide release from dorsal root ganglia neurons will be discussed. 
 
6.3. Experimental 
 
6.3.1 Materials and methods 
Organic solvents were from Fisher Scientific (Fair Lawn, NJ) and chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO). The PDMS prepolymer kit was obtained from 
Dow Corning (Midland, MI). Silicon wafers were purchased from WRS Materials (Spring City, 
PA). 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane  (OEG, 90%) was received from 
Gelest, Inc. (Morrisville, PA). SU8 2075 photoresist and developer were from MicroChem Corp 
(Newton, MA). AZ 4620 positive photoresist and AZ developer 400K were attained from AZ 
Electronic Materials Corp. (Somerville, NJ). Acidic peptide was synthesized by the Roy J Carver 
Biotechnology center (University of Illinois at Urbana-Champaign). Filtered artificial seawater 
(ASW) consisted of 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 26 mM MgSO4, 
2.5 mM NaHCO3, and 15 mM HEPES. 
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6.3.2 Substrate derivitization 
 Small pieces (3 cm by 2 cm) of cut silicon wafer were patterned with AZ4620 photoresist 
so that 2/3 of the silicon was bare. The patterned silicon was then treated with 
octadecyltrichlorosilane (0.8% v/v) in 70/30 hexanes/chloroform for 10 min, which was followed 
by a hexane rinse for 10 min as discussed elsewhere.
25
 Acetone was then used to remove the 
remaining photoresist and the partially functionalized wafer was put in an oven at 70°C for 3 
hours or overnight. The chip was then cooled, and put into a 0.8% v/v OEG in toluene overnight. 
The wafer was then rinsed with toluene for 1 hour while stirring. Finally, the chips were rinsed 
with methanol, and dried with N2 prior to use.  
 
6.3.3 Device fabrication 
 The microfluidic device consists of two separate layers- the bottom or flow channel layer, 
and the top, or pressure channel layer. The flow channel master was prepared using AZ 4620 
positive photoresist to a height of 25 μm. Wafers were heated to 200°C for 20 minutes to reflow 
the master and create rounded channels. Surfaces were exposed to octadecyltrichlorosilane for 4 
hours in a vacuum desiccator to ensure PDMS removal from the master. The pressure channel 
master was prepared by spinning SU8 2075 photoresist to a height of 100 μm. Small pieces of 
silicone tubing (Helix Medical, Carpinteria, CA) were glued onto the features of the SU8 master. 
Uncured PDMS was spun onto the flow channel master at 2050 rpm for 60 sec. The pressure 
channel master was placed in a tissue culture dish and 5:1 uncured PDMS was poured on top to a 
thickness of 1.5-2 mm. Both masters were placed in the oven at 70°C and were allowed to cure 
just until set. The PDMS pressure channel was removed from the master and was aligned on top 
of the flow channel master, and the entire PDMS block and flow channel master were placed in 
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the oven and cured together at 90°C overnight. Reservoirs within the PDMS block were made 
with a biopsy punch to 1 mm (Acuderm, Inc., Ft. Lauderdale, FL). The PDMS block is then 
aligned with the functionalized silicon wafer. Tubing and reservoirs were filled with ASW and 
neurons were loaded into the cell reservoir. Pressure channels were connected to an in-house 
built pneumatic solenoid valve system which is controlled by LabView software (National 
Instruments, Austin, TX). The program supplies and removes pressure, which causes the device 
channels to be closed or open, respectively.  
 Calibration measurements were performed on a simpler aspect of the main design. 
Instead of a two layer design, the calibration channels were fabricated from a 1 layer AZ 4620 
master. Silicon tubing was glued to the inlet feature on the master and 10:1 PDMS was poured 
over the octadecyltrichlorosilane treated master. The PDMS was cured at 70°C for 1 hour and 
was then cut into individual pieces and aligned with the derivitized silicon wafer. The design 
consisted of a single serpentine flow channel, instead of three channels.  
 
6.3.4 Standard peptide measurements 
 Peptide measurements that were used to confirm the proper functioning of the 
microvalves were performed in the 3-channel device design (Figure 6.1A), with the left and right 
microvalves turned on and the middle microvalve turned off. Calibration peptide measurements 
that were used to create a calibration curve used the modified 1- channel device design described 
above (Figure 6.1B). A 25 μL syringe connected the inlet tubing to a syringe pump (Harvard 
Apparatus, Holliston, MA). Milli Q water was flowed through the tubing and into the channel 
until it reached the main reservoir. 2 μL of the standard peptide solution was then added to the 
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reservoir and flow was resumed at 0.1 μL/min for 4 hours to completely push the peptide from 
the main reservoir into the channels. The syringe pump was stopped and solution within the 
channels was dried. An image was then taken of the device, and the PDMS block was removed. 
10 mg/mL 2,5-dihydroxybenzoic acid in 1:1 ACN:water was then sprayed onto the substrate. 
The substrate was adhered to a MALDI target with copper tape and was loaded into the 
instrument for imaging. An UltrafleXtreme™ TOF mass spectrometer (Bruker Daltonics) in the 
reflectron mode was used to analyze peptide releasates. Peptide calibration was performed with 
peptide calibration standard II (Bruker Daltonics). Following the imaging run, an image was 
generated in flexImaging (version, Bruker Daltonics) which showed the localization of the 
peptide within the channel. The minimum intensity was chosen based on verifications that the 
lowest intensity peaks observed had a S/N > 5. The channel length was measured. 
 
6.4 Results and discussion 
 
6.4.1 Device design and fabrication 
 Previous work in our lab has demonstrated the use of a silicon wafer and MALDI 
imaging to quantify peptide release in a method that is independent of peak area or height.
16
 This 
approach involves the C18 functionalization of a silicon wafer which promotes peptide 
adsorption through hydrophobic interactions. The system consists of a PDMS microfluidic 
channel which guides the peptide solutions as they interact with the substrate. Following peptide 
collection, the PDMS is removed and a MALDI matrix is applied to the substrate. The substrate 
is then analyzed by MALDI-TOF-MS imaging and the length of peptide adsorption is measured 
(Figure 6.1). Our previous work demonstrated experimental results which followed a theoretical 
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model. Multiple peptides present within the channels were shown to separate based on a TLC-
like separation. Finally, peptide release from Aplysia californica collected, characterized, and 
compared to a calibration curve agreed with previous release data.  
The goal of this project was to expand upon our previous approach and devices to create 
a design which provided quantitative information and temporal control over peptide collection, 
while providing accurate biological information regarding the neuron culture of interest. One of 
the limitations of the previous design involved the inability to perform controls directly on chip. 
Performing controls is essential to verifying that release occurred from chemical stimulation and 
not from physical or chemical stress on the neurons. In order to perform these controls on-chip, 
additional channels needed to be added to the design. Furthermore, additional channels will 
allow for the study of peptide release kinetics and comparisons between chemical stimulations. 
While our previous work had demonstrated a device with 3 channels which studied peptide 
release, this design often results in unwanted peptide migration down the other two channels 
(Figure 6.2). To selectively collect peptides within the channels, the design was modified to 
include microvalves, which are capable of opening and closing channels, removing unwanted 
peptide migration. Furthermore, the new design incorporates the ability to continually perfuse 
cells within the device, which is gentler than previously employed negative pressure. Finally, 
microvalve controlled stimulation channels have been added to the design to selectively 
stimulate neurons and study the conditions that govern release. 
The main device design consists of a media inlet which flows into the cell reservoir 
(Figure 6.3). Two microvalve controlled stimulation channels are perpendicular to the main 
channel. After the cell reservoir, the main channel diverges into 3 serpentine channels, which are 
controlled by microvalves. The cell reservoir is 1 mm in diameter to reduce dilution. Cells are 
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loaded directly into the reservoir and a PDMS coverslip is added to keep solutions in the device. 
The flow channels within the device are 200 µm wide by 50 µm high and rounded; pressure 
channels are 200 µm wide by 100 µm high. The microvalves are controlled by a pneumatic 
device connected to a LabView program. The microvalves can each be turned on or off and for 
varying amounts of time. 
To verify that the microvalves were capable of selectively collecting peptide release 
within a specific channel, a standard Aplysia peptide, αBCP, was spiked into the main reservoir. 
The left and right channels were closed and the middle channel was opened (Figure 6.3). The 
solutions were flowed through the middle channel only. αBCP was only observed in the main 
reservoir. In comparison to the previously shown 3-channel devices, this new device system is 
capable of selectively collecting peptides. The original device design consisted of straight 
channels. However, serpentine channels were added to allow for higher amounts of peptide to be 
detected (Figure 6.4). To further demonstrate fluidic isolation, an ink solution was spiked into 
the device (Figure 6.4.) The middle and right channels were closed, whereas the left channel was 
kept open. Ink solutions are unable to enter the closed channels, demonstrating the ability to 
fluidically isolate solutions within the device.  
 
6.4.2 Comparing peptide lengths 
 The quantitation of peptide release in the device system first requires creating a 
calibration curve which relates peptide amount to the length of adsorption down the channel. 
Since previous work demonstrated the creation of a calibration curve for two peptides from 
Aplysia californica, the first step was to show robust adsorption lengths for an Aplysia peptide 
for varying concentrations. Rather than recreating the calibration curve, several amounts were 
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chosen to demonstrate the robust quantitation between the same and different peptide amounts 
(Figure 6.5). Adsorption lengths observed between the same amount are consistent, showing that 
the creation of a calibration curve and ultimate quantitation is possible with this device system. 
 Future work on this project will investigate the quantitative role of neuropeptides in the 
dorsal root ganglia (DRG). The DRG neurons are sensory neurons which play a key role in 
transmitting information from the periphery to the spinal cord, where the information is then 
transferred to the brain.
29,30
 Neurons in the DRG provide an excellent model for studying injury 
and regeneration as processes extend into the periphery where regeneration can occur readily, 
and into the spinal cord, which provides an inhibitory environment for regeneration.
31-33
 
Additionally, DRG neurons play a role in both types of pain- nociceptive and neuropathic and 
thus provide a model for pain study.
2,3
 A quantitative study of peptide release from DRGs could 
provide key information comparing DRG normal functioning versus injury and even pain states. 
The next step for this device platform is to apply this system to a low-density DRG culture and 
study both the quantitative and temporal aspects of peptide release. 
 The first step in performing this study includes identifying the peptide(s) of interest from 
DRG tissue, cells, or release. A current study is underway to perform a peptidomic study of DRG 
tissue with LC-MS/MS. Once the peptides of interest are identified, a calibration curve can be 
created for each peptide using the method described above. Finally, a low-density DRG culture 
will be stimulated within the device and the resulting peptide adsorption length will be compared 
to the calibration curve and quantified.  
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6.5 Conclusions  
 The device system presented here offers an approach for the temporal and quantitative 
study of peptide release from neurons on-chip with mass spectrometry imaging detection. The 
adaptations shown here provide a greater control over chemical stimulation addition, provide for 
selective and temporal collections of peptides, and provide a gentler system for perfusing media 
and chemical stimulations to cultured cells.   
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6.6 Figures 
 
 
 
 
 
 
 
 
 
Figure 6.1 Schematic of MALDI imaging of microchannels. Following peptide collection onto 
the C18 functionalized silicon wafer, an image is taken. The PDMS channels are then removed, 
and matrix is applied via airbrush to the substrate. The wafer is placed onto a MALDI target and 
is inserted into the instrument. The MALDI laser rasters across the determined region, generating 
a mass spectrum at each spot. An overall mass spectrum is created and localization of a 
particular m/z of interest throughout the channels can be studied. 
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Figure 6.2 Mass spectrometry images for two Aplysia peptides, Egg Laying Hormone (m/z 
4359.5) and Acidic Peptide (m/z 2959.5) respectively. Unwanted peptide migration can be seen 
throughout all three channels when only the middle channel is activated. 
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Figure 6.3 MS image showing the precise localization of α bag cell peptide (αBCP m/z 1122.5) 
within the central channel of the device system. Left and right channels were closed during 
collection. Intensity on image corresponds to intensity for each individual spot and seen in top 
and bottom mass spectra. Top mass spectrum corresponds to a high intensity spot, whereas 
bottom mass spectrum links to weak intensity spot. 
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Figure 6.4 Schematic of three-channel device. Cells are loaded and cultured into the cell culture 
reservoir. Stimulations are added to the cultured neurons via microvalve-controlled stimulation 
channels. Peptides are collected onto C18 functionalized silicon wafers. Image on right shows 
fluidic isolation within the channels with ink solution. Left microvalve is open, whereas middle 
and right channels are closed. Ink is only observed in left channel. 
  
  
180 
 
 
Figure 6.5 MALDI images showing the two Acidic Peptide amounts within the channels. The 
first two images demonstrate 1 pmole, while the second two images are of 2 pmole. A robust 
response is observed between the same amount of standard peptide. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE OUTLOOK 
  
 Understanding the complex roles that neuropeptides play throughout the nervous system 
is a challenging task. Reducing complexity by moving these networks to a more well-defined 
space can reduce matrix effects and analyte averaging that occurs in vivo, rendering collection 
and detection more viable. The main objective of this dissertation was to develop analytical 
collection approaches capable of culturing and growing neuronal networks, applying chemical 
stimulations, and collecting released peptides for subsequent characterization with mass 
spectrometry (MS).  Microfluidic devices are well-suited for peptide collections and offer small 
sample volumes which reduce analyte dilution. Moreover, the extracellular environment can be 
precisely controlled through the use of fluid handling and microvalves for media perfusion and 
selective chemical stimulation additions. Two microfluidic devices were designed with the goals 
of identifying peptides and understanding both the quantitative and temporal aspect of peptide 
release. 
 The first device system described in Chapter 3 utilizes microvalve-controlled stimulation 
channels to selectively stimulate cultured neurons. Neurons within the device can be exposed to 
varying lengths of stimulation to study the effects that different chemical stimulations have on 
release. A difference in onset of peptide release was observed for two stimulation experiments of 
Aplysia californica’s bag cell neurons, using elevated K+ and insulin. Peptides were observed 
following 5 min of chemical stimulation with elevated K
+
, whereas 20 min of exposure was 
necessary for insulin stimulation to elicit release. Overall, this device system provides peptide 
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identifications and temporal information regarding the onset and duration of release. This device 
system is versatile. Any neuron or cell culture can be maintained in the device and stimulated 
with a wide range of chemical stimulations. This would allow for investigations into small 
molecule and amino acid transmitters. Additionally, this platform is not limited to neuroscience 
applications and could be applied to study secretion from a number of cell types.  
 Furthermore, this device system could be modified to include selective investigations of a 
cell soma and its processes as well as investigations at synapses by creating microgrooves in 
between culture reservoirs. This would open up investigations into neuron co-cultures and 
neuron-glia interactions. Finally, this collection method could incorporate separation on-chip 
with micro-capillary electrophoresis or liquid chromatography, and it could also be coupled to 
different detection techniques such as fluorescence.  
 Chapter 4 detailed investigations toward studying peptide release in the dorsal root 
ganglia (DRG). The first step involved the establishment of a healthy DRG culture with long, 
healthy process growth. Both DRG clusters and cultures were stimulated and putative peptides 
were detected. In order to confirm the identities of peptides found, the next was to perform a full-
scale peptidomics study of rat DRG tissue, cells, and releasates. The first survey of these samples 
resulted in the identification of over 550 peptides identified from 390 unique proteins. Many 
peptides with direct neuronal functions were identified as well as others involved in translation, 
transcription, transport, and cell structure. Minimal sequence coverage was observed for known 
Hemoglobin-derived peptides, which have been shown to have bioactive activities. This may 
suggest that Hemoglobin-derived peptides play a role in the DRG. The high abundance of 
protein degradation products is believed to be the major cause for not observing neuropeptides 
within the samples. Current work is focused specifically on neuropeptide detection within 
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samples. To improve neuropeptide sampling, a heat-treatment step was applied to samples 
immediately following dissection, and samples are currently being sequenced.  
 Emily Tillmaand will continue investigations toward chemical stimulations of DRG 
neurons using the above device system. In addition to studies involving chemical stimulations, 
another major aspect of Emily’s thesis research will involve investigating the nature of 
mechanical stimulations on neuropeptide release. Morphological and electrophysiological studies 
have shown that neurons respond to specific mechanical environments. However, there is a lack 
of studies exploring neuropeptide release following mechanical stimulations. Therefore, Emily 
will work closer with Taher Saif’s lab, which developed a mechanical platform used to stretch 
neurons.  
 The second device system is described in Chapters 5 and 6. This design provides a label-
free approach for on-chip quantitation and detection of peptide release. Similar to the first 
device, a neuronal network is cultured and stimulated within the device. Following stimulation, 
any released peptides will migrate down a treated polydimethylsiloxane (PDMS) channel across 
a C18 functionalized silicon wafer. Peptides will interact and adsorb to the surface through 
hydrophobic interactions. The PDMS channels can be removed from the substrate and a matrix-
assisted laser desorption ionization (MALDI) matrix is airbrushed onto the surface. MALDI MS 
imaging is then performed and a peptide map is generated across the channel locations. Since 
MALDI is not inherently quantitative, we devised a novel method to quantify peptide release by 
relating the length of peptide adsorption down a channel to the amount present. To this end, a 
calibration curve can be created for each peptide of interest. The length of adsorption following 
neuron release can then be plugged into the calibration curve to determine peptide amount. 
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Peptide release was quantified for two peptides from Aplysia californica bag cell neurons and 
results agreed with previous data.  
 One of the limitations of this device design was its inability to gain temporal information. 
Adding additional channels to the design enables both control and stimulation collections. 
Chapter 5 details modifications to the serpentine channel device by adding three microvalve-
controlled collection channels. These channels selectively direct peptide collections and reduce 
unwanted analyte migration observed in channels without microvalves. Several adsorption 
lengths were compared and verified between peptide amounts with an Aplysia peptide.  Once a 
full peptidomic study of the DRG is completed, future work in this device will involve 
quantifying peptide release for cultured DRG neurons. Key peptides of interest will be spiked 
into the device at varying amounts to create a calibration curve, and thus quantify release.  
 Since the DRG is well-suited for studying injury and regeneration, a potential future 
direction would be to study peptide amount for injury or axotomy across short or long time 
periods. A number of methods exist to enact injury on a process of interest. Compression can be 
performed be applying pressure to the process of interest using microvalves, and processes can 
be severed through the use of detergents or lasers. Investigating the up- and down-regulation of 
the resulting peptides or other signaling molecules may yield significant insight into the 
molecules involved in regeneration. Finally, different surface functionalization for quantifying 
small molecule or amino acid transmitters could also be investigated. 
 Two different device designs were described here. Both designs are complimentary, with 
each possessing distinct advantages. The stimulation device design provides the ability to 
selectively stimulate cultured neurons within the device and temporally collect peptide 
releasates. This device allows for unknown analysis of peptides. The second device offers both 
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quantitative and temporal collections of peptide release. To incorporate a microfluidic device 
into the neuroscience laboratory it needs to be robust, easy to fabricate, and versatile. Both 
devices detailed here fulfill those requirements and are readily amenable to neuroscience 
applications. At present, few microfluidic devices have been applied to neurotransmitters and 
neurotransmission. I expect that slight modifications of existing devices, especially 
compartmentalized devices, will allow for effective interrogation and collection of peptides and 
other signaling molecules in the future.  
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APPENDIX 
MICROFLUIDIC DEVICE FABRICATION 
 
 One of the most challenging aspects of my project was fabricating microfluidic devices 
which do not leak either gas or liquids from unwanted places. I have written this chapter to 
precisely detail tricks and important aspects of the design which will produce properly 
functioning stimulation devices. 
 
Material and methods 
 The following materials are necessary for proper device fabrication: design mask, 3 in 
silicon wafers, SU8 2075 negative photoresist and SU8 developer (MicroChem Corp., Newtown, 
MA), positive photoresist AZ 4620 and 400K developer (AZ Electronic Materials Corp., 
Somerville, NJ), isopropanol, polydimethylsiloxane pre-polymer kit (Dow Corning, Midland, 
MI), octadecyltrichlorosilane (Sigma, St. Louis, MO) biopsy punches (Accuderm, Ft. 
Lauderdale, FL), razor blade or knife, and substrate (glass, ITO, silicon, etc.). 
 
Fabricating the two-layer device 
 After successfully creating an appropriate device design in either Adobe Illustrator or 
Autocad, the University Printing Services can print the transparency mask. To order such a 
mask, choose 5080-dpi film transparencies. Upload your file to FTP server using the detailed 
instructions are on the website. Choose "Output type: Black and White 
transparency, Positive, Emulsion Down," for settings when ordering. 
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Flow channel layer 
 The following steps must be performed in a clean room to minimize dust and other 
contaminants from mixing into the small feature sizes. Remove AZ4620 photoresists from 
refrigerator and allow it to adjust to room temperature. Obtain a clean, silicon wafer and place on 
spinner. Be sure that wafer is perfectly centered prior to running. To create 25μm high channels, 
spin wafer at 500 rpm for 65 sec AT 100 rpm/sec ramp. Pipet approximately 3 mL of photoresist 
onto center of wafer and spin immediately after loading. Photoresist will not spin correctly if it 
sits on wafer too long.  After spinning, remove edge bead and place on hot plate at 110 °C for 5.5 
minutes. Remove wafer and allow it to cool for 20 min. Next, place wafer in UV contact aligner. 
The length of exposure will depend greatly on the energy output from your contact aligner. This 
step may take some trial an error. As an example, I exposed wafer to11 mW/cm
2
 of intensity for 
180 sec. After exposure, place wafer in 3:1 water: 400K developer and swirl wafer for the entire 
developer step. Note- AZ photoresists are highly susceptible to the presence of acetone. It is best 
to designate new glassware for AZ-only to prevent acetone contamination. After dissolving 
photoresist, clean wafer with isopropanol and dry with N2 gas. Rounded channels are necessary 
to completely seal microvalves. Therefore, the next step in the process is to heat the wafer to 110 
°C for 20 min. in order to reflow the rectangular channels into rounded channels (Figure 1).  
The next step in the process is to create PDMS channels. First, put ~ 1 mL of 
octadecyltrichlorosilane (OTS) onto a Kimwipe. Place both the Kimwipe and silicon master into 
a vacuum dessicator. Turn on the vacuum and allow the OTS to evaporate onto the wafer for at 
least 4 hours. This will ensure the removal of PDMS from the channels. Next, put the wafer back 
into the spinner and pour 20:1 onto the center of the wafer. Spin at 2050 rpm for 60 seconds to 
create a 50 μm high PDMS block. The extra PDMS over the channel will act as a membrane and 
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will deflect down to close the channel upon the application of pressure to the pressure channel. 
Place the PDMs covered wafer into an oven at 70 °C until the wafer is just set. This is very 
important to monitor, or there may be leaking in the device. Just set is when the PDMS is firm 
enough to cut through, but does not have a gummy consistency (~20 min).  
 
Pressure channel layer 
 Obtain a clean, silicon wafer and place on spinner. Carefully align wafer so that it is 
perfectly centered. To create 100 μm channels, spin wafer at 3000 rpm/sec  for 30 sec. Carefully 
pour 3 mL of SU8 2075 photoresist onto center of wafer and spin. After spinning, remove edge 
bead and place on hot plate at 65 °C for 5 min. Then place on second hot plate which is set at 95 
°C for 20 minutes. Allow wafer to cool to room temperature and then place in contact aligner and 
expose according to manufacturer’s instructions (http://www.microchem.com/pdf/SU-
82000DataSheet2025thru2075Ver4.pdf). Following exposure, return wafer to 65 °C hot plate for 
1 min, and then move to 95 °C hot plate for 5 min. Remove wafer and allow it to cool to room 
temperature. Place wafer in SU8 developer and swirl for about 10 min. To test for 
unpolymerized photoresist, spray wafer with isopropanol. If cloudy liquid appears, place wafer 
back into developer. When finished, rinse wafer with isopropanol and dry with nitrogen.  
 Cut approximately 1 cm pieces of silicone tubing and glue onto reservoir features of the 
master to create tubing connections for the valves. Then, pour 5:1 PDMS onto master around the 
silicone pieces and cure in oven for 70 °C until just set (~25 min.). Using an Exacto knife or a 
razor blade, cut out each individual device from the PDMS block and carefully align onto the 
flow channel PDMS using a microscope. Take the entire 2-layer device system and incubate in 
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an oven at 90 °C overnight. Biopsy punches can be used to generate reservoirs to the flow 
channels.  
Prior to any surface functionalizations, adhere the PDMS device to a glass coverslip and 
connect to the valve system to test proper functioning of the valves. Valves should also be filled 
with water or media before running cell experiments. This greatly reduces bubble formation in 
the channels. 
 
    
Figure A.1 Bright field images of AZ4620 positive photoresist before (left) and after (right) 
photoresist reflow to yield circular channels instead of rectangular. Channel heights were 
verified with a Sloan Dektak3 surface profilometer. 
 
